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Abstract 
Evoked potentials (EPs) are small phasic potentials that are elicited in 
conjunction with sensory, motor and cognitive events. EP variables have been assessed 
in patients with cirrhosis but in general, methods were inadequately standardized and 
study populations incompletely characterized, leading to some studies questioning the 
validity of EP’s in diagnosing and monitoring hepatic encephalopathy, while other studies 
indicated that there is only a low positive yield with these investigations. Few studies 
have attempted tri-modal sensory and cognitive recordings. 
Recorded waveforms may demonstrate altered morphology while possessing 
broadly normal latencies. Since EP analysis is usually performed solely in the time 
domain, latency measurements do not therefore highlight morphological changes to the 
waveform and so abnormalities may go unreported. 
The aim of this study was twofold (i) to measure sensory and cognitive EPs in patients 
with cirrhosis in relation to their neuropsychiatric status and (ii) to address frequency 
content in relation to neuropsychiatric status by examining EPs with two spectral 
techniques, the Fourier Transform (FT) and the Power Spectral Density Estimate (PSD). 
Seventy patients with biopsy–proven cirrhosis were classified using clinical, 
psychometric and EEG criteria as unimpaired or as having minimal or overt hepatic 
encephalopathy (HE).  Forty-eight healthy individuals served as controls.  Visual (VEPs), 
brainstem auditory (BAEPs) somatosensory (SSEPs) and cognitive auditory (P300) EPs 
were recorded under standardized conditions.  
Significant latency differences were observed in sensory EPs between patients 
and controls with patient subgroups differences being less significant.  The cognitive 
auditory P300 however, distinguished the patient subpopulations from one another. 
Frequency shifts are observed in all EP modalities with significant differences also 
occurring between patient groups. The sensitivity and specificity of the frequency-domain 
is comparable to that of the time-domain. 
Paired EP investigations analysed by latency indicate BAEP and P300 best 
discriminate any degree of encephalopathy; in the frequency domain it is the VEP 
combined with SEP and in the time-frequency domain it is the SEP. These findings 
suggest that EPs, when performed as a bank of multimodal tests and with spectral 
analysis, could provide a sensitive and specific method for the diagnosis and monitoring 
of hepatic encephalopathy.  
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Forward 
 
In this chapter Evoked Potentials (EPs) are defined as a neurological 
investigation, highlighting typical findings in a range of clinical applications and 
highlighting issues of reliability. This is followed by a methodological examination, 
by each recording modality, of the technical issues that need to be addressed in 
order to achieve consistent and reliable recordings. The role of stimulation, 
recording and post-processing parameters will be explored along with 
consideration of the effects of altering these factors. Confounding factors are 
identified and appropriate methodologies are then indicated. 
The next section (The Liver) introduces the pathological changes in cirrhotic 
liver disease, and from an extensive literature review mechanisms are suggested 
for the clinical changes seen in hepatic encephalopathy. The diagnosis and 
grading of encephalopathy will be addressed noting the current problems with 
diagnostic test sensitivity. 
  The following section (EPs in patients with hepatic encephalopathy) is 
based on a survey the literature of previous EP investigations in this patient 
group. Critical scrutiny to patient inclusion criteria and encephalopathic 
classification is made. The neurophysiological methods will also be examined in 
light of positive yields for each of these investigations. 
The final section of this chapter (Signal Processing, Neurophysiology and 
Evoked Potentials) is a broad survey of previous signal analysis studies 
undertaken on signals of neurophysiological origin. Signal processing methods 
are identified for both animal and human studies. The aims of the previous 
studies will also be considered and the extent of spectral analysis studies in 
patients with encephalopathy. 
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1.0  Preface to the Background 
Hepatic encephalopathy is one of the major complications of cirrhosis. 
Patients will have clinically apparent neuropsychiatric abnormalities, 
encompassing a wide spectrum of mental and motor disorders; other patients, 
although neuropsychiatrically clinically unimpaired, will show significant 
abnormalities in both psychometric and neurophysiological performance. The 
presence of hepatic encephalopathy therefore, whether minimal or overt, has a 
considerable impact on the execution of complex tasks - such as driving, 
memory, decreased attention and health-related quality of life. 
There is no “gold standard” diagnostic test for hepatic encephalopathy; as 
a result it is poorly diagnosed and in consequence is often sub-optimally 
managed.  Complete management may be unattainable due to the varying 
presentations and impairments experienced by patients as well as multiple 
possible pathophysiological aspects of the disease.  This brings us to the second 
problem: the exact pathophysiology of the syndrome is unknown.  In 
consequence, treatment is based empirically on the current concepts of its 
pathogenesis.  It follows that there is no one specific treatment but a number of 
possible treatments that can be used in tandem.  Possibly a battery of the tests 
which each assess different aspects of cerebral function is necessary to provide 
a reliable diagnosis – a multidimensional approach.  Currently however, many 
centres rely on clinical assessment to diagnose hepatic encephalopathy. Further, 
additional measures are used inconsistently, based on which is most easily 
accessible rather than one which has been validated or standardized. 
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Evoked potentials (EPs) have been used in earlier studies of cirrhotic 
patients to provide information for the detection and monitoring of 
encephalopathy. Both sensory and cognitive EP investigations have been 
reported, although few utilized   multimodal investigations, and none with four 
modalities. The electrophysiological criteria for indicating the presence of 
encephalopathy has been determined by visual inspection of the waveform; an 
increase in the appropriate peak latency of the recorded waveform indicating an 
abnormality. Latency findings can be subject to inter-operator variability; 
additionally, many of the previous studies were not conducted in dedicated 
environments or with the most current protocols; the methodologies therefore 
have been frequently sub-optimal. As a result the findings of these studies have 
been inconsistent, and with many inconclusive reports on their validity, EPs – 
particularly the sensory modes – are not currently considered to be a valuable 
adjunct to encephalopathic screening or monitoring. 
Spectral analysis methods are relatively resistant to inter-operator 
variation and can be automated if required. The characteristics of an EP signal 
allow it to be incorporated into computational software with ease; sensory and 
cognitive potentials have been analysed spectrally from a range of 
pathophysiologies but there are no reports of this form of analysis in patients with 
hepatic encephalopathy. Spectral methods have a further advantage in addition 
to the inter-operator robustness; if a patient produces and altered waveform, but 
the conventional latency peaks remain broadly within the normal range, the 
patient will be reported as a false-negative. The spectral content of such a 
Page 15 of 227 
waveform not apparent in a visual time-domain inspection, will be altered 
numerically and thus with a greater possibility of an abnormal finding. 
In order to evaluate the role EPs may have in the diagnosis and 
monitoring of hepatic encephalopathy this thesis will undertake two 
investigations: firstly, to record multi-modal sensory and cognitive potentials while 
using the most current clinical guidelines in electrophysiological recording; 
secondly, two spectral methods will be performed on the EP recordings. These 
three aspects of this investigation are unique in patients with hepatic 
encephalopathy. 
This thesis brings together elements of liver disease, neurophysiology and 
signal processing. The [two] liver and signal processing sections serve to set the 
scene and justify the requirement of this study. The first of the neurophysiology 
sections illustrates the complexities of EP recording while the latter is a critique of 
the previous attempts to assess encephalopathic patients with EP investigations 
presents the current state of research. The chapter as a whole therefore, 
provides a broad background for the patient type, the previous work undertaken 
and the rationale for the research in this study. 
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1.1 An Introduction to Evoked Potentials 
 
An evoked potential (EP) is a potential difference, or an electrical expression, 
of the brain’s reaction to  and processing of, changes in the external 
environment; these changes are commonly referred to as stimuli, and the 
physiological changes subsequent to stimulation share electrical features of both 
action potential volleys and the on-going electroencephalogram (EEG).  The 
electrical waveforms observed are usually named after the stimulus that elicited 
them; for example in the sensory system, a pattern reversal or strobe light flash 
will produce a visual evoked potential (VEP).  Electrical stimulation of peripheral 
nerves will produce a somatosensory (SSEP) and auditory stimulation will elicit a 
brainstem auditory response (BAEP). 
 
Fig 1.1 (below and overleaf). Illustrative examples of Visual, (A) Somatosensory (B) and 
Brainstem Auditory (C) evoked potentials, demonstrating the distinctive morphology of each 
sensory modality. The marked peaks bear the standardised nomenclature and are used for 
diagnosis. The latencies (msec) are typical for each of the peaks shown; (see appendix V for 
recording the montages for each of the waveforms). 
 
 (A) 
20ms 
±5µV 
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 (B) 
 (C) 
 
These sensory EPs are also known as exogenous responses. They are non-
cognitive and stimulus modality specific potentials that only indicate primary 
sensory afferent and cortical registration of a change.   
Cognitive evoked potentials arise as a result of cognitive neuronal networks 
processing sensory information.  These EPs are endogenous potentials; however 
they are not mode specific but are time locked to the central processing of 
afferent signals. Cognitive EPs are longer latency potentials - the best known 
being the P300 or event related potential (ERP).  Other endogenous ERPs 
±5µV 
5ms 
1ms 
±0.2µV 
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include the contingent negative variation (CNV) and the pre-motor 
‘bereitschaftspotential’ (BP).  
  (A) 
  
(B) 
Fig. 1.2 Illustrative examples of normal P300 (A) and Bereitschaftspotential (B) cognitive 
evoked potentials, demonstrating modality specific morphology. 
   
Any central neuronal activity that is triggered from the periphery and related to 
a time-locked cognitive process or a motor activity can be seen as an EP and 
therefore may have clinical applications in appraising or monitoring cerebral 
functions.  However, EP recording in human subjects does have limitations.  The 
data are recorded via surface electrodes and a wide range of artefacts are 
encountered. 
Cz - A1 
5s ±5µV  
111 
C3 - A1 
5s ±5µV 
 
111 
T = 0 msec 
±10µV 
100 ms 
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 The EP is a small voltage with a signal to noise ratio of less than 1;  it must 
therefore, be extracted from the background EEG by signal averaging (Cooper et 
al 1980; Dawson 1951), a technique originally devised  by George Dawson. In 
short, a waveform is produced by the summation of epochs – a stimulus 
presentation and its associated sampling of time related electrical concomitants.   
Waveforms obtained by this method assume that there is a perfect correlation 
between the onset of the stimulus and the response.  The stimuli must be 
perfectly reproducible and if many epochs or ‘sweeps’ are required, this may 
become a monotonous experience for the subject. 
A third issue is that of considerable inter-subject variability in the normal 
population.  This entails large sample sizes for normative data in order to 
discriminate between control and abnormal responses. Sensitivity and specificity 
of EP findings may be further complicated by modulation of neuronal activity, for 
example alertness or vigilance, which could affect the consistency of repeated 
recordings.  
Despite these limitations the EP has been found to be a reliable diagnostic 
investigation that yields objective and reproducible data in routine clinical 
practice.  This has been the case since the early 1970s where the VEP 
highlighted clinically silent lesions in the optic tracts in patients with multiple 
sclerosis, and illustrates the advantage that EPs may have over clinical 
examinations.  
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1.2 Evoked Potentials: approaches to patients with Hepatic Encephalopathy. 
 
 
Visual EPs 
 
VEPs can be robust diagnostic investigations since they elicit reproducible 
data in clinical settings; the data is an objective and sensitive measure of the 
integrity sensory tracts. In addition, clinical data has been obtained in a large 
number of normal subjects and in patients with a range of neurological diseases. 
As central nervous system conduction is also monitored, changes in patient 
state, over time, can be monitored objectively – and thus provide a quantitative 
adjunct to neurological examination.  
 Equipment, recording conventions in clinical neurophysiology, 
measurements and operational considerations must be approached 
systematically and consistently; the operational aspect is particularly significant if 
investigations are to occur across several sensory modalities or on more than 
one recording device. Preparation of the electrode / skin interface must be 
thorough; contact impedances must be checked numerically, and should be 
consistent within the test (to balance the amplifiers) and between subjects. A 
value of 2-3k is sufficient to promote common mode noise rejection. The 
positioning of the electrodes must also be consistent to allow for accurate inter-
patient comparisons as well as using previously obtained databases. The 10-20 
International System (Neidermeyer & da Silva F. 1982), Appendix I) is the most 
widely used. 
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Infection control requires that universal precautions be followed according 
to the clinical departmental guidelines. This is particularly important as we are 
deliberately abrading the skin in patients who may potentially be sources of 
hepatitis. The electrodes plug unto a head-box (Appendix I) that may also house 
the pre-amplifiers. This in turn is connected to the analogue-to-digital converter 
(ADC) by a cable to a remote viewing room. Channel selection and other 
instrumentation can then be adjusted without distracting the patient. This also 
minimises the electromagnetic interference incident on the pre-amplifiers. 
Impedance checking may also be done remotely – with the same advantages – if 
the recording montages are pre-programmed. 
The amplifier gain should be in excess of 100dB; this gain should be linear 
within a choice of selected bandwidths. A range of steps between 1-300Hz for 
the high pass and 100-3kHz for the low pass. The bandwidth is usually 
maintained by single order filters. Notch filters (50Hz) are not recommended, as 
they remove frequencies of interest and may introduce artefacts time-related to 
the stimulus, into the trace.  
Signal averaging systems have a number of important parameters which 
must be programmed correctly, or at least known and noted in order to assist in 
the interpretation of the data; this may be most important in artefact recognition 
or as a marker of malfunction. The numbers of channels, voltage resolution, time 
resolution and data points per channel are the most important items. The 
averager processes the signal, with artefact rejection, whilst sampling / holding 
an epoch. As this takes a finite time the stimulus rate and total run time must be 
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carefully considered. Since the VEP latency is affected by state of alertness, a 
prolonged run-time, or number of sweeps would have the advantage of improving 
the signal quality, but may induce drowsiness in the patient. 
A calibration signal, usually a square wave, should be injected such that 
the amplifiers and averager system process this input. It is more advantageous if 
the test signal has an independent or external origin. 
The stimulators, flash or pattern reversal, must also be accurately and 
consistently controlled. Visual angle (pVEP) once chosen and calculated, e.g. 
20, can only be maintained if the patient-monitor distance is constant. Check 
sizes are also chosen from a programmable range (35 - 70); these of course 
must be constant for a patient, but within a patient cohort some variations may be 
required to accommodate variable visual acuity. The luminance strongly affects 
the latency of the VEP and thus must be monitored, certainly between patients – 
but if possible throughout an individual recording. 
Amplifiers used in clinical neurophysiology are all differential amplifiers. 
Therefore the + (G1) input, for example from electrode 1, becomes more positive 
with respect to the – (G2) input, from electrode 2. The only possible alternative is 
the opposite connection. The G1 and G2 inputs may both be receiving a negative 
potential, but if there is a difference, i.e. G2 is less negative then effectively G1 is 
positive. A zero output will only occur when the inputs are identical. The amplifier 
output will cause the display to either deflect up or down; one of the most 
common sources of error when reading EPs is either not knowing the amplifier 
configuration, or that it has been changed from a previous programme setup. 
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This is particularly common on multimodal devices and is responsible for a trace 
being abnormal yet at the same time familiar. In the absence of a universal EP 
convention, an efficient approach would be to mark every trace with the amplifier 
configuration. A calibration signal would achieve this with the added advantage of 
providing a system check. Similarly there is no convention on assigning the 
active and reference electrodes to either of the amplifier inputs. Again, 
consistency between both patients and between modalities in individuals will 
ensure that clinical data is meaningful. 
Waveform nomenclature is also variable, as is demonstrated in the VEP 
literature set, and is usually based on either numbering the phase shifts 
chronologically (N1, P1, N2) or by labelling components after the value of the 
mean in a normal population, e.g. P100. There is a current trend however to label 
components after observational findings and not theoretical latencies. This 
however, usually causes confusion when interpreting waveforms the best 
approach is to be consistent and to use the system that the whole research group 
find the least ambiguous – possibly polarity-latency. 
Latency, in msec, refers to the ‘absolute’ latency – the time between the 
stimulus and a predefined point on the waveform. This reference point is usually 
a peak, but some measurements occasionally use the peak onset – or take off. If 
the signal averager is software controlled and gives a digital read out, the cursors 
must programmed and checked to ensure they are all reading in the same way. 
This will also apply to the other commonly used latency measurement – the 
‘interpeak latency’.  Unfortunately even manual placing of cursors may be 
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subjective in some cases, for example difficult waveforms such as bifids, or those 
with artefact. An acceptable approach would to have a strict protocol specifically 
for waveforms that were problematic – this would again ensure consistent data 
evaluation. 
Amplitude measurements (mV) are measured in the same way and may 
present the same difficulties. Cursors can be placed either baseline to peak of 
the waveform – known as “absolute” amplitude or peak-peak. The signal 
averagers do not calculate the baseline voltage; therefore a peak cursor 
measurement will be subjective. Peak-peak cursors will provide an accurate 
voltage, but the physiological activity causing the peak of the first wave may have 
nothing to do with the activity that produces the second opposite peak. For 
example in the SSEP, the N20 is followed by the P23 but are formed in 
anatomically distinct structures. Since amplitude measurements are less useful 
as diagnostic markers – due to a greater variation within normal controls – they 
are most useful when comparing hemispheres in single subjects; in this case the 
patient is their own control. Amplitude differences can therefore, when expressed 
as percentage differences in a subject, be used in monitoring or longitudinal 
studies. In this instance either amplitude method is acceptable, providing of 
course that the same measurements are taken within the group and individual. 
Determining the normal limits of a patient requires that each investigation 
(VEP, SSEP & BAEP) on each recording device have a normal population 
database, recorded with the same parameters that are used clinically. Most EP 
measurements have a normal distribution; therefore, standard deviations can 
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describe the upper limit of normal. As normal range must include 98% of the 
control population the only acceptable SD’s are 2.5 and 3 (98.8% & 99.7% 
respectively). 
In the advent of an absent or abnormal EP recording, a systematic 
approach to the methodology – in each modality – should be employed, based on 
an initial assumption that the observations are the result of technical error rather 
than conduction defect. This approach would be in addition to a repeated test. 
Adequate stimulation would be the first question; checks therefore would 
follow, including controls (frequency, duration & intensity), electrical continuity 
and signal averager synchronisation. Amplifier input / output checks would 
confirm the bandwidth, gain, recording electrode selection and recording 
electrode continuity / impedance.  A final check would be performed to confirm 
that the correct stimulator is correctly triggering the averager; this will include a 
memory check to ensure that the data is erased in between data-collection runs. 
If these post-recording checks are completed, and trial repetition produces clearly 
seen abnormal waveforms, then the possibility of technical factors can be 
excluded.  
 
Brainstem Auditory EPs 
 The brainstem auditory evoked potential (BAEP) is the preferred 
neurological investigation for the cochlear (VIII) nerve and brainstem auditory 
pathways. As with the other EP’s (visual & somatosensory) it is an objective and 
non-invasive test that yields reproducible potentials in clinical practice.  BAEPs 
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have been studied in large groups of normal controls and also in patients with a 
wide range of neurological disorders.  
The most common stimulus used for this investigation is a ‘click’, which is 
produced by delivering a square wave [electric] pulse to an earphone. The 
duration of the pulse is approximately 100-200s, with rates that can be varied 
from 0.5-100Hz. The polarity of the pulse determines the initial direction of the 
earphone diaphragm and hence if the sound wave is a compression or 
rarefaction click. White noise must be available for masking the contralateral ear, 
since a monaural stimulus click may cross to the opposite side and subsequently 
alter the waveform. To avoid disturbing the patient, the headphones should be 
controlled such that stimulus / white noise sides can be switched remotely, with 
each side having separate intensity controls.  
The stimulator (headphone) is calibrated with external sound level meters 
and the output recorded in decibels. Headphone calibration is not usually 
attended to on a regular basis. This can be excused in part since the relationship 
between the sound output in dB and the actual basilar membrane stimulation is 
dependent on subject variables such as shape of external canal, state of 
tympanic membrane and the mechanical condition of the ossicles and oval 
window. The subject hearing threshold is required as it will indicate the stimulus 
intensity required to produce a clear BAEP waveform.  A typical stimulus intensity 
is 70dB HL which will be 70dB above the threshold-of-hearing level for the 
stimulus. If the stimulator can be adjusted in small increments (e.g. 1dB) the 
hearing level can be assessed accurately. The methodology used for the 
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determination of this threshold level should comply with the British Society of 
Audiology recommended procedures (revised 2008). 
Surface electrodes are suitable for BAEP recordings. Electrode application 
will be with the conventional EEG technique, and the positions according to the 
10-20 International System. Skin preparation is achieved using the EEG 
technique. With this modality the averaged signal is of low voltage, therefore 
particular attention should be paid to the electrode contact impedance, 
maintaining them below 5k. 
Amplifier gains of 100-120dB should be available, with a pre-amplifier 
bandwidth of 50-150Hz (highpass) and 3kHz low pass. The sweep window 
should have a duration of 10-12ms with the automatic repetition set to not less 
than 1000.  
The potentials observed at the scalp subsequent to a stimulus are 
generated in the cochlear nerve, pons & midbrain. The action potential in the 
cochlear nerve appears at the ear as a negativity. The other waves (II-V) all 
appear at the scalp as positivities; if a non-cephalic reference is used for an ear 
recording wave one will have the opposite phase to waves II-V. Since waves III-V 
are clearer if they are recorded from the vertex, with wave II being of good 
amplitude from either position, the vertex or ear positions will provide maximum 
amplitudes. Therefore an ear (mastoid) – vertex bipolar montage can be used. 
Although not essential a second contralateral channel may be recorded to ensure 
that there is no wave I present in the non-stimulated side. Therefore the BAEP 
recording montage is 
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Ch 1: Ai - Cz 
Ch2: Ac-Cz  
‘i’ & ‘c’ are ipsi- and contra- to the stimulus. 
To reduce muscle artefact the patient must be supine with neck support. The 
recording should also be as remote as the cabling will allow; this may aid the 
patient to fall asleep during the investigation. Any further aid to comfort is 
essential in this sensory modality as muscle potentials artefacts are often 
encountered. 
 Stimulus intensities of below 65dB (HL) usually result in poorly defined 
peaks, therefore it is of no advantage to start at a lower stimulus; 75dB (HL) is 
often a more effective intensity. Stimulation is monaural as abnormalities, where 
reported, are often unilateral.  
 The BAEP waveform is of low amplitude, often necessitating over 1000 
sweeps to ensure a clearly defined signal. The stimulus rate will then dictate the 
duration of the investigation, but rates of over 10Hz elicit progressively degraded 
waveforms. Further, faster rates rarely reveal abnormalities that are not apparent 
at lower stimulation rates. 
 The polarity of the stimulus, i.e. to produce a compressed or rarefied 
sound wave) clearly alters the BAEP in normal controls. Wave I amplitude is 
greater with rarefied clicks due to positive pressure in the cochlea and on the 
window. Cochlear microphonics however, may add to and alter wave I. An 
alternating polarity will cancel this while having the additional benefit of reducing 
the amplitude of stimulus artefact seen on the trace.  
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 The stimulus is capable of travelling by bone conduction to the 
contralateral ear to stimulate it at an intensity of 40 or 50dB below the ipsilateral 
ear. Contralateral white noise masking at 40dB below stimulus will prevent cross 
stimulation; this in turn can be monitored on channel two of our montage.  
 Finally, as suggested in visual and somatosensory investigations, 
repetition and superimposition should be considered mandatory. The 
recommended minimum intertrial variability is 0.2ms for interpeak latency (IPL) 
measurements (Rowe 1981). Waveforms often reveal after only 500 repetitions 
whether or not they will be superimposed. Repeatability, therefore, is not a major 
undertaking even with the sweep numbers required for this test. 
Wave V is the most prominent and often first appearing peak. With a 
passband of 100-3kHz it occurs at 5.5ms starting above the baseline and 
descending farther below the base line. This below baseline trough is unique to 
wave V. Wave 1 appears after 1.4ms post stimulus as the first negative peak, 
and will be absent in the corresponding position of channel 2. Waves II – IV are 
inserted equidistantly between I-V; wave III is often attenuated in channel 2, can 
present two peaks, and in addition may be absent in channel 1 which, with no 
other changes is not an indication of abnormality. Waves II and IV are not 
commonly used for clinical interpretations; thus, the IPLs most commonly 
recorded are I-III, III-V & I-V. 
Peak latencies can be affected by non-pathological factors. Effects 
stimulus intensity, polarity, bandpass and rate have been extensively studied. 
Stimulus frequency content is determined by the square-wave duration. An 
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electrical squarewave of less than 200s will produce a decaying sinewave with 
a content of 500Hz –4000Hz. A change in frequency content will affect the 
amplitude and latency of all waves. A broader range for example will stimulate 
extended regions of the cochlea. As a wave may take 2-6ms to stimulate the 
entire cochlea, more than one of each BAEP component will be generated – the 
final waveform will consist of blended components and so appears unclear. 
Unfortunately, the usual first course of action when observing an unclear 
waveform would be to increase the stimulus intensity.  
Subject factors that affect BAEP latencies include age, gender, body 
temperature and drugs. With increasing age after childhood there is an increase 
in wave latencies; there are reports however, that suggest the differences are too 
small, i.e. of the order of 0.1msec (Rowe 1978), to change a BAEP result from 
normal to abnormal when mixed gender group are used for controls. There is 
agreement that females have shorter peak and IPL’s than males. The amplitudes 
are also bigger for all waves. Various studies have attributed many reasons for 
this but most are unconfirmed. One suggestion is that males have a higher core 
temperature than females. There is a correlation between peak latencies and 
body temperature, such that progressive lowering of the body temperature 
produces a wave V latency prolongation of 0.17ms/ºC below 32.5ºC (Picton et al 
1981). In addition, BAEP latencies correlate with circadian alterations of 
temperature during sleep – 0.2ms/ºC (Marshall & Donchin1981). 
Interpeak and peak latencies of BAEP’s are not significantly affected by 
medications that otherwise affect the CNS. This includes patients that have had 
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toxic doses that have rendered the EEG isoelectric (Drummond J. et al 1985; 
Stockard & Sharbrough 1980). Anaesthesia decreases amplitude but the 
latencies are not significantly affected. The effects of alcohol, both acute and long 
terms are unclear. 
Despite the factors that affect latency, the main BAEP peaks are 
consistent in healthy controls and have been utilised successfully in clinical 
practice. BAEPs have been found to be unchanged after over 8 hours of 
continuous testing, and unchanged within individuals tested repeatedly over 
several months. This, with the resistance to anaesthesia, indicates that the 
auditory EP modality is a particularly robust avenue of investigation.  
 
Somatosensory EPs 
SEPs are clinically utilised by such a range of practitioners that, 
unfortunately, there exists a multitude of protocols. This is further complicated by 
variable waveform nomenclature. Most SEP recording protocols have evolved 
from the American EEG Society (J Clin Neurol 1986 3 pp43-92) and most 
practices retain some of the original guidelines. Equipment, recording convention 
and operational issues will be based on this protocol while adjusting for 
methodological problems encountered at the Royal Free Hospital.  
The preferred stimulus for an SEP is an electrical pulse since it can be 
precisely controlled and produces potentials of the greatest amplitude. The 
stimulator should be capable of delivering a square wave at range of frequencies 
(1 – 100Hz) and at a range of durations (10s – 2ms). Stimulus durations 
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normally used are 100s & 200s, the higher duration used in patients with 
suspected peripheral neuropathies. Constant current and constant voltage 
stimulators are both available (voltage being more common) with no significant 
difference reported in the waveforms produced. Constant current devices have 
the advantage of allowing the stimulus to be described in mA, the amplitude 
being directly proportional to the number of fibres stimulated. The current from a 
constant voltage output is not reliably calculated since impedance is both 
unknown and variable. 
Recording electrodes are of the conventional EEG type; needle electrodes 
may produce a cleaner and larger trace but patient comfort is a higher priority, 
particularly where the investigations may be prolonged. The conventional method 
for attaching EEG electrodes is used, i.e. using the 10-20 International System 
for placement system and attempting low and consistent impedances. Ground 
electrodes may also be of the EEG surface type; however, a flexible strip of 
metal, covered with saline soaked Velcro, and placed proximal to the stimulus 
provides the most effective patient ground. In addition, this arrangement greatly 
reduces stimulus artefact appearing on the trace. 
Some recording systems require less operator intervention than others; a 
parameter, for example may be unchangeable from the manufacturers settings, 
alterations to accommodate new guidelines therefore, being somewhat limited. 
Otherwise, SEPs are normally recorded at gains of 100 – 120dB, with a pre-
amplifier band of 1-30Hz highpass to 3kHz lowpass. An averaging window of 
100ms should have a sampling interval of 0.2ms. If the sweep setting has an 
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automatic stop it should be set to 1000, and a trial should not be stopped before 
500 stimulus repetitions unless it is exceptionally clear. It is obvious that a repeat 
trial is performed for superimposition.  
Channel derivations are based on the principle waveforms which are 
recorded most effectively when the electrode site is close to the voltage 
generator (Chiappa et al 1978). A four channel montage is standard; this will 
record  i) brachial plexus potential, the electrode being placed on Erbs’ point; ii) 
cervicomedullary potentials, CVII for the dorsal root entry zone, and CII for the 
dorsal column spinal nuclei; iii) somatosensory cortical potential, electrodes 
placed 2cm posterior to the ispsilateral C4 / C3 positions of the 10-20 System. All 
active electrodes are referred to Fz. An upper limb SEP montage would therefore 
be:  
Ch 1 : C3 / C4 – Fz 
Ch 2 : CII – Fz 
Ch 3 : CVII – Fz 
Ch 4 : Erb - Fz 
 
Stimulus sites for upper limb SEP are commonly median, ulnar and radial 
nerves. The actual site is treated to reduce contact impedance as for recording 
electrodes; the ground lead site should also be treated in this way. The cathode 
of the stimulator should be proximal, otherwise the action potential may be 
reduced (anodal block). Stimulus intensity should be maximal in order to 
stimulate all fibres; patient comfort however, will be an overriding factor. The 
major cause of an apparently delayed cortical potential is that only the group II 
(slower) afferent fibres have been activated. Unilateral stimulation is normal, as 
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pathologies may be literalised. Bilateral stimulation - where lateralisation is not an 
issue – may be feasible if obtaining a large potential is a priority. This may be the 
case in post-operative monitoring. The low voltage nature of the potentials 
generated in EP’s dictates that a large number of stimuli are required. It is 
tempting, therefore, to increase the stimulation rate in order to reduce the 
investigation time. A rate of 5Hz is often reported (Pratt et al 1980), however 
many traces may have their clarity improved with a reduced rate, 2Hz being the 
current departmental protocol.  
The typical stimulus duration is 0.2ms and will be supplied from an 
isolated power supply. It is helpful if this parameter is adjustable as a longer 
pulse width may be required to elicit a response from patients with peripheral 
neuropathies. Finally, it cannot be over stressed that trial repetition is mandatory; 
it is not unusual to record four investigations in order to ensure a measure of 
repeatability.  
Waveform identification and therefore peak latencies can be demonstrated 
by example but cannot be described easily in writing. In short, the Erbs potential 
appears as a diphasic (positive-negative) waveform and is recorded as N9. The 
upper cervical chord CVII and lower brainstem CII have a merged waveform such 
that CVIII is a lobule in a larger peak CII, recorded as N11 & N13 respectively. 
The cortical potential is a well formed isolated peak recorded as N20. Absolute 
latencies are dependent on variables that are not all reproducible from one 
department to another. This may also be true when moving between different 
recording devices. Normal standards, therefore, should be collected for each 
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department and for each device; there are however, many studies available that 
have large numbers of normal data and that yield consistent results. 
There are various non-pathological factors which may affect the results. 
Technical factors include stimulus intensity, rate and bandpass. In addition, 
patient factors may possibly include age, gender, limb temperature and 
medication. 
Age changes in adults have not been researched as extensively as for the 
visual and auditory modalities. Unfortunately there are contradicting reports. 
Some studies that have found no significant changes in N19 & P23 latencies 
across a range of 19 – 70yrs, while other reports suggest there is a moderate 
(~0.3ms) increase in N19 latency between age 50 – 60yrs but no change 
thereafter. There is a similar unclear relationship between conduction times and 
gender. 
Peripheral nerve conduction velocity is significantly affected by limb 
temperature; it is normal practice in electromyography to both measure and 
control the temperature. It is accepted that a rising of limb temperature by 1ºC 
can shorten the N19 latency by 0.7 – 1.0ms, most protocols refer to (Bolton C. et 
al 1981; Matthews & Small 1979). Consistent limb temperature is a factor that will 
be relatively straightforward to achieve in a departmental study. 
Short latency SEP’s are particularly unaffected by drugs.  Notably when 
barbiturates, carbamazepine or diazepam are present at a dose that affects the 
background EEG, the SEP is preserved. Phenytoin conversely is associated with 
prolonged SEP latencies. 
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The SEP is an objective, reproducible, non-invasive method of 
investigating the sensory system. Interpretation depends partly on familiarity with 
a large normal control database. In addition to technical expertise, a pertinent 
medical history from each patient will assist the waveform interpretations where 
they may be affected by clinical factors. 
 
Auditory Cognitive EPs: P300 
The central nervous system can respond to external stimuli in two distinct 
ways. In one, the exogenous, potentials are modality specific and reflect 
physiological processing of a sensory afferent message and its cortical 
destination. They are therefore non-cognitive. Endogenous potentials share, in 
common with the former, a time-locked relationship with the stimulus. However, 
they are not modality specific and they reflect the activity of the pathways 
involved in cognitive processing of sensory information. Exogenous EPs depend 
on the characteristics of the stimulus while endogenous EPs depend on the 
nature of the task once the sensory information has arrived at the cerebral cortex.  
Cognitive potentials occur with a longer latency in comparison to sensory 
potentials and so both cannot be easily visualised in the same recording protocol.  
The current strategy is to compare EPs generated by a stimulus requiring 
attention – the target, embedded randomly in a series of stimuli not requiring 
attention – non-target. The difficulty here is clearly to ensure that non-target 
stimulation does not elicit a cognitive response.  
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Cognitive potentials are generally recorded several milliseconds after 
sensory EPs and so are often termed long-latency endogenous EPs. The best 
known is the P300; others frequently studied include the contingent negative 
variation (CNV) and the movement related bereitschaftspotential (BP). The P300 
is a symmetrical positive wave seen maximally over the midline in the central and 
parietal regions. It occurs with a latency of between 250 – 600ms, depending on 
the stimulus type. It is elicited by the so-called ‘oddball’ paradigm; this requires 
the presentation of unexpected infrequent stimuli randomly interspersed among 
frequent stimuli. The difference would be in the frequency (tone) if the stimulus 
was auditory, as is the case in this study. 
 Visual, somatosensory and auditory modalities can all elicit a P300 
response (Desmedt & Robertson 1977; Snyder et al 1980; Barrett et al 1987)  
and their morphologies are similar, although latencies may differ. The amplitude 
of the P300 is affected by the probability of the target or rare stimulus. There are 
three factors that affect the target presentation – the overall probability, the local 
sequence and the interstimulus interval (ISI). The P300 amplitude increases as 
the target frequency decreases (Polich J. 1987). Maximum amplitudes occur with 
the target rate at 10-15%. Most neurophysiology departments use 20% in their 
clinical protocols. The local sequence refers to the preceding stimuli, such that if 
two target stimuli are presented sequentially the amplitude will be lower than if 
the rare tone was preceded by four or five common tones. In addition, if the 
target stimulus occurs at a regular interval it will not be unexpected and so the 
amplitude decreases.  
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 The amplitude of the P300 increases as the ISI increases, or as the target 
probability decreases. This appears to be more significant than overall probability 
(Fitzgerald & Picton1981); where ISI’s are below 300ms latencies are also 
prolonged.  A ‘pseudo-random’ sequence, with the appropriate ISI, will therefore 
contain a random presentation of rare stimuli but will avoid local the local 
sequence effects. The stimulus rate is usually once per second, as should be the 
sweep duration. 
Recording issues include technical and patient factors. The commonly 
used bandwidths are 0.1 to 1Hz and 30 to 100Hz for high- and lowpass 
respectively. Three midline channels should be used – Fz, Cz and Pz, referenced 
to linked mastoids, A1 and A2. An eye movement channel is required to identify 
blink artefact; this can be used for sweep rejection by amplitude, and is 
particularly important for the target stimulus and channel. The P300 can be 
variable within a subject, therefore in common with other EPs; a repeated and 
superimposed trial will ensure reproducibility. However, habituation may be a 
problem as it can occur in long latency cognitive studies which involve a novel or 
rare stimulation paradigm (Polich 1986). It is currently unclear to what extent task 
dependent EPs are affected. 
The age of the patient, their level of attention and the difficulty of the task 
can affect the latency of the P300. The subject must be awake and alert in order 
to produce a P300 waveform (Barrett et al 1987). Decreasing vigilance is 
associated with decreasing amplitude while drowsiness eliminates the evoked 
response. Behavioural assessment of attention is therefore advantageous and a 
Page 39 of 227 
recordable response to the target stimulus will provide an appropriate estimate; 
pushing a button, for example, on the rare tone will allow the operator to assess 
attention while the reaction time can indicate changes in alert levels.  
The difficulty in discrimination in the oddball paradigm affects the latency 
such that as the task becomes more challenging the P300 latency increases 
(Polich 1987). In an auditory paradigm for example, the latency will increase if 
there is insufficient difference between the two presented tones of the stimulus.  
The age of the patent has a positive correlation with P300 latency (Barrett 
et al 1987; Picton et al 1984; Polich et al 1985). Latency increases by 
approximately 1ms per year after 20 years of age. A regression line for age and 
latency has not been found by all researchers however; in addition, there 
appears to be a reduction of latency in paediatric studies where the minimum 
latency varies between 15 – 25 years of age.  
Cognitive EPs: current status  
Research into cognitive function has attempted to correlate EP latency 
with clinical changes. Some alterations have been reported but specificity and 
sensitivity are currently unclear. Diagnosis and monitoring of dementia is one of 
the areas where the earliest investigations were made; studies with dementia of 
mixed aetiologies all reported prolonged latencies but some of these were not 
statistically significant. However, patients selected for Alzheimer’s type (St. Clair 
et al 1985) observed a 70% abnormality with no false positives. Studies 
attempting to differentiate subtypes of dementia (Goodin & Aminoff 1986) are 
hampered by patients producing incorrect responses which may alter the latency 
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more than the underlying pathology. In addition, there is a significant latency 
overlap between the control group and patient’s, particularly where the dementia 
is mild. 
There have been many cognitive studies in patients with schizophrenia; 
many report alterations in amplitude but most do not report any significant 
change in latency (Brecher et al 1987). This patient group tends to have less 
correct responses, longer reaction times and frequently reduced motivation – all 
of which affect any task driven EP. In these studies there is also a great overlap 
between the control and patient groups (Morstyn et al 1983).  
Other patient groups investigated include Parkinson’s and Huntingdon’s 
dementia where significant changes have been reported for auditory P300 
latency (Goodin & Aminoff 1986; Rosenberg et al 1985). Metabolic 
encephalopathies have also been investigated; patient studies of chronic renal 
failure, Down’s syndrome and alcoholism have all reported prolonged P300 
latencies, including sub-groups which clinically have no cognitive impairment.  
The application of cognitive EPs is problematic since there is no ‘gold-
standard’ protocol that has been approved for clinical neurophysiology 
investigation. Further, the evidence of overlap between patient with control data 
and variability within the control group, suggests that the P300 may be limited in 
its usefulness as a clinical tool. In addition to instrumentation factors, patients 
with altered cognitive function must be closely monitored for behavioural 
features, as inattention and accurate task performance greatly affect the P300 
outcome. 
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1.3 The Liver  
 
The liver is the largest internal organ in the body and is located in the right 
hypochondrium.  It performs several key functions in the body including 
metabolism of proteins, carbohydrates and lipids, formation of bile, hormone and 
drug inactivation and detoxification.  Injury to the liver can occur acutely, usually 
due to infection with hepatotrophic viruses or drugs, or chronically, usually as a 
result of chronic alcohol misuse or chronic infection with hepatitis B or C.  While 
the majority of individuals with acute hepatitis recover, with no long-term 
sequelae, the development of cirrhosis is associated with a number of 
complications reflecting loss of hepatocellular function and/or the development of 
portal hypertension.  These complications include; jaundice, fluid retention, 
bleeding from oesophageal varices and hepatic encephalopathy. 
 
Injury to the liver 
Injury to the liver can occur acutely, usually due to infection with 
hepatotropic viruses or hepatotoxic drugs, or chronically, mainly as a result of 
excess alcohol ingestion or chronic infection with hepatitis B or C.  Chronic injury 
results, in a proportion of individuals, in the development of cirrhosis which is 
characterised by the presence of severe fibrosis or scarring with evidence of 
regeneration in the form of nodules of ‘normal’ liver tissue; as a result, the normal 
architecture of the liver is disrupted (Figure 1.3).   
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Figure 1.3:  Macroscopic and microscopic views of a normal and a cirrhotic liver.  The outline and 
surface of the normal; liver are smooth and the liver tissue arranged in orderly lobules around a 
central vein.  The outline and substance of the cirrhotic liver are nodular and irregular with 
disruption of the normal architecture by fibrous bands and nodules of regenerating tissue.  
 
Complications of Cirrhosis 
The development of cirrhosis results in a reduction in the number of liver 
cells available to carry out its major functions.  Thus, when the functioning cell 
mass of the liver drops below a critical level its activity is impaired.  This is 
referred to as hepatocellular failure.  In addition the presence of fibrosis and 
nodules in the liver impede the passage of blood through the liver parenchyma 
and this leads to an increase in the pressure within its main vascular supply 
Normal Liver 
Central Vein 
Cirrhosis of the liver 
 
Fibrous tissue 
Regenerating nodule 
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system.  This is referred to as portal hypertension; it also has significant 
consequences (Table 1.1).   
Table 1.1:  Complications of the development of cirrhosis 
 
Hepatocellular failure 
 
Function 
 
Consequences 
Breakdown of plasma bilirubin Jaundice 
Protein synthesis 
Albumin  
Clotting factors 
 
 
Fluid retention - oedema 
Easy bruising/ bleeding 
 
Sodium and water homeostasis Fluid retention - oedema 
Detoxification 
 
Impaired drug handling 
Impaired handling of circulating neurotoxins 
 
Portal hypertension 
 
Consequences 
 
Splenomegaly leading to: 
A reduction in red blood cells - anaemia 
A reduction in white blood cells (leucopaenia) - impaired immunity 
A reduction in platelets (thrombocytopaenia) – poor clotting and bleeding 
 
 
Portal-systemic shunting leading to: 
Development of oesophageal/gastric varices – gastrointestinal bleeding 
Bypassing of the liver by neurotoxic material – hepatic encephalopathy 
Direction of the retained fluid into the abdominal cavity – ascites 
 
In many individuals the presence of cirrhosis is not accompanied by the 
development of hepatocellular failure and/or portal hypertension.  They may be 
asymptomatic or else suffer from no more than minor lethargy and tiredness.  
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These individuals are referred to as having compensated cirrhosis.  In others, 
however the cirrhosis becomes ‘decompensated’ following the development of 
portal hypertension and/or hepatocellular failure; they may present with jaundice, 
bleeding from varices; spontaneous bleeding; ascites and peripheral oedema 
and/ hepatic encephalopathy. 
 
Classification of Cirrhosis 
Cirrhosis is categorised in relation to its aetiology and to its functional 
capacity.  The aetiology of is determined on the basis of clinical, laboratory, 
radiological and histological variables.  The functional severity of their liver injury 
is assessed using the Pugh modification of the Child’s grading system (Pugh et al 
1973).  This system is based on assessments and numerical classifications of 
five variable of which two are clinical and three are laboratory based.  Each 
measure is scored from 1 to 3, with 3 indicating the most severe or greatest 
degree of abnormality.  The sum of the five scores is used to assign a Child’s 
grade of A, B or C with A indicating the least degree of compromise and hence 
the best prognosis (Pugh et al 1973). 
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Table 1.2:  Child-Pugh Scoring System for functional hepatic reserve 
Variable Points scores for increasing severity 
1 2 3 
Serum bilirubin (µMol/l) 
(5-17) 
<34 34-50 >50 
Plasma albumin (g/L) 
(35-55) 
>35 28-34 <34 
Prothrombin time (s) 
Seconds prolonged >16 
1-4 4-6 >6 
Ascites None Mild 
Moderate or 
refractory 
Hepatic encephalopathy None Grade I-II Grade III-IV 
Pugh’s Score:  5-6  Child’s Grade A 
   7-9  Child’s Grade B   
   10-15  Child’s Grade C 
Compensated: Scores 5-7; Decompensated: Scores 8-15 
 
 
Hepatic Encephalopathy 
Hepatic encephalopathy (HE) is the term used to describe the 
neuropsychiatric abnormalities which arise in patients with acute and chronic liver 
disease although this thesis will be focused on the syndrome which accompanies 
cirrhosis.  Although hepatic encephalopathy is one of the major complications of 
cirrhosis and has a considerable impact both on quality of life (Ferenci P 2002 et 
al; Groeneweg et al 1998) and survival (Merkel et al 1989; Butterworth 2000) it is 
often under-diagnosed and, therefore, sub-optimally managed.   
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There is general agreement that hepatic encephalopathy is a metabolic/ 
neurophysiological rather than a structural disorder of the brain and is, therefore, 
potentially reversible.  Approximately 20-30% of patients with cirrhosis manifest 
clinically overt neurological and/or psychiatric changes and are thus classified as 
having overt hepatic encephalopathy; these individuals invariably show 
abnormalities of psychometric performance and/or abnormalities of their 
electroencephalogram (EEG)  A further 30-40% of patients with cirrhosis display 
no clinically detectable symptoms or signs, but do show impairment of 
psychometric and/or EEG performance; these individuals are classified as having 
minimal hepatic encephalopathy.  Finally, 20-30% of patients with cirrhosis show 
no neuropsychiatric abnormalities and no defining psychometric or 
electrophysiological abnormalities: these individuals are classified as 
neuropsychiatrically unimpaired.  
Pathophysiology 
The pathogenesis of hepatic encephalopathy is not known.  It is highly 
unlikely that any one factor alone is responsible for the generation of the 
syndrome and thus at present a “‘multiple-hit’ hypothesis” (Wright et al 2007) is 
favoured.  This implicates gut derived toxins, especially ammonia, systemic 
inflammation and changes in the auto-regulation of cerebral haemodynamics.  
Other gut-derived toxins and disruption of multiple neurotransmitters and 
neurotransmitter systems are also implicated. 
There is agreement on the importance of gut-derived neurotoxins, 
especially ammonia in the pathogenesis of hepatic encephalopathy.  Ammonia is 
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derived in the gut from ingestion of nitrogenous substances which are broken 
down by bacterial ureases and amino acid oxidases.  The majority, however, is 
derived from the uptake of glutamine in the intestine, which, through the actions 
of glutaminase, forms glutamate and ammonia (Desjardins et al 1999; Olde 
Damink et al 2003). In the normal liver, ammonia is detoxified by conversion to 
urea in periportal hepatocytes via the urea-cycle and to glutamine in perivenous 
hepatocytes via glutamine synthetase.   
In patients with cirrhosis the fibrotic changes within the hepatic 
parenchyma impede the passage of blood resulting in the establishment of 
portosystemic shunts which allow nitrogenous breakdown products from the 
intestine to pass from the portal venous system directly into the systemic 
circulation without the interposition of the hepatic detoxifying filter.  In addition, 
the detoxification of the products that are extracted by the liver is suboptimal in 
the presence of hepatocellular failure.  Thus potentially neurotoxic substances 
can impinge directly on the brain (Figure 1.4).  
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Figure. 1.4. Passage of gut-derived neurotoxic material into the systemic circulation in cirrhosis as a result of 
ineffective hepatic detoxification and portal systemic shunting of blood 
 
In hepatocellular failure, 
toxins are not removed 
effectively from the blood 
entering the systemic 
circulation from the liver. 
With portal hypertension 
blood enters the systemic 
circulation directly through 
portal-systemic collaterals. 
 Marc Rayan Page 49 of 227 09/07/2013 
 
Brain ammonia uptake has been shown to be significantly increased in 
both acute and chronic liver failure, due to increased permeability of the blood-
brain barrier and alterations in cerebral blood flow (Butterworth 2002).  Evidence 
from PET studies confirms that ammonia diffuses into the brain easily (Abou-Assi 
& Vlahcevic 2001).  The brain does not possess urea cycle enzymes and thus 
ammonia is detoxified exclusively in astrocytes to glutamine via the enzyme 
glutamine synthetase.  Glutamine efflux from astrocytes occurs by passive 
diffusion into the extracellular fluid and CSF.  This may be affected by changes in 
pH.  Therefore, in states of acute hyperammonaemia, glutamine accumulates in 
astrocytes, causing them to swell (Haussinger et al 2000) (Figure 1.5).  This has 
been identified as the “glutamine hypothesis” (Brusilow 1986) of cerebral oedema 
in fulminant hepatic failure (Blei & Stolze Larsen 1999).  This same brain swelling 
is not seen to any extent in patients with cirrhosis with hepatic encephalopathy 
although, in vivo proton-magnetic resonance-(1H MR)-spectroscopic studies have 
suggested that astrocytes may show some change in their cell volume 
(Haussinger et al 1994; Laubenberger et al 1997).  
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Figure 1.5. Cerebral ammonia detoxification.  GS=Glutamine synthetase.  Ammonia is converted 
to glutamine in the astrocytes by glutamine synthetase and accumulates here. 
 
The astrocyte clearly plays a pivotal role in cerebral ammonia 
detoxification and in the presence of persistent hyperammonaemia develops 
changes of Alzheimer Type II degeneration with nuclear enlargement, peripheral 
margination of chromatin and prominent nucleoli. These changes can be induced 
experimentally in cultured astrocytes by exposure to ammonia, indicating that HE 
is a disorder of glial cells, with neuronal dysfunction the consequence 
(Haussinger et al 2000). Alzheimer Type II astrocytes also have altered 
expression of key astrocytic proteins including glial fibrillary acidic protein, 
glutamate transporters and “peripheral-type” (mitochondrial) benzodiazepine 
receptors (Butterworth 2002). 
The changes in astrocytic function which occur in response to 
hyperammonaemia causes alterations in neurotransmission (Haussinger et al 
2000) (Figure 1.5) Ammonia also directly inhibits excitatory postsynaptic 
potentials, thereby depressing overall central nervous system function.  The 
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ammonium ion also inhibits the tricarboxylic acid cycle enzyme ketoglutarate 
dehydrogenase, thus inhibiting cerebral glucose metabolism (Lai & Cooper 
1986). This could impair brain energy metabolism, however it appears to be a 
late effect in chronic liver failure.  Ammonia also has a stimulatory effect on L-
arginine uptake resulting in increased production of nitric oxide and inhibition of 
the storage of glutamate in astrocytes (Butterworth 2000). 
 
 
Figure 1.6. Disruption of central neurotransmission in hepatic encephalopathy.  With astrocyte 
damage, glutamine synthetase activity and glutamate uptake decrease leading to glutamatergic 
synaptic dysfunction. 
 
 
The evidence for the role of ammonia and glutamine in the pathogenesis 
of hepatic encephalopathy is compelling even through the correlation between 
arterial ammonia concentrations and the degree of hepatic encephalopathy is 
sometimes poor; hepatic encephalopathy can be present in the absence of 
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elevated ammonia levels and low levels of ammonia have neuroexcitatory effects 
(Abou-Assi & Vlahcevic 2001). However the correlation between concentrations 
of glutamine in the CSF and the presence and degree of hepatic encephalopathy 
is excellent (Romero-Gomez et al 2004).  The severity of neuropsychiatric 
symptoms also correlates with brain concentration of glutamine (Butterworth  
2002). 
 
Neurotransmitters and receptors 
Gene expression of a number of neurotransmitter-related proteins is 
increased in the presence of hepatic failure (Merkel et al 1989).  Many of the 
early neuropsychiatric symptoms of hepatic encephalopathy such as altered 
sleep patterns have been attributed to modification of serotonin, a monoamine 
neurotransmitter (Abou-Assi & Vlahcevic 2001). Increased expression of the 
monoamine oxidase gene and thus increased activity of the enzyme and 
increased density of catalytic sites on the enzyme protein have been reported  in 
autopsied brain tissue of cirrhotic patients with hepatic encephalopathy 
(Mousseau et al 1997). 
Increased expression of the “peripheral-type” benzodiazepine receptor 
located on the outer mitochondrial membrane of the astrocyte, has been 
identified in brain extracts from portacaval-shunted rats and attributed to 
increased cerebral concentrations of ammonia and/or manganese level 
(Desjardins et al 1997; Butterworth 2000). This receptor could be involved in the 
maintenance of the energy metabolism of astrocytes and cholesterol uptake by 
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the mitochondria resulting in a generation of ‘neurosteroids’ (Butterworth 2000). 
Increase in receptor level may result in alterations of monoamine and amino acid 
neurotransmitter function as well as modified cerebral perfusion in chronic liver 
failure. 
Hepatic encephalopathy also demonstrates effects on opiate and 
catecholamine pathways (Wright et al 2007). The interaction between these 
neurotransmitters and other key factors already identified in the pathogenesis of 
hepatic encephalopathy is significant and so the true influence of 
neurotransmitters in hepatic encephalopathy is difficult to identify (Wright et al 
2007). For example, the uptake of tryptophan, from which serotonin is derived, is 
facilitated by elevated ammonia levels (Young et al 1975). 
 
 Diagnosis  
The diagnosis of hepatic encephalopathy in patients with cirrhosis is 
based on historical and clinical evidence and the use of surrogate markers to 
delineate neuropsychiatric status. 
Evidence for changes in daily living, including the sleep-wake cycle, 
cognitive impairments and energy levels should be sought from the patient 
themselves and from family and friends.  A detailed neuropsychiatric examination 
must also be performed including a mental-state examination, cranial nerves 
examination and a motor and sensory examination.  Patients may manifest subtle 
or florid clinical symptoms relating to a number of cerebral systems, e.g: 
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 Cortical 
o Cognitive deterioration 
o Personality change 
o Psychiatric abnormalities 
o Disturbed consciousness 
 
 Extra-pyramidal and cerebellar 
o Dysarthria 
o Ataxia 
o Tremor 
o Cogwheel rigidity 
 
 Spinal 
o Spasticity 
o Paraplegia 
 
The changes in mental state are classified using West Haven criteria 
which were described by Conn and co-workers in 1977 (Conn et al 1977) and 
adapted from an earlier classification suggested by Parsons–Smith. (Table 1.1) 
(Parsons-Smith et al 1957) 
Table 1.1. The West Haven criteria of altered mental state in hepatic encephalopathy 
(Blei et al 2001; Amodio et al 2004) 
Grade Description 
0  Lack of detectable changes in 
personality or behaviour.   
 *Asterixis absent. 
I  Trivial lack of awareness.   
 Shortened attention span.   
 Dyscalculia.  (Impaired addition or 
subtraction.)   
 Hypersomnia, insomnia, or inversion 
of sleep pattern.   
 Euphoria or depression or anxiety.   
 Asterixis can be detected. 
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II  Lethargy or apathy.   
 Disorientation.   
 Disorientation of time.   
 Inappropriate behaviour.   
 Obvious personality change.   
 Slurred speech.   
 Obvious asterixis. 
III  Gross disorientation.   
 Bizarre behaviour.   
 Somnolence to semi-stupor.   
 Confused.   
 Responsive to stimuli.  
 Asterixis generally absent. 
IV  Coma. 
*Asterixis – flapping tremor of the wrist. 
These criteria are not universally accepted, primarily because they do not 
allow clear differentiation between patients with Grade 0 and I.  Blei and Cordoba 
(2001) and Ferenci et al (2002) have, in consequence,  suggested minor 
modifications to the West Haven criteria but more recently  Amodio et al have 
suggested a more radical modification in the hope of providing a more practical 
universally applicable tool (Table 1.2). 
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Table 1.2. Suggested modification of the West Haven criteria for the grading of 
mental state in patients with cirrhosis (Amodio et al 2004). 
Grade Description Proposed operative definition 
0  No abnormality detected  
I  Trivial lack of awareness 
 Euphoria or anxiety 
 Shortened attention span 
 Impairment of addition or 
subtraction 
 Not able to complete TMT-Aa in 
120 sec (individuals with ≥ 5 
years of education), or 
 Naming ≤7 animals in 120 sec 
 Orientated in time and space 
II  Lethargy or apathy 
 Disorientation for time 
 Obvious personality change 
 Inappropriate behaviour 
 Disorientation in time: (≥3 items 
incorrect): 
- Day of the week 
- Day of the month 
- The month 
- The year, and 
 Orientated in place 
III  Somnolence to semi-stupor 
 Responsive to stimuli 
 Confused 
 Gross disorientation 
 Bizarre behaviour 
 Disorientated in place: (≥2 items 
incorrect): 
- State/country 
- Region/county 
- City 
- Place 
- Floor/ward, and 
 Disorientated in time, and 
 Reduction of Glasgow score (8-
14)i 
IV  Coma, unable to test mental 
state 
 Unresponsive to pain stimuli 
(Glasgow score <8)  
 
a TMT-A: Trail-Making Test A (Reitan 1955) 
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When consciousness is impaired, the Glasgow coma scale (GCS) is used 
to assess the severity of the condition.  It is calculated by assessing verbal, motor 
and ocular responses and summing the total values to provide an overall 
score.(Table 1.3)   
 
Table 1.3. The Glasgow coma scale (Longmore et al 2005) 
Best motor response Best verbal response Eye opening 
6 Carrying out request 
(‘obeying command’) 
    
5 Localizing response 
to pain 
5 Orientated   
4 Withdraws to pain 4 Confused 
conversation 
4 Spontaneous eye 
opening 
3 Flexor response to 
pain 
3 Inappropriate speech 3 Eye opening in 
response to speech 
2 Extensor response to 
pain 
2 Incomprehensible 
speech 
2 Eye opening in 
response to pain 
1 No response to pain 1 None 1 No eye opening 
 
Use of the above criteria does not preclude the use of other tools such as 
the Mini Mental Score Test or Abbreviated Mental Test. 
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Neuropsychometric Assessment 
Psychometric tests can be used to demonstrate the disturbances of 
cognition including perception, memory, learning, executive functions, expression 
(language, constructive abilities, voluntary motor control) and mental activity 
(attention, concentration and psychomotor speed) characteristic of this syndrome 
(Amodio et al 2004; Ortiz et al 2005). Weissenborn et al (2001b) recommend use 
of a test battery comprising number connection tests (NCTs) A and B, the line 
tracing test, the serial dotting test and the digit symbol test.  This test battery 
which is called the psychometric hepatic encephalopathy score (PHES), although 
recommended by the international working party on hepatic encephalopathy is 
still not internationally accepted.  Scores in the PHES battery however are 
affected by many variables including age, gender and number of years in 
education (Montagnese et al 2004). Therefore, simple thresholds of raw data are 
inappropriate.  Tests must be appropriately validated and standardised within the 
populations in which they are to be applied.   
Recently a system for scoring the PHES battery was devised for use in the 
UK which has two unique features.  First it provides a new system for scoring the 
line tracing test (LTT).  This test has two components: time (LTTt) and errors 
(LTTe), which have been variously considered as either dependent (Amodio et al 
1996) or independent (Weissenborn et al 2001) variables.  A method for scoring 
the LTT which is based on a model which relates times and errors has been 
incorporated into the new scoring schema.  Second, the scoring system includes 
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adjustment for important confounding variables such as age, years and location 
of education and ethnic origin (Marks et el 2008). 
 
Neurophysiological Assessment 
Neurophysiological tests include electroencephalography (EEG) which 
records the electrical activity of the brain cortex and evoked potentials (EP) which 
examine discrete firing patterns of populations of cells in response to a stimulus 
(exogenous EP), or to a passive or active cognitive task (endogenous EP).  
These tests provide a more objective measure to quantitatively grade hepatic 
encephalopathy (Kircheis et al 2007). Neurophysiological tests are very useful for 
investigational purposes, especially in those in whom neuropsychological tests 
are difficult to interpret due to age or co-morbidities.   
The EEG is useful for detecting, assessing and monitoring hepatic 
encephalopathy.  The majority of EEGs recorded in healthy individuals are 
dominated by a basic rhythm concentrated in the posterior area of the scalp in 
the alpha range (8-13Hz).  If the EEG is of low voltage or is dominated by fast 
activity this rhythm can be difficult to distinguish (Niedermeyer 1999). The main 
criterion for diagnosing hepatic encephalopathy by electroencephalography is 
slowing of the posterior basic rhythm from the alpha range (8-13Hz) towards the 
theta (4-7Hz) and delta (1-4Hz) ranges (Montagnese et al 2007).  
The EEG can be analysed visually, though this is subject to inter- and 
intra-operator variability.  Spectral EEG analysis has been shown to be a more 
reliable measure (Amodio et al 1999) as it provides an automated estimate of the 
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dominant EEG frequency and the component contributions.  The diagnosis of 
hepatic encephalopathy is generally based on changes in the EEG mean 
dominant frequency.  However, topographical changes have also been noted 
including ‘anteriorization’ of the posterior basic rhythm.  This can be viewed, if 
prominent, on a visual analysis.  It can also, however, be quantified by analytical 
techniques such as spatio-temporal decomposition, (SEDACA) (short epoch, 
dominant activity, cluster analysis) which separates the main components of the 
EEG and defines their distribution across the scalp.  SEDACA separates the 
activities recorded in the EEG into sets of paired temporal and spatial 
components.  The temporal components (waveforms) provide the time courses of 
the separated EEG activities, while the corresponding spatial components (head-
maps) illustrate the distributions of the waveforms across the scalp.  The 
temporal components are scaled according to their relative contribution to the 
original EEG.  Electrode, muscle and eye artefacts are separated leaving 
artefact-free components available for analysis (Montagnese et al 2007). 
Diagnostic sensitivity of the EEG varies from 43% to 100% for overt 
hepatic encephalopathy (Montagnese et al 2004; Montagnese et al 2007). EEG 
abnormalities have also been detected in 8 to 40% of clinically unimpaired 
patients, however this also depended on the techniques used (Montagnese et al 
2004). In their review, Montagnese, and co-workers describe how, despite 
discrepancies over the sensitivity of EEG in diagnosing hepatic encephalopathy, 
EEG alterations in cirrhotic patients “generally reflect the patients’ 
neuropsychiatric status, the effects of treatment, dietary manipulation, and 
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surgical/nonsurgical shunt creation” and “correlate well with health-related quality 
of life “(Montagnese et al 2004).  
 
Evoked Potentials 
Evoked potentials (EPs) are small phasic potentials which occur with 
sensory, motor and cognitive events.  As described earlier there are: 
 Exogenous (sensory) – elicited by direct stimulation of visual, auditory or 
somatosensory systems. 
 Endogenous (cognitive) – cognitive activity. 
 Movement-related – the preparation for movement and its execution. 
All varieties of exogenous EPs have been used in studies of minimal hepatic 
encephalopathy.  Delays in conduction were identified; however, these changes 
could also have been the result of alcohol consumption or diabetes.  Endogenous 
EPs reflect cognitive changes and so would, in theory, be a better indicator of 
minimal hepatic encephalopathy.  The P300 has been studied in cirrhotic patients 
with hepatic encephalopathy.   The P300 is a large positive deflection in voltage 
at a latency of approximately 300ms in the EEG which is elicited by different 
tasks; the most common task used is the oddball paradigm.  The amplitude of the 
P300 reflects the amount of attentive resources devoted to a task and the latency 
of the P300 reflects the speed of stimulus classification before a response is 
selected.  The use of P300 latency elicited by the oddball paradigm has been 
identified as a sensitive tool to detect minimal hepatic encephalopathy in many 
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studies (Davies et al 1990b; Weissenborn et al 1990). However, the data are 
conflicting (Amodio et al 2005).  
At present, therefore, there is no gold standard test for the diagnosis of 
hepatic encephalopathy and the classification of patients is based on arbitrary 
principles.  The following schema is the one most commonly adopted. 
 Overt Hepatic Encephalopathy 
The diagnosis is based on the elucidation of abnormalities of 
neuropsychiatric status and requires a detailed neurological examination and 
assessment of mental state using the modified West Haven criteria.  These 
patients invariably show abnormalities in their psychometric assessment and/or 
the neurophysiologic assessment.   
 Minimal Hepatic Encephalopathy 
Patients with minimal hepatic encephalopathy, by definition, show no 
clinical evidence of neuropsychiatric abnormalities—otherwise the diagnostic 
criteria applied to minimal hepatic encephalopathy are not secure.  The working 
party for the 11th World Congress of Gastroenterology produced a consensus 
that at least two of the following neuropsychological tests should be used: NCT-
A; NCT-B; block-design test; and digit-symbol tests, with, where possible a 
quantitative neurophysiologic tool such as EEG with mean dominant frequency or 
P300 auditory evoked potentials.  They also noted that the PHES battery might 
prove useful (Ferenci et al 2002). Thus the diagnosis should be based on the 
absence of clinical features together with impaired performance of at least two of 
the four psychometric tests recommended, with adjusted normative scoring, 
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and/or an abnormal neurophysiological test result (Ferenci et al 2002; Kharbanda 
et al 2003).  
Patients with minimal hepatic encephalopathy have been previously 
termed subclinical or latent hepatic encephalopathy, though its importance 
should not be minimised.  These individuals, despite their apparent normalcy, 
show significant impairment of several activities of daily living including complex 
task execution such as driving (Schomerus et al 1981; Watanabe et al 1995), and 
there is clear evidence that their earning capacity is detrimentally affected (Ortiz 
et al 2005) as is their quality of life (Groeneweg et al 1998). In addition PET 
scanning has shown a significant decrease in glucose utilization in several 
cortical regions which correlate with the patient’s cognitive function even in 
minimal hepatic encephalopathy (Lockwood et al 2000). It has also been shown 
that minimal hepatic encephalopathy predicts the occurrence of overt hepatic 
encephalopathy (Romero-Gomez et al 2001) and that it can be successfully 
treated (Watanabe et al 1997).  
 Neuropsychiatrically Unimpaired 
Patients who are classified as neuropsychiatrically unimpaired show no 
clinical, psychometric or neurophysiological abnormalities. 
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Current Problems 
Hepatic encephalopathy is an often neglected complication of chronic liver 
disease.  It is poorly diagnosed and in consequence is often sub-optimally 
managed.  There are two main difficulties: 
 
1.  There is no “gold standard” diagnostic test.  Indeed this may be unattainable 
due to the varying presentations and impairments experienced by patients as 
well as multiple possible pathophysiological aspects of the disease.  It may be 
that a battery of the tests described which each assess different aspects of 
cerebral function is necessary to provide a reliable diagnosis – a 
multidimensional approach.  In their review of diagnostic methods for hepatic 
encephalopathy Montagnese et al (2004) described how due to the wide range of 
diagnostic modalities and the lack of a consensus as to the value of each, many 
centres either rely solely on clinical assessment to diagnose hepatic 
encephalopathy or inconsistently use an additional measure which is most easily 
accessible rather than one which has been validated or standardized.  Indeed it 
is difficult to validate the findings of most studies as no consensus has been 
reached on the diagnosis and classification of patients.   
 
2. The exact pathophysiology of the syndrome is unknown.  In consequence, 
treatment is based somewhat empirically on the current concepts of its 
pathogenesis.  It follows that there is no one specific treatment but a number of 
possible treatments that can be used in tandem.   
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The major treatment effort centres on reducing the generation, absorption and 
elimination of potentially neurotoxic material from the body.  In addition there are 
some centrally acting agents that can be employed in specific instances: 
 Decrease of ammonia load: 
o Enemata 
o Non absorbable antibiotics 
o Non absorbable disaccharides 
o L ornithine L aspartate 
o Sodium benzoate 
o Probiotics and zinc supplements 
 
 Action on CNS: 
o Bromocriptine 
o BCAA 
o Flumazenil 
 
The disaccharides lactulose and lactitol are the current mainstays of 
treatment and are usually well tolerated, cheap and effective.  Some patients can 
experience some cramping, diarrhoea or flatulence, however once the dose is 
titrated, side effects are minimal.  A recent meta-analysis evaluating the benefit of 
non-absorbable disaccharides versus placebo or no treatment in the treatment of 
hepatic encephalopathy showed no significant effect on hepatic encephalopathy 
grade or mortality (Als-Nielsen et al 2004). However, many trials were excluded 
from this analysis and lactulose continues to be effective as a therapy (Morgan et 
al 1989; Watanabe et al 1997).  Lactulose has been shown to improve cognitive 
function and health-related quality of life (Prasad et al 2007).  
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In the absence of a diagnostic gold standard and without a good evidence 
base for current treatment regimens it is not surprising that unless symptoms are 
florid, hepatic encephalopathy is frequently not recognised or considered.  Ortiz 
et al (2005) noting the lack of a well-standardised screening test identified two 
groups of patients who should undergo screening for minimal hepatic 
encephalopathy: 
 
 Patients at risk of accidents, such as active drivers 
 Patients with cognitive complaints such as; psychomotor 
performance; decreased attention; or poor memory, or decline in 
work performance. 
 
However, the simplest approach would be to screen all patients with 
cirrhosis for evidence of hepatic encephalopathy and to treat accordingly or even 
more pragmatically to simply treat all patients with cirrhosis with lactulose or 
lactitol.  Therefore, the search for better diagnostic tools and better insights into 
the pathogenesis continues.  
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 1.4 Evoked Potentials in patients with hepatic encephalopathy 
An extensive review of the literature revealed several single and multimodal 
EP studies; these are summarised (appendix II). 
VEP. 
Twenty-one VEP patient studies were carried out from 1983 – 2001. Nine of 
these studies were dedicated visual evoked investigations, the remainder 
consisting of mixed EP’s (uSSEP & BAEP). 
The combined patient total is 584; one study was dedicated to a paediatric 
patient group (Nora et al 2000), with age (mean SD) 8.62.5, range 5 - 15 yrs.  
The mean age of the adult patients, where stated, was 45.210.6 yr. Four papers 
stated the age range rather than the mean age, while eight papers did not state 
the range; where it was stated, the age range of the total patients in VEP studied 
was 13 – 78 yr. 
The aetiologies varied markedly across the VEP patient group, and can be 
broadly divided into three sets. 
Exclusively cirrhotic: 8 studies 
Cirrhosis with other aetiologies: 9 studies 
Alcoholic cirrhosis 
Hepatitis (viral and autoimmune) 
Primary Billiary Cirrhosis 
Non-cirrhotic firbrosis 
Extra-hepatic billiary atresia 
Paracetamol overdose 
Malnutrition 
ALD 
Cryptogenic 
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Non-cirrhotic liver disease: 5 studies 
Cholestatic liver disease 
Hepatocellular liver disease 
Hepatitis B 
The selection criterion for patients was not stated in five of the studies. 
Four papers selected on an ‘inclusion’ basis, while the remainder used an 
‘exclusion’ criterion. 
INCLUSION EXCLUSION 
 No clinical signs of hepatic 
encephalopathy (HE0) 
 No history of alcoholism 
(Mehndiratta et al 1990) 
 No medication within previous 
24hrs that has a known 
neurological effect 
 Normal visual acuity 
 Normal ERG 
 Abnormal visual acuity 
 Neurological disorders 
 Sedation within 24hrs  
 Psychotropic medication 
 Metabolic disorders including 
diabetes and uraemia 
 Overt HE (Demirturk 2001) 
 History of alcoholism (Nora et al 
2000) 
 Malnutrition 
 Treatment with Lactulose & 
 Neomycin (Zenerolli et al 1984) 
 GI bleeding 
 
The assessment of hepatic encephalopathy was varied, but (Parsons-Smith 
1957) was the system most adopted for classification. 
Parsons-Smith (1957) 9 
Child-Pugh 2 
Adams & Foley (1953) 1 
Zenerolli (1984) 1 
Zeive (1987) 1 
Conn / Child-Pugh 1 
MMSE & Reitan 1 
Not stated 3 
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The diagnosis of the underlying pathology was less varied, although it was 
not stated in five of the investigations.  Serum biochemistry was used in ten 
studies (five of which had accompanying liver biopsy); biopsy as the exclusive 
method was stated in eight studies.  The visual stimulus for seven studies was 
flash, while a pattern reversal stimulus (pVEP) was used in the remaining patient 
groups 
Flash VEP: five of the seven studies recorded one channel only; the 
recording electrode positions corresponded to either the 10-20 International 
System (EEG) or the Modified Maudsley placements. The two groups that 
recorded bilaterally (Caellas et al 1985; Davies et al 1990a) did not use standard 
clinical neurophysiological recording electrode positions.  The number of sweeps 
(flashes) per run was also variable, with one study not stating.  Three studies 
were under 120 sweeps - the minimum standard – while only two were above 
(200 sweeps).  One patient group (Sollazo et al 1983) used a variable number 
(40 – 480) with no further elaboration.  Four of the groups did not state the filter 
pass band; all three of the remainder have either the low pass or high pass at an 
inappropriate setting, and with (in the one case stated) an excessively steep roll 
off  - 60dB - compared  to a typical setting of 12dB.  
PVEP: one study did not describe the electrode recording positions, while 
three recorded from more than one parieto-occipital channel.  The remaining 
studies all reported one occipital electrode for recording P100; all the pVEP 
investigations recorded from standard 10-20 electrode placement positions.    
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In the pVEP patient groups, one study did not state the sweep number. 
Four of the studies were below the clinical standard acceptable (minimum of 128) 
where the stated numbers were 70, 40-100, 100, 64-128. Again, where a variable 
sweep number is stated, there is no further elaboration. The amplifier passband 
was reported in four cases; three were acceptable bandwidths, but one of these 
described a roll off of 24dB. The remaining group stated a low pass of 1kHz 
which is high for visual studies and results in the trace being subject to EMG 
artefact. 
Post processing procedures were not stated 15 of the study groups. One 
stated “repeated” but with no specific information; two used 4 runs and three 
used 2 runs.  Once the reliability of the separate runs were checked by 
superimposition, it is unclear in these six patient groups whether they were 
summated to make a grand average in order to produce the reported latency 
values.  When comparing the patient to the control group for statistical analysis 
purposes, only eight studies stated their working definition of abnormal latency. 
One used a numerical value of P100 >122ms, or interocular difference of >7ms 
(Demirturk 2001). The other studies used the control group and defined abnormal 
as latency above control mean + SD: two studies used 1SD and 3SD, while three 
studies used 2SD. 
Of the seven studies that utilised the flash stimulus only one found no 
significant differences between the patient and control groups for both P100 and 
N145 potentials.  This was the paediatric study (Nora et al 2000) with a patient 
group selected from liver transplant candidates.  The stimulus & recording 
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parameters were in keeping with clinical neurophysiology protocols (one channel 
recording); therefore the result may reflect the unique nature of the patient group.  
In addition, although sedative medication within 24 hr of clinical examination was 
an exclusion criterion, chloral hydrate was given when necessary to ensure 
patient compliance.  A second study (Demirturk 2001) did not find significant 
differences in VEP latencies in the patient groups but no specific control group 
was studied; the EP investigations were used here to study the effect of 
eradication of Helicobacter pylori and the subsequent changes in NH3 levels.  
This study did not state the amplifier passband but did have a suitable sweep 
number (200). 
The other studies all showed some differences between the patient and 
control groups, varying from all components, to either P100 only or N145 only.  In 
two studies the N1 and N2 potentials also showed significant differences 
between controls and HE0 groups. 
 In the patients who underwent pVEP’s only two studies showed clear 
significant differences between test and control subjects; there were differences 
between HE0 and HE1 and differences obtained from N75 & P100 potentials 
respectively.  However, of those that did not, one demonstrated evidence of a 
correlation of VEP to clinical evolution (Bombadari et al 1985).  This study also 
reported a lower sweep number (70) than recommended and an unstated filter 
passband.  (Guedon et al 1993) also reported no statistically significant 
differences between patient groups but control latencies were shorter.  In this 
study the control group consisted of a mix of healthy and extra-hepatic 
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diagnoses.  A pre- and post TIPS study (Kuba et al 1996) that reported no 
significant differences between controls and patients, had a study group of 
‘hepatic cirrhosis’ with no specific aetiologies stated.  Conversely, (Sawhney et al 
1995) reported the VEP P100 as being not a significant marker for chronic liver 
disease; the aetiologies in this case were varied and included a large proportion 
of patients with alcoholic cirrhosis.  A study of exclusively non-alcoholic cirrhotics, 
with HE0-1, (Tarter R et al 1987) found that there were no correlations between 
P100 latencies and the extent of hepatic injury as defined by biochemical 
parameters – including indocyannine green clearance.  However, as this was a 
correlation study the latencies of N75, P100 & N145 were not tested against 
normal (healthy) controls. 
In summary, investigations with  fVEP yield significant differences in 70% 
of the test groups. Unfortunately the flash stimulus is reported to be less sensitive 
to conduction defects and has a greater normal subject variation (Halliday 1973; 
Shahroki et al 1978). The role of the flash VEP may be questioned therefore in 
the light of pattern reversal stimulation.  However, beyond the obvious issue of 
patient compliance, fVEP has the further advantage of stimulating wider area of 
the retina, and so recruiting a larger rod population into the retinal generators.  
Since rod and cone signals are largely processed in separate areas of the 
cerebral cortex, it would be advantageous to include flash stimulus in the case of 
an encephalopathic process that may have diffuse effects. The percentage 
positive yield may be further increased by a more robust EP methodology and 
careful selection of the patient and control groups.   
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It is disappointing that such a large proportion of the pVEP investigations 
describe no statistically significant differences.  Some of this may be attributed to 
inappropriate instrumentation and post-processing.  In addition, the selection of 
the patient or control types in some studies may have led to a predisposition for 
the pVEP P100 to become ineffective as a marker.  Pattern shift stimuli are most 
suitable for half-field recordings - a method not reported in any of the studies.  
Half-field stimulation produces waveforms with better component identification 
and are more sensitive to early neurological effects (Halliday 1985), and can 
detect delays which may be masked by full-field waveforms. 
The VEP investigation in patients with hepatic encephalopathy may be of 
use as a diagnostic marker – in contrast to the impression from some of the 
previous studies. Flash VEP’s can possibly be made more sensitive by 
employing robust methodology.  This could be used in addition to pattern VEP, 
not an alternative, again with strict methodology and the incorporation of half-field 
stimulation.  This combined VEP can be further optimised by strict inclusion / 
exclusion criterion, in particular, any history of alcoholism. 
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BAEP 
 12 BAEP patient studies were carried out from 1985 – 1995.  Three 
of these studies were dedicated auditory evoked investigations; the remainder 
consists of mixed EP’s (Visual and / or Somatosensory). The combined patient 
total is 400 adults.  The mean age of the patients was 41.96.8 yr.  The age 
range was stated in only three studies, and combines to give, for the BAEP group 
a range of 27 – 71yr.  
The aetiologies vary markedly across the BAEP patient group, and can be 
divided into four sets. 
Cirrhotic – unspecified, cryptogenic, idiopathic : 4 studies 
Cirrhosis - Alcoholic: 1 study 
Chronic active hepatitis: 6 studies 
 Non Cirrhotic Liver disease: – 2 studies 
hepatocellular carcinoma 
metabolic coma secondary to hepatic insufficiency 
The selection criterion for patients was stated in all but one of the studies, 
(Trzepacz et al 1989a). Two papers selected on an ‘inclusion’ basis, while the 
remainder used an ‘exclusion’ criterion. 
INCLUSION EXCLUSION 
 No clinical signs of 
encephalopathy (HE0) 
 No previous history of alcoholism 
 No medication within previous 
24hrs 
 > 6weeks elapsed since previous 
variceal bleed 
 Normal tonal audiometrry 
 
 previous h/o alcoholism 
 previous h/o hepatitis 
 psychiatric illness 
 neurological trauma 
 current medication affecting CNS 
 infection 
 diabeties, renal failure, uremia 
 sedation within previous 24hrs 
malnutrition 
 
 Marc Rayan Page 75 of 227 09/07/2013 
The assessment of hepatic encephalopathy was varied, but Parsons-Smith 
(1957) was the system most adopted for classification. 
 
Parsons-Smith (1957) 6 
Zeive (1987) 1 
Conn  3 
MMSE & Reitan 1 
Not stated 1 
 
The diagnosis of the underlying pathology was less varied; it was not, 
however, stated in three of the investigations.  Serum biochemistry was used in 
six studies (it was the exclusive diagnostic method in one study – (Mehndiratta 
M.M. et al 1990).  Specific biochemical parameters were described in two patient 
groups; serum albumin, NH3 and PT were common to both of these studies.  The 
other parameters included globulin, indocyanine green clearing, alkaline 
phosphatase and transaminases.  The other diagnostic methods were 
ultrasonography and histopathology.  
In this EP cohort, three studies found no electrophysiological changes in 
the patient group (Sandford et al 1987; Tarter et al 1989; Trzepacz et al 1989a).  
One study was not strictly an investigation into encephalopathy - the study used 
a population of patients with cirrhotics of mixed aetiology and divided them into 
delirium / non-delirium groups, the later serving as the control group.  The two 
Sandford / Tarter studies both had patient populations of non-alcoholic cirrhotics; 
one however (1987) did not have a separate control group, while the other, 
although not showing significant difference cf  controls, did demonstrate a 
difference within the patient sub-groups (biliary cirrhosis chronic active hepatitis).  
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 In addition, none of these study groups specified the use of contralateral 
white noise masking, and all stated their stimulation intensity in dB(SPL), with no 
indication of patient hearing threshold levels. It is also unclear from these three 
studies whether the final average used for latency calculations was 
superimposed from more than one run, or if two or more trials were performed for 
reproducibility. 
In comparison to the previous VEP survey, a higher proportion of the 
BAEP studies reported some significant differences (cf controls), i.e. >70% 
compared with ~45%.  One study reported findings only in the peak latencies 
(one or more of waves I-V), while one study reported changes confined to 
interpeak latencies (IPL’s I-V or III-V).  The remaining studies all demonstrated 
significant electrophysiological changes cf controls in peak and IPLs.  It may be 
possible to increase the positive yield of this investigation by addressing some of 
the instrumentation issues. 
Stimulation parameters are neither consistent across the positive studies 
nor do they correspond to current neurophysiological protocols. For example 
square wave type for stimulation should be alternating; of the studies surveyed 
one used alternating, the remaining using rarefaction (4), compression (1) or not 
stated.  The stimulus intensity, possibly the most crucial EP attribute, was 
delivered relative to the hearing threshold in only four of the patient groups, the 
remainder using an absolute intensity which varied from 85-130dB.  
White noise contralateral masking was reported in only one study 
(Mehndiratta et al 1990) but the SPL intensity is not specified.  The remaining 
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studies did not stimulate with masking.  Other stimulating parameters, i.e. rate 
and duration, were less variable and all fell within neurophysiological protocols. 
The recording parameters, where fully stated, varied little across the 
studies, with amplifier passband, recording sites, number of sweeps and sample 
window appearing with consistent values and in keeping with current 
neurophysiological protocols.  Stated active electrodes were A1/A2 while the 
reference is Cz; pre-amplifier passband is 100-3kHz.  It is notable that the two of 
three studies that reported no significant electrophysiological changes did not 
fully specify the recording parameters. 
 
Post processing was not fully reported in six of the studies. Four studies 
did not define ‘abnormal’ within their patient groups; the remainder that did 
specify all concurred with a reported abnormal latency as control mean+3SD. 
Confirming reproducibility by repeating trials was reported by only three studies 
(Picton et al 1984; Pozzessere et al 1988; Trzepacz et al 1989a).  Two runs were 
recorded per investigation, but it is unclear whether these were simply used for 
superimposition or added to make a ‘grand average’.  Finally, only three studies 
clearly stated that R & L ears were stimulated separately; these studies were 
then able to demonstrate which changes occurred bilaterally and which, if any 
occurred unilaterally.  The remaining reports, therefore could be presenting 
unilateral data or bilateral data obtained from a summation of averaged trials.  
In summary, BAEPs have been successfully employed as an adjunct to 
psychometric testing in the cirrhotic patient group.  It is feasible that the 
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sensitivity of the brainstem investigation could be increased with minimal 
alterations to the previous study methodologies. Well researched stimulus and 
recording parameters and a robust post processing protocol may be sufficient to 
increase the positive diagnostic yield. In addition, the incorporation of a strict 
exclusion criterion by eliminating confounding factors that affect conduction 
velocities (e.g. diabetes & alcoholism), may further enhance the sensitivity of this 
investigation. 
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SSEP. 
13 SSEP patient studies were carried out from 1983 – 1998.  One of these 
studies was a review article with no novel experimental data reported.  One 
report was a single case study on a recovering liver transplant patient.  Of the 
remaining 11, four were dedicated somatosensory evoked investigations; the 
remainder consisted of mixed EPs (visual and / or auditory). 
The combined patient total is 552 adults. The mean age of the patients 
was 42.412 yr. The age range was stated in only three studies, and combines to 
give, for the SEP group a range of 17 – 74yrs.    
The aetiologies vary markedly across the SEP patient group, and can be 
divided into four sets. 
Cirrhotic – unspecified, cryptogenic, idiopathic  
Cirrhosis – Alcoholic 
Chronic active hepatitis 
 Non Cirrhotic Liver disease:  
hepatocellular carcinoma 
metabolic coma secondary to hepatic insufficiency 
 
 
The selection criterion for patients was not stated in four of the studies; 
two papers selected their patients on an ‘inclusion’ basis, while the remainder 
used an ‘exclusion’ criterion. 
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INCLUSION EXCLUSION 
 No clinical signs of 
encephalopathy (HE0) 
 No medication within previous 
24hrs 
 
 previous h/o alcoholism 
 psychiatric illness 
 neurological trauma 
 current medication affecting CNS 
 infection 
 diabeties, renal failure, uremia 
 sedation within previous 24hrs 
 malnutrition 
 GI bleeding 
 Overt HE 
 
 
The assessment of hepatic encephalopathy was varied:  
Parsons-Smith (1957) 5 
Conn  4 
MMSE & Reitan 1 
N/A 1 
Not stated 1 
 
The diagnosis of the underlying pathology was not stated in four of the 
investigations.  Serum biochemistry was the exclusive diagnostic method in two 
studies, while biopsy only was reported in three studies. The remaining reports 
combined biopsy and serum biochemistry, with additional methods.  Specific 
biochemical parameters, where described, included serum albumin, NH3 and PT 
(which were common to all biochemical studies).  The other diagnostic methods 
were ultrasonography and endoscopy.  
 
In the SEP cohort two studies categorically stated that the somatosensory 
evoked potential adds no further information to a cirrhotic patient study 
(Mehndiratta et al 1990; Sandford et al 1987), while one report suggests that the 
SEP only alters in moderate-severe hepatic injury (Tarter et al 1987).  
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In both negative studies, the stimulus intensities were described as 
producing only ‘discernable’ & ‘minimal’ thenar muscle twitches respectively. 
Sandford et al (1987), in addition, did demonstrate a L / R side asymmetry such 
that there was a significant difference (p=<0.01) for a right limb N20 peak latency; 
they achieved this while using a sweep of 64 per average. Mehndiratta et al 
(1990) stimulated and recorded bilaterally but simply reported N19 and P23 
latencies; there is no data to suggest if one limb only was reported or if bilateral 
latencies were combined. Neither of these studies reported on IPLs.   
Tarter (1987) suggests that SEP sensitivity is low; however this study did 
not set out to test cirrhotic patients against controls, but attempted to 
demonstrate univariate correlations between a range of assessment methods, 
including IGC and fasting NH3.  There was no healthy control patient group to 
compare the SEP findings with.  
The SEP survey, in comparison to the VEP & BAEP studies, produces the 
highest positive outcomes with 77% demonstrating a patient cf control significant 
difference (VEP = 45%, BAEP = 70%).  Where cervicomedullary potentials were 
recorded in addition to the cortical components, one study found the peripheral 
latencies to be normal in the presence of an abnormal cortical potential.  The 
remaining studies, reported abnormalities in both the cortical and distal 
potentials. 
Stimulating parameters, where stated, were variable, within the positive 
yield, and only one reported a maximal twitch, which is specified in current 
clinical guidelines.  Stimulus rate and polarity (i.e. prevention of anodal blocking) 
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were not consistent across the SEP group, and may account for the overall yield.  
Where the findings were moderately significant, stricter attention to stimulating 
parameters may have increased the differences seen between controls and 
patients. 
Recording parameters were frequently not fully stated; where they were, 
there was little variation between studies and were close to accepted protocols.  
One exception was the sweep number which was only acceptable in six of the 
nine cases that stated it.  Electrode positioning however, was consistent and 
acceptable across this study group. 
Post processing was only clearly reported in two studies (Trzepacz et al 
1989a; Yang et al 1986).  Reproducibility, or the number of runs per trial, is 
unstated for most of the reports.  Similarly, where right and left limbs were 
stimulated and recorded, only two studies reported the findings separately; 
therefore the findings of the remaining reports may be a combined average or a 
‘preferred’ limb.  Only three studies failed to define the ‘abnormal’ latency values. 
The remainder, however were not consistent, with mean + 1, 2, 2.5 & 3SD all 
being employed; one paper, despite having a large control group, used absolute 
latencies for their normal values (N20 <22ms, P30 25-35ms). 
This is an encouraging survey, more so than the visual and brainstem 
auditory investigations.  The SEP studies have in common with the other 
modalities, the need to standardise the stimulus and recording parameters; in 
many cases these are not in keeping with current neurophysiological protocols.  
A strict recording regimen may possibly improve the positive yield of this already 
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effective investigation.  Patient selection, of course, will have to be similarly 
robust in order to prevent pathologies that affect the ascending pathways from 
becoming a confounding factor. 
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Cognitive  P300 
 
The overview is based on 12 patient studies carried out from 1976 – 2007. 
Eleven of these studies were dedicated P300 evoked investigations; the other 
was an assessment of the CNV investigation in this patient group. The combined 
patient total is 631 adults. The age of the adult patients, where stated, was 
45.912.5 yrs. The age range was indicated only in 3 papers; the age range from 
these studies was 19 – 75 yrs. 
The aetiologies varied across the P300 patient group, and can be divided 
into three sets. 
Exclusively cirrhotic: 4 studies 
Cirrhosis with other aetiologies: 7 studies 
Hepatitis (viral B, C, B&C) 
Primary Billiary Cirrhosis 
Gauchers Disease 
Drug overdose 
Cancer 
Cryptogenic 
Haemochromatosis 
 
Non-cirrhotic liver disease: 1 studies 
Hepatocellular liver disease 
 
The selection criterion for patients was not stated in one of the studies. 
The other papers selected on an ‘exclusion’ basis. There was no specific 
‘inclusion’ criterion stated, but this could be inferred in some studies from the 
stated methodology. 
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INCLUSION EXCLUSION 
 Language native to country of 
research centre 
 No alcohol within 2 weeks / 6 
months / 2 years 
 Normal sensory function 
 
 Alcoholic toxicity 
 Sedatives or centrally acting 
medication 
 Neurological conditions 
 Other major diseases 
 Overt HE (SHE / minimal HE 
studies) 
 
The assessment of hepatic encephalopathy was varied, but Conn et al 
(1977) was the most adopted for classification. 
 
Parsons-Smith (1957) 2 
Holm (1980) 1 
Conn 4 
Not stated / unspecified ‘clinical’ 
features 
5 
 
The diagnosis of the underlying pathology also varied, although it was not 
stated, or unspecified, in three of the investigations. Histology was used as the 
only diagnostic method in two studies, and in combination with imaging with a 
further one. Serum biochemistry was used in four studies; two were exclusive to 
the diagnosis, while one study each combined biochemistry with imaging and 
MMSE / NCT. This latter study was a pre- and post- transplant assessment.   
Specific biochemical parameters were not described in 2 patient groups; 
both of the other groups specified albumin, prothrombin time and bilirubin. The 
remaining study also stated venous ammonia & urea levels.  
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The P300 stimulus for 4 studies was visual, (three exclusively and one 
investigation both visual and auditory), while the remaining patient groups were 
stimulated by auditory paradigms only.  
 
 Visual P300 
Three of the four studies recorded one channel only (Oz), while the other 
study (Giger-Mateeva et al 2000) recorded all 4 midline positions. The recording 
electrode positions of all investigations corresponded to the 10-20 International 
System. The number of sweeps (flashes) per run was also variable, with one 
study (Giger-Mateeva et al 2000) using an ‘approximate’ with no further 
elaboration. Similarly, the ratio of common-to-rare varied so that in combination 
with the sweep numbers the patients would receive rare patterns numbering as 
little as 35 (Giger-Mateeva et al 2000) or up to 50 (Kulger et al 1992; Reeves et 
al 2007). In addition the rare visual angle varied in presentation, with 12.5′, 15′ & 
200′ check sizes and one not stated. Two studies utilised a larger check size for 
the common stimulus, and two studies utilised smaller checks for the common 
stimulus.  Stimulus intensity (luminance) and contrast was stated in two of the 
four studies and was appropriate for evoking visual responses.  
All four of theses studies stated the filter passband; three had either the 
low pass or high pass at an inappropriate setting, one having a particularly 
narrow bandwidth. 
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Auditory P300 
Four studies did not describe any electrode recording positions. Of the 
remaining five studies, three recorded from one midline channel, while only one 
(Amodio et al 2005) recorded from the other midline electrode positions. All the 
auditory P300 investigations recorded from standard 10-20 electrode placement 
positions.  
In the auditory P300 subgroup two studies did not state the sweep number 
while another stated a 20 minute limitation. The presentation of the rare tone 
varied in terms of the number of stimuli, with 32, 40, 150 & 160 stated. Six 
studies used 1000Hz & 2000Hz pairs of stimuli, one study 500Hz & 100Hz pairs 
and one study not stating. The rare tone was of higher frequency than the 
common tone for five studies and the opposite for the remaining two.  
Stimulus intensity was stated in five of the eight auditory studies. Where 
given the value was appropriate for this sensory modality; however only one 
study indicated dB SPL, but no study stated how the intensity related to patient 
hearing threshold. 
The amplifier passband was reported in all but one case; however, only 
one study (Gallai et al 1995) stated a bandwidth that would be acceptable for 
recording in a clinical neurophysiology department.  
Post processing procedures were stated in all but one of the study groups. 
Of these, seven identified the waveform morphology and so defined the peak for 
latency measurement. Abnormality was defined statistically in seven studies, by 
amplitude in two studies and not stated in two studies. Statistical abnormality 
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defined with a control group latency used mean + 2SD in six studies and +2.5SD 
in one. 
The reliability of the separate runs was not checked, in any study, by repetition 
and superimposition of sequential recordings. Therefore it is unclear whether the 
latency measurements are obtained from a ‘grand average’. 
Of the four studies that utilised visual stimulation only one found no 
significant differences between the patient and control groups for the P300 
latency. The stimulus parameters were in keeping with clinical neurophysiology 
protocols for VEP recording, however the amplifier bandwidth for recording was 
excessively narrow and only 35 rare presentations were averaged. In addition the 
exclusion criteria were particularly concise, stating only neurological and hepatic 
diseases. The aetiologies and assessment of HE was not stated. The other visual 
studies all showed some differences between the patient and control groups; all 
studies indicate that cirrhotics can be distinguished from controls while one study 
discriminated between cirrhotic and non-cirrhotic liver disease, but could not 
separate unimpaired and minimal HE.  
 In the patients who underwent auditory P300’s two studies stated that 
P300 findings are unspecific and provide little additional information in this patient 
group. One study (Hollabach et al 1997) described no significant differences 
between encephalopathic subgroups (HE0, HE1 & HE2), although there was a 
clear difference in latencies between all patients and controls. There was 
however, no correlation between P300 latency and Child’s score. A similar 
finding occurred in the other study (Amodio et al 2005) where the P300 is only 
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found to be altered where the EEG and psychometry are also abnormal. The 
former investigation stated appropriate recording parameters but did not state 
sweep number, instead indicating a variable rare tone presentation ratio. The 
latter study did not use the latency values for analysis but age-adjusted the 
measurements and obtained reference values from a database of control 
latencies. In addition to having no control data for the actual study, the stated 
highpass filter was relatively low, giving this patient group the narrowest 
recording passband of all the studies.  
 It appears that cognitive evoked potentials can highlight neurological 
alterations in patients with hepatic encephalopathy. Although there have been 
relatively few studies in this modality, the majority of investigations have indicated 
significant differences between patients and controls despite non-standardised 
stimulation, recording and post-processing protocols. The use of a more robust 
EP methodology may also highlight differences between the patient groups, 
particularly if strict inclusion / exclusion criteria and HE classification methods are 
adhered to.  
To conclude, the P300 cognitive evoked potentials have been recorded  in 
patients with hepatic encephalopathy; findings in previous studies are variable, 
but, when used as part of an array of investigations, they may be useful in 
monitoring neuropsychiatric status. 
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1.5 Signal Processing, Neurophysiology and Evoked Potentials. 
 
Introduction: waveform analysis. 
 The reading and interpretation of electrophysiological data has traditionally 
been undertaken by direct visual observation of the recording.  This involves a 
level of inherent subjectivity in judgement, which can, by definition, result in 
significant intra- and inter-observer variability in interpretation.  There is, therefore 
a need to provide an adjunct to direct interpretation a mathematically derived 
instrument which would remove the subjectivity of interpretation and which might 
provide further interpretive detail and meaning to the signal. 
 In physiological recordings a waveform can be defined as a single valued 
function of time or, f(t).  Much of medical literature omits labelling the ‘t’ axis 
because the shape of the waveform is considered to be more important than any 
further attempt at a quantitative analysis. A waveform may be periodic, e.g. f(t) = 
f(t + T), for a respiratory signal where T represents the time period between 
contributions, or f(t) = Sin 2t, for a 2 cycle/second sine wave.  
In neurophysiology and other disciplines involving biological signals 
waveforms are non-periodic.  These more arbitrary waveforms such as an 
ongoing ‘background’ EEG need to be broken down into a sequence of ordered 
segments, each contributing to f  at a delayed time t, such that f(t) at t = nT (the 
period between each contribution).  A set of functions will then be related through 
the process of integration.  
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 Continuous repeating waveforms can be represented by a summation of 
simple sinusoidal waves: the Fourier Series.  This effectively breaks waveforms 
such as the EEG down into component sine and cosine waves.  Raw EEG data 
is non-periodic and so the Fourier Transform converts a continuous signal into 
another function from waveform x(t) to X(ω) or X(f): 
 
X(ω) = 
∞∫-∞ x(t)e
–jωt . dt 
....... (eqn 1) where ω is in rad)* 
Or, 
 
X(f) = 
∞∫-∞ x(t)e
–j2πft . dt 
.............. (eqn 2) where f is in Hz)* 
 
*(after Kaiser 1994) 
 
This is simpler to process and interpret and as it is independent of the 
signal source it may be applied as a general analytical tool.  If a waveform 
contains periodic and non-periodic components the Fourier Transform will reveal 
the quantitative contribution of each to the overall signal – in terms of its 
frequency spectrum – and can then be examined in the frequency-domain.  The 
Fourier transform may be implemented by digital computation, the Fast Fourier 
Transform (FFT), which is an efficient version of the discrete or DFT. 
 The spectral density of a wave can be used to determine the power of a 
signal as a function of the frequency distribution, and is often associated with 
descriptions of finite stochastic waves. Power spectral density (PSD) is an 
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indication of the energy in the waveform per unit frequency (dB/Hz).  The power 
is usually the square of the FFT magnitude while the frequencies are either 
normalised or scaled with various constants (e.g. 1 / 2π).  The standard non-
parametric PSD method is a periodogram, which provides an estimate of the 
energy present.  It is an estimate because window functions are employed to 
correct spectral bias – the consequence of a truncated epoch in a finite time-
series; smoothing is also required because the variance of a given frequency in 
an unprocessed FFT spectrum does not decrease as the number of computed 
samples increases.  
 While the spectral density function PSD is derived from the FFT an 
intermediate stage, the so called autocorrelation function, which employs the 
Fourier cosine transform only, must be calculated.  As a result the magnitude and 
frequency information is retained but the phase information is lost.  The method 
of autocorrelation and the limitations of FFT will be revisited in the final 
discussion. 
A survey of spectral analysis of EPs is summarised in table 7.5 (Appendix III). 
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A brief survey of signal analysis: animal studies 
 Signal analysis for neurophysiological investigations has been utilized for 
the past three decades.  Ongoing and elicited neuronal activity has been studied 
for all sensory modalities while some motor system investigations have also been 
undertaken.  
Some studies have investigated aspects of instrumentation and were 
performed on healthy animals. For example, characteristics of stimulus 
parameters have been investigated for auditory (Kawasaki 1993; Finneran & 
Houser 2007), somatosensory (Beyssen 2004), and visual EPs (Asher 2007).  
The latter study which was undertaken in macaque monkeys also demonstrated 
that noise bands can be easily identified.  The spectral analysis methods were all 
based directly on a FFT or a FFT derived spectral estimate for example PSD.  
The other approaches to analysis include investigations into the correction of 
spectral leakage (Felix et al 2005; Felix 2009), which involves further calculations 
to derive coherence coefficients. Methods of invasive electrocortical recording 
have also been studied (Franowicz & Barth 1995).  
Signal analysis has been often employed to assess the effects on the nervous 
system of anaesthetics, analgesics and sedatives (Freye & Hartung 1983; Kaplan 
1977; Russell et al 1995), have been reported using FFT based methods, 
including compressed spectral array (CSA). Although these studies all reported 
power band changes in the background raw EEG, changes in the somatosensory 
evoked potentials were only reported in the time-domain, i.e. amplitude and 
latency measurements. Notable exceptions were early studies of the dose-effects  
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of the inhaled anaesthetic halothane, (Guarino 2004; Imas et al 2004) where 
PSD was used to analyse the VEPs. Investigations of the relationship between 
CNS anatomy and physiology using signal analysis have also utilised EPs.  The 
effect of cell specific neurotoxins has helped to highlight functional areas of the 
hippocampus (Heale et al 1995); here the activity of discrete cell populations in 
sensory processing is monitored by frequency-domain analysis.  More recently a 
relationship between the sensory and higher cortical areas been demonstrated 
(Liang 2002).  In visual processing in the macaque monkey PSD and coherence 
analysis has shown that a synchrony develops in the anticipation of a sensory 
input.  The electrophysiological activity isolated in this case was of an oscillatory 
nature in the beta-range.  
Central nervous system trauma, particularly hypoxic ischaemia, has been 
studied using spectral analysis of both SEPs and MEPs  (Simpson et al 1993a; 
Simpson et al 1993b; Brauna et al 1996).  
Aspects of induced CNS dysfunction have been highlighted in the frequency 
domain, again with multi-modal sensory EPs.  PSD analysis of VEPs has been 
undertaken in pharmacologically induced epileptic seizures (Fernandez-
Guardiola 1988). The visual system is also the sensory mode of choice for 
investigations into experimental diabetes (Yargicoglu 1998). A particularly 
relevant metabolic model – induced hepatic encephalopathy - has been studied 
using both visual and auditory EPs (De Groot et al 1985). Unfortunately, although 
PSD was carried out on the raw EEG data the VEP and BAEP were studied for 
latency and morphology changes only. 
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A brief survey of signal analysis: human studies 
Signal processing has also been used, albeit sporadically in human studies. 
Much of the work undertaken in healthy subjects has centred on the investigation 
of various aspects of instrumentation in physiological recordings. 
The effects of stimulus parameters for SEPs for example, rate and intensity 
(Rush JL 1976) was one of the earliest major studies to employ the FFT to 
highlight redistribution and enhancement of harmonic energy. The stimulus for 
motor evoked potentials (MEPs) also requires careful parameter selection (Kiers 
1993), and the effects of intensity, coil size state of subject alertness and muscle 
tone can be visualised by the FFT method.  In the visual system the effects of 
varying stimulus frequency, contrast, luminance and of monochromatic sensitivity 
have all been investigated and demonstrated with FFT derived PSD; the 
positions of the peaks in the α- and δ-power EEG bands are stimulus frequency 
dependant (Srinivasan 2006).  Similarly, the dominant spectral bands are altered 
for different contrasts and also for mono- versus binocular stimulation (Spileers 
1992), whilst the dominant FFT harmonic also varies as a function of wavelength 
(colour) and intensity of the light stimulus (Frederiksen 1993).  
Filter application also lends itself to study by PSD methods, particularly in 
evaluation or comparison of digital and analogue methods.  Digital filters can be 
selected to impose zero shift, confirmed by FFT, or compared with analogue 
filters for specific EP bandwidths (Kavanagh et al 1988; Skuse & Burke 1990; 
Shimoyama 2000).  The PSD is also well suited for final evaluation of 
autocorrelation/coherence analytical methods that attempt to improve signal to 
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noise ratios (Dobie & Wilson 1989; Winterer 1999). This has been studied 
extensively as EP signals have such a low amplitude with respect to the 
background EEG.  
Post-stimulus oscillations are of interest in somatosensory cortical function 
since middle latency (fast) and longer latency (slow) activity can confirm 
involvement of other structures possibly involved in cognitive processes.  FFT 
based power analysis of cortical activity has revealed dominant power bands 
phase locking with stimulus (Cheron 2007). However, the analysis used the EP 
measurements in the time-domain only. 
Functional neurodevelopment has been the subject of study for many years. 
Evaluation of sensory maturation in humans can be investigated with FFT 
analysis for raw EEG and EP data.  Median and maximum power bands can 
show maturational alterations in the visual system (Manas et al 1997), with 
hemispheric asymmetries. Unfortunately, the VEP recordings were assessed for 
latency only.  In the auditory system dominant spectral bands gradually evolve 
from a distinct neonatal appearance to an adult profile by migrating to higher 
frequencies (Lippe & Martinez-Montes 2009). 
Other evoked potentials that are not used in routine neurophysiology have 
also been investigated with signal processing methods. Emotional responses 
albeit by visual stimulation and occipital recording) produce FFT spectral bands 
that relate to the amplitude of skin conductance, i.e. emotional effect (Keil 2008). 
Olfaction potentials have also been investigated in a comparison of FFT and 
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Fractal Dimension (FD) analysis (Murali & Vladimir 2007); it is of interest here 
that FFT was insensitive to stimulation but the FD is altered for a range of stimuli. 
Signal processing methods have been employed to evaluate the effects of 
psychoactive drugs, such as chlorpromazine and olanzapine-and antivertiginous 
neuroactive medications such as cinnarizine, dimenhydrinate and betahistine on 
neurophysiological variables in healthy individuals.  Significant drug dose / 
plasma level dependant changes were observed n the EEG power spectra with 
both psychoactive and neuroactive drugs, (Hubl 2001; Laurian & Baumann 1981; 
Schneider  2003).  Changes were also observed in various sensory and cognitive 
EPs but the measurements were limited to assessments of wave latency and 
amplitude.  
Somatosensory EPs are frequently used for surgical and anaesthetic 
monitoring and coma assessment. Spectral SEP changes have been noted in 
studied of analgesia and depth of anaesthesia for SEPs (Bromm 1987), and 
AEPs (Capitanio 1997), although later studies only used the α-power on EEG for 
assessment although AEP amplitudes were monitored (Bischoff 1998; Plourde 
1997). Similarly evaluations of coma monitoring methods (with FFT derived 
CSAs) study auditory and somatosensory EPs for latency only, in both diagnosis 
of brain death (Shiogai 1989; Shiogai 1993), and for predictive outcome (Liesiene 
2006; Tsubokawa 1990). 
Signal analysis methods have been applied to study neurophysiological 
recording in patients with diverse disease states.  Patients with multiple sclerosis 
(MS) are frequently tested with multimodal sensory EPs; early FFT studies of 
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VEPs indicated that spectral peaks are altered in the pathological state (Bobak 
1983; Trick et al 1984), although latency measurements may increase the 
diagnostic yield.  Similarly, early studies of the main peaks in BAEP recordings 
revealed reduced power across the three main bands (Kamath et al 1987).  
Diagnosis of epilepsy and evaluation of patients suffering from migraine 
attacks are frequent sources of referral for neurophysiology and neurology 
investigations; although imaging and the EEG are the main investigations 
performed, the role of EPs has been evaluated.  Focal seizures (Meador et al 
1988a; Meador et al 1988b; Nuwer 1988) show altered PSD profiles on the EEG, 
normalising post-surgery, while encephalopathic myoclonus has a spectral profile 
similar to cortical myoclonus (Canafoglia 2003).  In the latter case, however, 
(Nuwer 1988) the SEP has been used only for latency measurements. FFT data 
from VEPs recorded during migraine attacks in adults (de Tommaso 1998) 
highlight dynamic changes in the main frequency components during the acute 
phase, while in juveniles (Marrelli 2001), there are significant differences between 
patients and controls.  
Studies within the field of psychiatry have also encompassed evoked 
potentials and signal processing methods.  Visual and auditory EPs have been 
analysed with PSD in patients with schizophrenia and show reduced power and 
frequency shifts (Jutai et al 1984; Krishnan 2009); a study of a subpopulation of 
psychiatric patients with substance abuse (Braverman & Blum 1996), has 
revealed significant power changes in the EEG spectra, but the EPs, including 
the cognitive P300, were only assessed for latencies.  Cognitive decline has also 
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been documented in Alzheimer’s and older people with non-specific decline. A 
VEP study compared FFT windowing techniques (Moody et al 1989) in this 
patient group, suggesting misclassifications were possible.  Further studies again 
quantified the EEG and not the EP (i.e. P300 latency measurements only) 
(Zappoli 1991a; Zappoli 1991b); this also occurred for evaluations of treatment of 
this patient group (Gallois 2002; Zimmermann 1982). 
Studies on a diverse range of metabolic pathologies have embraced 
neurophysiological waveforms as possible indicators of systemic function and in 
turn have performed PSD analysis on the recorded data.  The effects on the 
central nervous system of hypoglycaemia, (VEP), prolonged kidney dialysis (VEP 
& SEP), treatments for phenylketonuria (VEP), lead toxicity (all sensory & P300) 
and effects from the Chernobyl incident (SEP), have all been investigated  (Araki 
& Sato 2000; Harrad et al 1985; Lewis et al 1978; Loganovsky 2000; Pietz 1995). 
However, all of these studies performed quantitative analysis on the raw EEG 
data, but utilised the EP only for latency. 
There is a frequent occurrence of neurophysiological studies where the EEG 
is spectrally analysed - with positive results - but concomitant EP recordings are 
reported in the time-domain. In addition to the above, paediatric investigations of 
autism and other learning difficulties (Ogawa 1989; Pinkerton 1989) fall into this 
category. Studies in on the effects of lesions caused by stroke have also used 
EPs in this way with sensory (Iwayama 1979; Kusske et al 1980) and motor 
investigations (Gerloff 2006) used for latency confirmation, although the latter 
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study did employ EEG coherence analysis to investigate MEP stimulus following 
responses.  
The metabolic pathology of greatest interest in this study hepatic 
encephalopathy, and attempts to utilise neurophysiological data for detection and 
grading also has a long history. The earlier studies noted EEG α- and θ- power 
reductions in PSD in chronic liver disease in the presence of neuropsychiatric 
change (Trzepacz et al 1989b), while treatment of the condition resulted in 
clinical improvement and (Higuchi 1994) an increase in α-power increased and 
decrease in δ-power In these cases SEP, BAEP (former) and P300 (latter) were 
all recorded but used for latency confirmations. Visual EPs have also been 
adopted, as an adjunct to the EEG, for use in diagnosis of hepatic and 
encephalopathy and while spectral analysis of the EEG reveals a shift towards 
the lower frequencies (Kuba et al 1996), the EPs demonstrated sensitivity to the 
clinical state, but again in the time-domain. Spectral EEG analysis has also been 
accompanied by cognitive P300 investigation (Amodio et al 2005). The EP did 
not appear to correlate well with cognitive alteration (R = -0.03; p=0.76); spectral 
EEG was the most sensitive but only latencies were measured for the P300. 
 
There has been an interest in using signal processing methods to quantify 
neurophysiological waveforms since the mid 1970’s. Both animal and human 
experimental models have demonstrated that spectral peaks are observable and 
can be altered under a range of conditions. Instrumentation variables have been 
addressed, with some useful studies on EP stimulus parameter effects. 
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Investigations into animal and clinical physiology have been most varied, with a 
wide range of non-neurological pathologies studied with EEG and EP 
quantification. Signal processing of EPs within both neurology and hepatology 
appears to have been directed into EEG investigation, with the EPs used in the 
morphological context and a reduced emphasis on its signal content.  
  
 Marc Rayan Page 102 of 227 09/07/2013 
 
1.6 The Research Question and Aims of this Study 
There is currently no ‘gold standard’ for the diagnosis or monitoring of 
hepatic encephalopathy; the research question in this thesis is - can the evoked 
potential investigation, in combination with frequency analysis, provide a method 
for identifying this syndrome. 
 
The aims of this study are: 
1. 
Biopsy-proven cirrhotic patients, with independently classified neuropsychiatric 
status, will be subjected to VEP, BAEP, SEP and P300 investigations; latency 
data will be analysed to determine if there are significant alterations to latency 
occur between patients and healthy control subjects; comparisons will also be 
made between unimpaired, minimal and overtly encephalopathic patient groups.  
2. 
Voltage data from EPs will be examined by the spectral methods FT and PSD to 
determine if there are significant power and/or frequency differences between 
patient and control subjects and between patient groups. 
3. 
Where significant differences exist, to determine which analysis method (time-
domain, frequency-domain or time-frequency combination), has the greater ability 
to identify neuropsychiatric status. 
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Summary. 
EPs are quantitative, reproducible and sensitive extension of the 
neurological examination; they are an objective and primarily numerical 
measure of cortical function. Each EP modality requires careful attention to 
stimulation and recording parameters which must be standardised across the 
patient groups. Patient clinical history is required as is maintenance of 
compliance during the investigation.  
Hepatic encephalopathy is a neuropsychiatric complication of liver 
cirrhosis. The underlying pathophysiology is not fully understood and it may 
involve several processes. There is no diagnostic gold standard for hepatic 
encephalopathy and therefore may be under-diagnosed leading to quality of 
life issues.  
Previous EP recordings in patients with hepatic encephalopathy reveal low 
to modest positive yields; (VEP 45%, BAEP 71%, SSEP 77% and P300 66%). 
Some studies have inappropriate acquisition methodologies or unsuitable 
post processing methods, while others have inconsistent selection criteria 
with heterogeneous test groups. Neuropsychiatric characterisation was also 
inconsistent and often incomplete. 
An extensive survey of the literature reveals that spectral analysis 
methods have been performed on signals of neurophysiological origin; the 
previous studies range from animal sources to various human pathologies. 
EEG and EP frequency and power analysis has also been studied in normal 
subjects to investigate instrumentation issues. However, there are 
comparatively few studies specifically in hepatic encephalopathy; in these 
cases the EEGs were spectrally analysed while the EPs used for latency and 
morphological comparisons only. Frequency analysis of sensory and cognitive 
EP recordings therefore, has not been undertaken. 
The inconclusive EP history in this patient group combined with the 
absence of spectral processing form the basis of the research question: can 
spectrally analysed EPs identify neuropsychiatric changes in patients with 
hepatic encephalopathy.  
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The utility of latency and spectral analysis methods in evoked 
potential recordings from patients with hepatic encephalopathy. 
 
Chapter 2: Methods 
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Forward 
 
The previous chapter highlighted some of the issues that have hindered 
the diagnosis of hepatic encephalopathy. These include patient selection criteria 
and classification of encephalopathy which have been variable across the 
previous studies. The EP methodology has been similarly inconsistent; many 
studies have utilized unsuitable instrumentation parameters while few have 
investigated multiple modalities. 
The patient population groups in this study were subject to standardised 
inclusion and exclusion criteria. The assessments of mental state and 
psychometric performance were made under standardized conditions by 
consistent observers. Similarly the EP recordings were performed by a single 
observer using the clinically appropriate protocols and a consistent environment 
throughout. All patients and controls were systematically investigated, across all 
modalities, within an hour of neuropsychiatric assessment. 
The previous chapter also surveyed the application of frequency analysis 
in signals of neurophysiological origin. The majority of the previous studies 
investigated the EEG with much less emphasis on EP signals. A range of signal 
processing methods have been employed, although there has been very little 
application specifically in encephalopathic subjects for either animal models or 
clinical studies. The Fourier Transform and the power spectral density estimate 
are the two most reported analysis methods; these were both applied 
systematically to the multimodal EP signals obtained from the patients and 
controls.  
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2.1 Ethics. 
The study was conducted according to the Declaration of Helsinki (Hong 
Kong Amendment) and Good Clinical Practice (European guidelines). The 
protocol was approved by the Royal Free Hampstead NHS Trust Ethics 
Committee, Ref 6112 (appendix IV). All participating subjects provided written, 
informed consent. 
 
2.2 Control population. 
A control population of 48 healthy volunteers (25 men, 28 women; mean age 
39.8 [range 22-68] years) were recruited from colleagues working at the Royal 
Free Hospital, London, all with no previous neurological history. None had a 
history of liver disease, drank alcohol in excess of 20g daily, took prescription or 
over-the-counter medications or was visually impaired. 
 
2.3 Patient population. 
The test population consisted of 70 patients (47 men, 78 women; mean age 
[range] 55.1 [37-80] years) with biopsy-proven cirrhosis who were recruited 
between 2004 and 2008. The aetiology of the cirrhosis was determined using 
clinical, laboratory, radiological and histological variables. The severity was 
assessed using the Pugh modification of the Child’s grading system (Pugh et al 
1973). All patients were clinically stable at the time of the study. Patients were 
excluded if they were over 80 years of age; if they had suffered an episode of 
major hepatic decompensation within seven days of the assessment date; had 
significant cardiac, respiratory or renal failure; insulin dependent diabetes 
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mellitus; cerebrovascular disease; epilepsy; a history of significant head injury or 
other conditions likely to affect cerebral function. Patients were also excluded if 
they had misused alcohol or drugs in the previous three months; if their manual 
dexterity was impaired; if they could not speak English or obey spoken 
commands; or were taking psychoactive medications. 
 
2.4 Study Procedure 
Each recruited subject was assessed in a single session lasting approximately 
two hours. All EP assessments were completed dedicated recording room by a 
trained neurophysiologist. Electrode position notation corresponds to the 10-20 
International System measuring system (Neidermeyer & da Silva 1982). The 
EEGs and psychometric tests were performed in a dedicated clinical 
neurophysiology department. The procedures were carried out in the same order 
using a standard set of instructions from scripted texts. 
 
2.5 Neuropsychiatric Assessment 
Patients were clinically assessed by two hepatologists, working independently, 
and their mental state classified, using the West Haven Criteria (Conn et al 1977) 
as either clinically unimpaired or as showing features of overt hepatic 
encephalopathy. Psychometric performance was assessed using the PHES 
battery (Weissenborn et al 2001) which comprises five paper and pencil tests: 
digit symbol (DS), number connection A (NCT-A) and B (NCT-B), serial dotting 
(SD), and line tracing (LTT), which has both time and error components (LTTt 
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and LTTe). The PHES data in the original patient population were adjusted and 
scored using UK normative reference data (Marks et al 2008). Composite scores 
of less than two standard deviations below mean reference values were 
considered abnormal (Saxena et al 2001). Neuropsychiatric status on the day of 
the study was classified as: (i) unimpaired – no clinical evidence of hepatic 
encephalopathy and no psychometric abnormality; (ii) minimal hepatic 
encephalopathy - no clinical abnormalities but impaired psychometric 
performance; (iii) overt hepatic encephalopathy - clinically evident 
neuropsychiatric disturbances. 
 
2.6 Evoked Potentials 
Evoked potentials for visual, brainstem auditory, somatosensory (median nerve) 
and auditory cognitive modalities were recorded in one continuous session using 
an Oxford Medelec Synergy™ 8-channel dedicated recording device.  
Stimulation, recording and instrumentation settings were applied using BSCN 
approved protocols. Waveform peaks were identified as follows: VEPs - N75, 
P100 and N145; SEPs - N9, N13 and N20; BAEPs waves I – V; Cognitive 
Auditory - P300 (see Figs 1.1 & 1.2). All runs were repeated and inspected for 
superimposition prior to saving and analyzing.  Measurement cursors for latency 
were placed on waveform peaks using Synergy Reader™ version 10 software. 
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2.7.Protocols for evoked potential recording. 
 
2.7.1 VEP 
Recording sites 
• Active electrodes are placed at O1, Oz, and O2 
• Reference electrode at Fz 
• Ground is placed at Cz 
• Bipolar/common reference montage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Recording parameters 
• Minimum of 1-100Hz bandwidth 
• No notch filter 
• 250msec timebase 
• 120 reversals per trial 
• At least two reproducible traces 
Pattern Stimulation 
• Check size: two sizes -  1° and 15´ checks 
• Contrast: >75% 
• Reversal rate:1.9/sec 
• Luminance: white >280cd/m2 
• Visual Field: >15deg 
Fz 
Oz 
O2 O1 
Fig 2.7.1: Recording electrode placement for VEP 
VEP 
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Other Techniques. 
• Position patient with line of sight slightly above fixation point 
• Ensure head is supported and try to relax patient. 
• Ensure proper refraction and that the pupil is not occluded (e.g.. ptosis) 
• Watch for fixation, and monitor on-going EEG - encourage patient to 
remain alert 
• Monitor blink rate 
 
 
Fig 2.7.2 (above): a typical pVEP setup. 
 
 
 
 
 
 
 
 
 
 
 
 
 Marc Rayan Page 111 of 227 09/07/2013 
2.7.2 BAEP 
 
Recording sites  
 Bipolar montage: Channel 1 Cz-A1; Channel 2 Cz-A2 
 Active electrodes: A1/A2    
 Reference electrode: Cz 
 Ground: Fpz 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recording parameters 
• Time-base: 
Threshold: 15 - 20ms 
Neurological: 12 - 15ms 
• Filters:  
Threshold - 20Hz - 1.5 KHz 
Neurological - 100Hz - 5 KHz 
• Sweep: 1500 - 3000     
• Reps: 2 - 3 
• Masking noise: 40dB below stimulus intensity 
 
 Cz 
A2 A1 
Gnd 
Fig 2.7.3: Recording electrode placement for BAEP 
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Stimulus parameters 
 
• Stimulus Type: broad band click 
• Stimulus Rate: 8-11/sec  
• Stimulus Intensity: 80-100dB 
• Stimulus Click Polarity: ‘Alternating’ (condensation/rarefaction) 
Masking noise 
• The stimulus is conducted by the skull and may reach the opposite ear 
and although being attenuated by 50-60dB, can still excite it. 
• Masking noise is constant white noise and is used to prevent this 
cross-stimulation during testing. 
• Intensity of 40dB below the stimulus intensity.   
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2.7.3 SEP 
 
Upper limb recording – median nerve 
 
 
Fig 2.7.4: Upper limb recording placement. 
 
Recording parameters 
• Time base: (upper limb):  50ms 
• Filter bandpass: 1-5Hz - 2.5-3KHz 
• Epochs: 200 - 250 
 
Stimulus parameters 
• Electrical pulse-constant current 
• Duration: 0.05 - 0.5ms 
• Rate: 2 – 5Hz 
• Intensity:  approx. 3x sensory threshold 
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2.7.4 Cognitive Auditory P300 
 
Recording sites 
• Bipolar montage: 
Channel 1: Fz-A1/A2 
Channel 2: Cz- A1/A2 
Channel 3: Pz- A1/A2 
Channel 4: Oz- A1/A2 
Active electrodes: Fz, Cz, Pz & Oz 
• Reference electrode: A1/A2 - combined 
• Ground: Fpz 
 
Fig 2.7.5: Recording electrode placement for P300 
 
 
Recording parameters 
 
• Time-base:500ms 
• Filters: 0.10Hz - 100Hz 
• Sweep: 100    
• Reps: 2 (odd / even averaged separately) 
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Stimulus parameters 
 
• Stimulus Type: pure tone ‘pip’, pseudorandom 
• Common probability: 0.8 
• Rare probability: 0.2 
• Stimulus frequency :  
• Common 1000Hz 
• Rare 1500Hz 
• Stimulus Rate: 1/sec  
• Stimulus Intensity: 50dB above hearing threshold 
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2.8 Frequency analysis  
Each patient recording comprised of two superimposed EP runs, per modality, for 
each hemisphere; left and right side waveforms were then added to make a 
grand EP average for the patient. The signal voltage data from each EP modality 
was exported and processed in Matlab™ (version 7.2). Each waveform was 
subjected to Fourier Transform (FT) and power spectral density estimates (PSD) 
computation. The frequencies of the main and secondary harmonics (peaks) 
were identified from the FTs; the maximum power, mean power and frequency at 
maximum power were recorded from the PSDs. 
2.9 Statistical analysis. 
Statistical analysis was performed with Minitab™ (version 16). Distributions of EP 
data sets were tested by the Anderson-Darling test. Differences between non-
normally distributed group variables were examined using the Kruskall-Wallace 
test; subsequent comparisons within the group made with the Mann-Whitney test.  
The sensitivity and specificity of each EP investigation was assessed using ROC 
curve analysis; this was performed for the main latency peaks identified for each 
EP modality. Similarly for the frequency domain, ROC analysis determined 
sensitivity and specificity for each parameter: PSD (peak power, mean power and 
frequency at peak power) and FT (main and secondary harmonics). 
 The ROC data was used to determine a threshold for each parameter to 
distinguish between neuropsychiatrically impaired and unimpaired patients. For 
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practical purposes, the control and unimpaired patients were combined into one 
group and the minimal and overt HE were combined into a second.  
Multivariate analysis was performed by binary logistic regression, using the 
thresholds obtained from the ROC analysis, to determine the diagnostic validity 
of the latency and frequency tests in various combinations. 
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Summary 
 A population of patients and controls were recruited, selected and 
assessed for their degree of neuropsychiatric impairment; EPs were then 
performed in multi-sensory and cognitive modes. Voltage data was subjected to 
frequency and power analysis by FT and PSD methods, the observer / operator 
being blind to the neuropsychiatric state of the patient. The latencies of the main 
components, the frequencies of the main peaks and the power at these peaks 
were statistically analysed. Comparisons between controls and patients and 
between patient groups were made, as were sensitivity / specificity of time and 
frequency domain investigations, both separately and in combinations. 
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The utility of latency and spectral analysis methods in evoked 
potential recordings from patients with hepatic encephalopathy. 
 
Chapter 3: Results 
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Forward. 
Controls and patients with hepatic encephalopathy were recruited, 
adhering strictly to standardised inclusion and exclusion criteria. Multimodal 
evoked potentials were obtained for the four test populations: (controls, 
unimpaired patients and patients with minimal and overt hepatic 
encephalopathy).  
EP latency data for each modality were examined by non-parametric 
comparative statistical analysis to determine whether any differences occurred 
between patients and controls or between patient sub-groups. The frequency 
domain data (FT and PSD) from each EP modality was similarly examined by 
comparative statistical methods. 
 Both time-domain and frequency-domain data were applied in ROC 
calculations to determine the sensitivity and specificity for latency, frequency and 
power thresholds in each EP modality. Using thresholds with appropriate 
sensitivity and optimal AUC’s (area under curve) latency, frequency and power 
values were selected for multivariate binary logic regression analysis, in order to 
distinguish between the neuropsychiatrically impaired and non-impaired.
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3.1 Subjects. 
 
The liver disease was alcohol-related in 50 (71%), cryptogenic in 3 (4%); 
alcohol/hepatitis B or C infection in 5 (7%); primary billiary cirrhosis in 3 (4%) and 
miscellaneous in 9 (13%). Functionally, 36 (51.5%) of the patients were classified 
as Child’s Grade A, 20 (28.5%) as Child’s Grade B, and 14 (20%) as Child’s 
Grade C (Table 3.0.1). 
Evoked Potentials were recorded from 48 healthy control subjects (25 men, 23 
women; mean [range] age 39.8 [22 – 68] years), and from 70 patients with 
biopsy-proven cirrhosis (47 men, 23 women; mean [range] age 55.1 [37 – 80] 
years). On the day of study, 27 (38.6%) of the 70 patients were classified as 
neuropsychiatrically unimpaired, 13 (18.6%) as having minimal and 30 (42.6%) 
as having overt hepatic encephalopathy.  PHES and EEG variables were 
significantly different between controls and patient subgroups (Table 3.0).   
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Table 3.0: Demographic and assessment variables in the study population, by 
degree of neuropsychiatric impairment. 
 Controls 
(n=48) 
All patients 
(n=70) 
Unimpaired 
(n=27) 
Minimal HE 
(n=13) 
Overt HE 
(n=30) 
Age 39.8 
(22-68) 
55.1 
(37-80) 
54.5* 
(43-76) 
57.2* 
(43-76) 
54.7* 
(37-78) 
Gender 
(% male) 
52 67 55 69 76 
Child-Pugh 
(5-15) 
 7.3±2.9 
(5-14) 
5.7±1.9 
(5-12) 
5.7±1.0♦♦ 
(5-8) 
9.9±2.6## 
(6-14) 
PHES 
(z score) 
 -1.6±1.7 
(-8.1; 1.1) 
-0.5±0.8 
(-1.8; 0.8) 
-2.0±1.4# 
(-4.1; 1.1) 
-3.0±2.0## 
(-8.1; -1.5) 
PHES abnormal 
n (%) 
 16 
(29.6) 
0 
(0) 
7 
(53.8) 
9 
(60) 
EEG 
MDF P3-P4 (Hz) 
 9.4±2.2 
(4.9-16.9) 
10.5±1.3 
(8.1-12.4) 
9.6±1.7♦ 
(6.4-12.3) 
8.0±2.7## 
(4.9-16.9) 
Theta P3-P4 
(%) 
 26.4±17.4 
(5.7-72) 
14.4±6.6 
(5.7-29.8) 
31.8±19.3# 
(10.9-72) 
37.9±15.5## 
(8.0-65.5) 
Abnormal EEG 
report: n (%) 
 25 
(42) 
0 
(0) 
7 
(54) 
18 
(86) 
Data are expressed as mean ± standard deviation (range) or absolute number (%). 
PHES data were available in 54 patients (unimpaired = 26, minimal = 13, overt 15);  
P3P4 spectral EEG data were available in 60 patients (unimpaired = 26, minimal = 13, 
overt = 21). 
Significance of the differences between the control population and the patient subgroups: 
*p <0.001  
Significance of the differences between the unimpaired patients and the patients with 
minimal/overt HE: #p <0.005; ##p <0.001 
Significance of the differences between the patients with minimal and overt HE:  
♦p <0.05; ♦♦p<0.001 
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Table 3.0.1: Liver disease aetiology in the study population, by degree of 
neuropsychiatric impairment 
 
Aetiology Unimpaired 
(n=27) 
Minimal HE 
(n=13) 
Overt HE 
(n=30) 
Alcohol-related 
n (%) 
22 
(81.5) 
11 
(84.6) 
17 
(56.6) 
Alcohol + HCV 
n (%) 
1 
(3.7) 
2 
(15.4) 
2 
(6.7) 
PBC 
n (%) 
- - 3 
(10) 
Cryptogenic 
n (%) 
1 
(3.7) 
- 2 
(6.7) 
Haemochromatosis 
n (%) 
1 
(3.7) 
- - 
NASH 
n (%) 
1 
(3.7) 
- 1 
(3.3) 
n/a 
n (%) 
1 
(3.7) 
- 5 
(16.7) 
 
Data is expressed as absolute number (%); aetiology data was available for 64 
patients. HCV – hepatitis C virus; PBC – primary billiary cirrhosis;  
NASH – non-alcoholic steatohepatitis 
 
3.2 Evoked Potential Latencies. 
 
3.2.1 Visual Evoked Potential (VEP). 
 
Three patients (2 overt and 1 unimpaired) were unable to tolorate stimulation 
for both eyes; these data sets are derived from one hemishere only. One overt 
patient could not tolarate the test. One overt patient had an unreadable N145 
peak; their N145 data set therefore comprised of one hemisphere. 
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VEP latencies were prolonged in all three patient subgroups compared to the 
healthy controls (Table 3.1); the N75 and P100 peak latencies were significantly 
prolonged in all three patients’ subgroups (Figure 3.1) while the differences in 
latencies between patients and controls were less marked for the N145 peak. A 
significant difference for the N145 also occurred between the unimpaired patients 
and those with minimal HE. 
 
 
Table 3.1: VEP latencies in healthy control subjects and patients with cirrhosis, 
by degree of neuropsychiatric impairment 
Evoked 
Potential 
Controls 
(n = 48) 
Unimpaired 
(n=27) 
Minimal  
(n= 13) 
Overt 
(n=29 / 28*) 
VEP (ms)     
N75 73.7±5.5 80±8.2*** 79.1±8.8** 81.5±7.2**** 
P100 101.7±4.5 106.5±5.5*** 110.1±7***** 108.1±7.7**** 
N145* 137.0±10.2 137.8±10.8º 145.6±12* 142.2±9.9 
Data are expressed as (mean ± SD) for VEP latencies  
Significance of the difference from controls: *p < 0.05; **p <0.01; *** p <0.005; ****p <0.001;  
*****p <0.0001. 
Significance of the difference from patients with minimal HE: °p < 0.05;  
 
(Overleaf Fig 3.1: Visual Evoked Potentials)
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Figure 3.1: Visual Evoked Potentials 
 
•  LEFT: Recordings obtained from pattern     
 stimulation with main waveforms marked: 
 
              control,  
     patient with overt HE 
 
•  BELOW: Box plots of results from controls, and 
patient groups: unimpaired, minimal HE, overt HE  
 
Data are median, mean and 95%CI; significant 
differences are inset. 
 
 * p = <0.05 
** p = 0.01   
*** p = 0.005 
**** p = 0.001 
***** p = <0.0001 
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 3.2.2 Somatosensory Evoked Potentials (SSEP) 
 
Two overt patients were unable to tolarate stimulation on both limbs; these 
data sets are derived from one hemishere only. One overt patient could not 
tolarate the test.  Two patients (one minimal HE  and one unimpaired)  had an 
unreadable N20 peak for one hemisphere;  their data sets were unilateral for 
N20. 
Significant differences are found between the control and all patient 
groups for the N9 and N13 peaks, the overt HE patients having the greatest 
difference and the minimal HE the least (Table 3.2). The cortical N20 component 
demonstrates significant latency differences between the controls and the 
unimpaired and overt patients but not for the minimal HE group. There are no 
differences observed between the patient groups for any of the peaks. 
 
 
Table 3.2: SEP latencies in healthy control subjects and patients with cirrhosis, 
by degree of neuropsychiatric impairment. 
 
Evoked 
Potential 
Controls 
(n = 48) 
Unimpaired 
(n=27) 
Minimal  
(n= 13) 
Overt 
(n=29) 
SEP (ms)     
N9 9.9±0.7 11.0±1.2*** 10.6±1.4* 11.3±0.8***** 
N13 13.2±0.9 14.7±1.4*** 14.8±1.8** 14.9±0.9***** 
N20 19.1±1.0 20.9±1.5**** 20.4±2.0 20.9±1.5***** 
Data are expressed as (mean ± SD) for SEP latencies  
Significance of the difference from controls: *p < 0.05; **p <0.01; *** p <0.005; ****p <0.001;  
*****p <0.0001. 
 
 
 
(Overleaf Fig 3.2: Somatosensory Evoked Potentials ) 
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Figure 3.2: Somatosensory 
Evoked Potentials 
• LEFT: Waveforms obtained by 
electrical stimulation of the median 
nerve at the wrist, with peripheral, 
cervico-medullary and cortical 
markers. SSEP data from: 
   control   
   patient with minimal HE 
   patient with overt HE  
• BELOW: Box plots of results from 
controls and patient groups: 
unimpaired, minimal HE, and overt 
HE. 
Data are median, mean and 95% CI; 
significant differences are inset. 
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3.2.3 Brainstem Auditory Evoked Potentials (BAEP). 
 
One unimpaired and three overt patients were unable to tolarate stimulation of 
both ears; these data sets are derived from one hemishere only. Two patients (one 
overt HE  and one unimpaired)  had an unreadable  ‘wave V’ peak for one 
hemisphere; the wave V data for these patients comprise of one hemipshere only. 
 
Significant differences occur between the unimpaired and overt HE patients 
vs. controls for BAEP wave III (Table 3.3, Fig 3.3). Wave V demonstrated similar 
changes where all three test groups were significantly different from the control 
group. Additionally, between patient groups the overt HE’s significantly differed in 
latency from the unimpaired patients.  
 
Table 3.3: BAEP latencies in healthy control subjects and patients with cirrhosis, by 
degree of neuropsychiatric impairment. 
Evoked 
Potential 
Controls 
(n = 48) 
Unimpaired 
(n=27) 
Minimal  
(n= 13) 
Overt 
(n=30) 
BAEP (ms)     
Wave III 3.7±0.2 3.8±0.2** 3.7±0.2 3.9±0.2*** 
Wave V 5.6±0.2 5.8±0.2*+ 5.8±0.3** 5.9±0.3***** 
Data are expressed as (mean ± SD) for BAEP latencies  
Significance of the difference from controls: *p < 0.05; **p <0.01; *** p <0.005; *****p <0.0001. 
Significance of the difference from overt HE: +p < 0.05. 
 
 
 
 
 
 
(Overleaf Fig 3.3 : Brainstem Auditory Evoked Potentials 
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Figure 3.3 : Brainstem Auditory 
Evoked Potentials 
• LEFT: Recordings obtained from a 
click  stimulus with main 
waveforms marked: 
            control,  
    patient with overt HE 
 
•  BELOW: Box plots of results from 
controls and patient groups: 
unimpaired, minimal HE and overt 
HE.  
Data are median, mean and 95%CI; 
significant differences are inset. 
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3.2.4 Auditory Cognitive Evoked Potential (P300). 
 
Four overt patients were unable to comply with the test. One overt and one 
minimal HE patient were co-operative but had unreadable waveforms. One 
unimpaired patient was co-operative but was unable to understand the instructions 
of the test; their waveform was excluded. 
 
Cognitive P300 latencies were prolonged for all patient groups compared to 
the control population, with the overt HE group more significantly than the 
unimpaired or the minimal HE patients (Table 3.4). The mean P300 peak latency of 
the overt HE patient group was also significantly prolonged compared to the two 
other patient populations, the minimal HE more than the unimpaired patient group 
(Fig 3.4) 
 
 
Table 3.4: P300 latencies in healthy control subjects and patients with cirrhosis, by 
degree of neuropsychiatric impairment. 
Evoked 
Potential 
Controls 
(n = 48) 
Unimpaired 
(n=26) 
Minimal  
(n= 12) 
Overt 
(n=25) 
Auditory Cognitive (ms) 
P300 306.5±19.4 354.3±55.4**+ 351.8±44.9**+++ 401.5±42.4*****  
Data are expressed as (mean ± SD) for the P300 latencies – derived from electrode Pz 
Significance of the difference from controls:  **p <0.01, *** p <0.005, *****p <0.0001. 
Significance of the difference from patients with overt HE: +p < 0.05, +++p <0.005. 
 
 
 
 
 
 
(Overleaf Fig 3.4: Cognitive Auditory (P300) Evoked Potential 
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Figure 3.4: Cognitive Auditory (P300) Evoked 
Potential 
• LEFT: Waveforms obtained from an auditory ‘odd-ball’ 
stimulus; the frequent tone is the dashed line, the rare 
tone average is solid. The P300 marker is present in the 
control subject: 
    control subject 
    unimpaired 
    minimal HE 
    overt HE 
• BELOW: Box plots of results from controls and patient 
groups: unimpaired, minimal HE and overt HE. 
 
Data are median, mean and 95% CI; significant differences 
are inset. 
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3.3 EP Frequency and Power analysis (I): Fourier Transforms 
 
 Voltage data was exported for frequency and power computation for a 
population of controls and patients. The control group consisted of 17 EP data sets 
(13 men, 4 women; mean age [range] 43.8 [22 – 68] years). 41 sets of patient EP 
data were analysed; (22 men, 21 women; mean age [range] 54.2 [41 – 78] years). 
On the day of the EP recordings the patients were classified into their 
neuropsychiatric status as either unimpaired (n = 18; 44%) or having minimal (n = 
11; 27%) or overt (n = 12; 29%) hepatic encephalopathy. 
 
3.3.1 Fourier Transform – VEP 
All patient waveforms comprised of a bilateral grand averaged VEP. 76% 
(13/17) of the controls demonstrated two or more main frequency peaks (Fig 3.5), 
compared with 56% (10/18) unimpaired HE, 45% (5/11) minimal HE and 8% (1/12) 
overt HE. 
For the main and secondary peaks there were significant differences between 
the patients and controls (Table 3.5). The main peak (FFT-1) in the healthy controls 
had a higher frequency than the unimpaired and the overt HE patients. Similarly, for 
the secondary peak (FFT-2) the control group frequency was higher than for both 
the unimpaired and the minimal. Statistical analysis for the overt HE group was not 
possible as the FFT-2 peak was absent in all but one patient. There are also 
differences between patient groups.  For the secondary peak frequency FFT-2, the 
unimpaired group has a higher frequency than the minimal HE’s.  
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Table 3.5: VEP frequency in healthy control subjects and patients with cirrhosis, by 
degree of neuropsychiatric impairment. 
 
Evoked  
Potential 
Controls 
(n = 17) 
Unimpaired 
(n=18) 
Minimal  
(n= 11) 
Overt 
(n=12) 
VEP (Hz) 
FFT-1 1.02±0.2 0.59±0.4**** 0.84±0.5 0.63±0.4* 
FFT-2 1.98±0.5 1.53±0.2**ºº 1.16±0.4**** 1.40±0 
Data are expressed as (mean ± SD) for VEP frequency components.  
Differences from controls: *p < 0.05, **p <0.01, *** p <0.005, ****p <0.001, *****p <0.0001. 
Differences from: minimal HE: °p < 0.05, °°p < 0.01 
 
(Overleaf Fig 3.5: Discrete Fourier Transforms   of Visual Evoked Potentials). 
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Figure 3.5: Discrete Fourier Transforms   
of Visual Evoked Potentials. 
 
 LEFT: Frequency components from 
control (far) and patients: unimpaired 
(mid) and overt HE (near) 
 BELOW: Left – VEP traces from 
controls (upper) and patients: 
 unimpaired (mid), overt HE (lower). 
Right - Box plots of results from 
controls and patient groups: 
unimpaired, minimal HE and overt HE. 
Data are median, mean and 95% 
CI; significant differences are inset. 
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3.3.2 Fourier Transform – SSEP 
The data from one overt patient was derived from a unilateral signal.  
Two components, the main (FFT-1) and secondary (FFT-2) are observed in 
the frequency domain (Figure 3.6). Two peaks occur in all healthy controls and in all 
patients across the HE groups; the independence of FFT-1 sub-populations was 
rejected, but accepted for FFT-2. The unimpaired HE group had a significantly 
higher frequency than the healthy controls, minimal HE and overt HE patients (Table 
3.6) 
Table 3.6: SSEP frequency in healthy control subjects and patients with cirrhosis, by 
degree of neuropsychiatric impairment. 
Evoked  
Potential 
Controls 
(n = 17) 
Unimpaired 
(n=18) 
Minimal  
(n= 11) 
Overt 
(n=12) 
SSEP (Hz) 
FFT-1 6.44±2.8 7.59±4.2 5.80±2.6 6.64±2.9 
FFT-2 25.88±6.7 35.53±10.99****ººº+ 28.80±8.33 27.56±11.0 
Data are expressed as (mean ± SD) for SSEP frequency components.  
Differences from controls: ****p <0.001. 
Differences from overt HE: +p < 0.05. 
Differences from: minimal HE: °°°p < 0.005. 
 
 
 
 
(Overleaf Fig 3.6: Discrete Fourier Transforms of Somatosensory Evoked Potentials). 
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Figure 3.6: Discrete Fourier Transforms of 
Somatosensory Evoked Potentials. 
 
 LEFT: Frequency components from 
control and patients: (far left - right) 
unimpaired, minimal HE  and overt HE 
 BELOW: Left – SSEP traces from 
controls and patients: (upper – lower) 
unimpaired, minimal HE and overt HE. 
Right - Box plots of results from 
controls and patient groups: 
unimpaired, minimal HE and overt HE.  
 
Data are median, mean and 95% CI; 
significant differences are inset. 
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3.3.3 Fourier Transform – BAEP 
 
 
The data from one overt patient was derived from a unilateral signal.  
Two components, the main (FFT-1) and secondary (FFT-2) are observed in 
the frequency domain. The two peaks occur in all healthy controls and across all 
patient groups (Fig 3.7).  
The unimpaired patients demonstrated a significantly higher frequency 
compared to the controls and other patient groups for the FFT-1 peak. No other inter 
group differences were observed.  
For the secondary FFT-2 peak the minimal and overt HE patients had a 
significantly lower frequency compared to the healthy controls and the unimpaired 
groups (Table 3.7) 
 
Table 3.7: BAEP frequency in healthy control subjects and patients with cirrhosis, by 
degree of neuropsychiatric impairment. 
Evoked  
Potential 
Controls 
(n = 17) 
Unimpaired 
(n=18) 
Minimal  
(n= 11) 
Overt 
(n=12) 
BAEP (Hz) 
FFT-1 31.57±22.1 57.17±38.35*ººº+++ 32.25±27.6 24.01±6.0 
FFT-2 94.49±32.2 89.07±31.1ºº+++ 62.50±32.1*** 58.89±22.1*** 
Data are expressed as (mean ± SD) for BAEP frequency components.  
Differences from controls: *p <0.05, ***p <0.005 
Differences from overt HE: +++p < 0.005. 
Differences from: minimal HE: °°p < 0.01, °°°p < 0.005 
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Figure 3.7: Discrete Fourier 
Transforms of Brainstem Auditory 
Evoked Potentials. 
 
 LEFT: Frequency components 
from control and patients: (far left 
- right) unimpaired, minimal HE  
and overt HE 
 BELOW: Left – BAEP traces from 
controls and patients: (upper – 
lower) unimpaired, minimal HE 
and overt HE. Right - Box plots of 
results from controls and patient 
groups: unimpaired, minimal HE 
and overt HE.  
Data are median, mean and 95% CI; 
significant differences are inset. 
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3.3.4 Fourier Transform – P300 
All patient waveforms consist of a signal midline signal (derived from 
electrode Pz). Consistency was confirmed by averaging odd and even sweeps 
separately and adding superimposed signals to make an average for the individual. 
Two main frequency peaks, the main (FFT-1) and secondary (FFT-2) are observed 
in the auditory P300; these occurred in all healthy controls and in all individuals for 
the patient sub-groups (Figure 3.8).   
The unimpaired patients had a significantly higher main (FFT-1) peak 
frequency compared to the minimal and overt HE patients (Table 3.8). No significant 
differences were observed for the secondary peak. 
 
 
Table 3.8: P300 frequency in healthy control subjects and patients with cirrhosis, by 
degree of neuropsychiatric impairment. 
 
Evoked  
Potential 
Controls 
(n = 17) 
Unimpaired 
(n=18) 
Minimal  
(n=11) 
Overt 
(n=12) 
P300 Auditory Cognitive (Hz) 
FFT-1 0.29±0.1 0.35±0.1ºº+++ 0.28±0.1 0.32±0.2 
FFT-2 2.02±0.5 1.93±0.5 1.87±0.6 2.05±1.1 
Data are expressed as (mean ± SD) for P300 frequency components.  
Differences from overt HE: +++p < 0.005. 
Differences from: minimal HE: °°p < 0.01. 
 
 
 
 
 
 
(Overleaf Fig 3.8: Discrete Fourier Transforms of Cognitive P300 Auditory Evoked Potentials). 
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Figure 3.8: Discrete Fourier Transforms of 
Cognitive P300 Auditory Evoked Potentials. 
 
 LEFT: Frequency components from 
control and patients: (far left - right) 
unimpaired, minimal HE  and overt HE 
 BELOW: Left – BAEP traces from 
controls and patients: (upper – lower) 
unimpaired, minimal HE and overt HE. 
Right - Box plots of results from 
controls and patient groups: 
unimpaired, minimal HE and overt HE.  
Data are median, mean and 95% CI; 
significant differences are inset. 
 
** p = 0.01 
*** p = <0.005 
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3.4 EP Frequency and Power analysis (II): Power Spectral Density Estimates (PSD) 
 
3.4.1 PSD – VEP 
There is a significant reduction in peak frequency between the controls and 
both the minimal HE and overt HE patients (Figure 3.9). There are also differences 
within the patient groups; a significant reduction in peak frequency is observed 
between the unimpaired patients and both the minimal HE and overt HE groups 
(Table 3.9). No significant differences occurred between any group for the VEP 
maximum power or mean power. 
 
 
Table 3.9: PSD estimates of VEPs in healthy control subjects and patients with 
cirrhosis, by degree of neuropsychiatric impairment. 
Evoked  
Potential 
Controls 
(n=17) 
Unimpaired 
(n=18) 
Minimal  
(n=12) 
Overt 
(n=12) 
VEP  
 P(max) dB/Hz -4.31±4.3 -6.37±5.7 -4.52±3.5 -4.66±5.2 
 P(mean) dB/Hz -58.57±5.1 -51.29±31.6 -58.39±4.9 -58.42±3.9 
F(peak) Hz 12.11±3.9 11.12±4.2°°°++++ 7.95±4.6**** 6.1±3.5**** 
Data are expressed as (mean ± SD) for VEP frequency at peak power.  
Differences from controls: ****p <0.001. 
Differences from overt HE: ++++p <0.001. 
Differences from: minimal HE: °°°p <0.005. 
 
 
 
 
(Overleaf Fig 3.9: Power Spectral Density (PSD) Estimates of Visual Evoked Potentials). 
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Figure 3.9: Power Spectral Density (PSD) Estimates of Visual 
Evoked Potentials. 
 
 LEFT: PSD components from control (upper-far) and 
patients: unimpaired (upper-near), minimal HE  and overt 
HE (lower-far & near) 
 
 ABOVE: Box plots of results from con                                                                                                                                                                                                                                              
trols and patient groups: unimpaired, minimal HE and overt 
HE.  
 
Data are median, mean and 95% CI; significant differences are 
inset. 
 
 
 
 
 
 
 *** p = <0.005 
**** p = <0.001 
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3.4.2 PSD – SSEP 
 
There is an increase in peak cortical SSEP power for all patient groups 
compared to the controls (Figure 3.10), with the greatest significances seen with the 
unimpaired and minimal HE patients. Differences between patient sub-populations 
are not significant at the 0.05 level.   
There is a significant reduction of the frequency at peak power across all 
patient groups compared to the control subjects; there is also significant decrease in 
frequency at peak power between the unimpaired and minimal HE patients (Table 
3.10). 
 
Table 3.10: PSD estimates of SSEPs in healthy control subjects and patients with 
cirrhosis, by degree of neuropsychiatric impairment. 
Evoked  
Potential 
Controls 
(n = 17) 
Unimpaired 
(n=18) 
Minimal  
(n= 11) 
Overt 
(n=12) 
SSEP  
P(max) dB/Hz -21.24±4.0 -15.91±6.6**** -14.07±5.2***** -14.49±6.9* 
P(mean) dB/Hz -52.20±5.7 -51.94±21.9 -44.58±35.7 -43.8±35 
F(peak) Hz 69.70±14.0 41.76±28.6***°° 25.72±13.48**** 30.66±27.37**** 
Data are expressed as (mean ± SD) for SSEP peak power and frequency at peak power. 
Differences from controls: *p < 0.05, *** p <0.005, ****p <0.001, *****p <0.0001. 
Differences from: minimal HE: °°p <0.01. 
 
 
 
 
 
(Overleaf Fig 3.10: Power Spectral Density (PSD) Estimates of Cortical Somatosensory 
Evoked Potentials).
 Marc Rayan Page 144 of 227 09/07/2013 
 
 
 
 
C
o
n
tr
o
l
U
n
im
p
a
ir
e
d
M
in
im
a
l
O
v
e
rt
-35
-25
-15
-5
Maximum power of cortical SSEPs
(means are indicated by solid circles)
P
o
w
e
r 
/ 
fr
q
u
e
n
c
y
 (
d
B
/H
z
)
C
o
n
tr
o
l
U
n
im
p
a
ir
e
d
M
in
im
a
l
O
v
e
rt
0
10
20
30
40
50
60
70
80
90
100
Cortical SSEP - frequency at peak power
(means are indicated by solid circles)
F
re
q
u
e
n
c
y
 (
H
z
)
Figure 3.10: Power Spectral Density (PSD) 
Estimates of Cortical Somatosensory Evoked 
Potentials. 
 ABOVE: PSD components from control 
(upper-left) and patients: unimpaired (upper-
right), minimal HE and overt HE (lower- left 
& right). 
 LEFT: Box plots of results from controls and 
patient groups: unimpaired, minimal HE and 
overt HE.  
Data are median, mean and 95% CI;  
significant differences are inset. 
 
*p = 0.05 
**p = <0.01 
*** p = <0.005 
**** p = <0.001 
*****p= <0.00001 
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3.4.3 PSD – BAEP 
 
There is a reduction in the frequency at peak power of the patients compared 
to the healthy controls, which is highly significant for the minimal and overt HE 
groups (Figure 3.11). The frequency reduction of the minimal and overt HE patients 
is also significant compared to the unimpaired group (Table 3.11). 
 
 
Table 3.11: PSD estimates of BAEPs in healthy control subjects and patients with 
cirrhosis, by degree of neuropsychiatric impairment. 
Evoked  
Potential 
Controls 
(n = 17) 
Unimpaired 
(n=18) 
Minimal  
(n= 11) 
Overt 
(n=12) 
BAEP  
P(max) dB/Hz -37.97±2.8 -38.23±3.8 -37.37±4.7 -34.96±24.9 
P(mean) dB/Hz -47.5±63.7 -73.82±7.2 -65.27±41.0 -36.0±74.6 
F(peak) Hz 174.9±83.9 152.4±81.1°°°°++ 87.39±36.0***** 83.96±20.5**** 
Data are expressed as (mean ± SD) for BAEP frequency at peak power. 
Differences from controls: ****p <0.001, *****p <0.0001. 
Differences from: minimal HE: °°°°p <0.001 
Differences from overt HE: ++p <0.01. 
 
 
 
 
 
 
 
 
(Overleaf Fig 3.11: Power Spectral Density (PSD) Estimates of Cortical Brainstem Auditory 
Evoked Potentials). 
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Figure 3.11: Power Spectral Density (PSD) Estimates of Cortical 
Brainstem Auditory Evoked Potentials. 
 
 ABOVE: PSD components from control (upper-left) and patients: 
unimpaired (upper-right), minimal HE and overt HE (lower- left & 
right). 
 
 LEFT: Box plots of results from controls and patient groups: 
unimpaired, minimal HE and overt HE.  
 
Data are median, mean and 95% CI;  
significant differences are inset. 
 
**p = <0.01 
**** p = <0.001 
***** p = <0.0001 
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3.4.4 PSD - P300  
 
A significant reduction in peak frequency occurs in all patient groups compared to 
the healthy controls (Figure 3.12); differences in frequency reduction are also significant 
between patient sub-groups (Table 3.12). Unimpaired patients have a significantly higher 
peak frequency than the minimal and overt HEs, while the peak frequency of the minimal 
HE patients is also significantly higher than the overt HEs.   
 
Table 3.12: PSD estimates of Cognitive P300 potentials in healthy control subjects 
and patients with cirrhosis, by degree of neuropsychiatric impairment. 
Evoked  
Potential 
 
Controls 
(n = 17) 
Unimpaired 
(n=18) 
Minimal  
(n= 11) 
Overt 
(n=12) 
P300 Auditory Cognitive  
P(max) dB/Hz -2.13±4.1 -1.07±8.6 -0.15±6.6 -0.88±5.8 
P(mean) dB/Hz -39.85±5.7 -41.29±3.2 -41.81±3.8 -42.59±3.9 
F(peak) Hz 7.71±2.6 5.87±2.3*°°°°++++ 3.83±1.5*****+ 2.64±0.9***** 
Data are expressed as (mean ± SD) for P300 frequency at peak power. 
Differences from controls: *p < 0.05, *****p <0.0001. 
Differences from overt HE: +p < 0.05, ++++p <0.001 
Differences from: minimal HE: °°°°p <0.001,  
 
 
 
 
 
 
(Overleaf Fig 3.12: Power Spectral Density (PSD) Estimates of Cognitive P300 Auditory 
Evoked Potentials).
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Figure 3.12: Power Spectral Density (PSD) Estimates of 
Cognitive P300 Auditory Evoked Potentials. 
 
 ABOVE: PSD components from control (upper-left) 
and patients: unimpaired (upper-right), minimal HE 
and overt HE (lower- left & right). 
 
 LEFT: Box plots of results from controls and patient 
groups: unimpaired, minimal HE and overt HE.  
 
Data are median, mean and 95% CI;  
significant differences are inset. 
 
*p = <0.05 
**** p = <0.001 
*****p= <0.0001 
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3.5 Sensitivity and Specificity Analysis 
 
ROC curve analysis identified thresholds which could discriminate any 
degree of hepatic encephalopathy. The ‘negative’ group consisted of the data 
from controls and unimpaired patients combined; the ‘positive’ group consisted of 
the minimal and overt HE patient data combined. Where there are multiple 
latency peaks for an EP the optimal waveform marker is highlighted (tables 3.13 
& 3.14). 
3.5.1 Sensitivity and Specificity – EP latencies 
 
 
Table 3.13: Latency thresholds of evoked potentials distinguishing healthy 
controls and unimpaired patients from minimal and overt HE patients. 
 
Evoked Potential / 
threshold (ms) 
Sensitivity 
(%) 
Specificity 
(%) 
Positive 
predictive 
value (%) 
Negative 
predictive 
value (%) 
Area 
under 
curve 
VEP 
>74.15 N75 80.0 54.0 55.7 78.8 0.67 
>103.0 P100 73.3 51.5 52.3 72.8 0.68 
>145.05 N145 43.2 82.3 63.8 66.7 0.62 
SSEP 
>9.95 N9 81.8 53.8 60.2 77.7 0.73 
>13.55 N13 86.3 50.0 59.5 81.1 0.75 
>20.05 N20 79.5 59.6 62.7 77.4 0.72 
BAEP 
>1.54 wave I 75.0 40.8 52.9 64.8 0.59 
>2.75 wave II 55.6 56.2 53.0 58.8 0.56 
>3.76 wave III 78.2 49.0 57.6 71.8 0.68 
>5.0 wave IV 69.5 40.8 51.0 60.2 0.62 
>5.75 wave V 76.1 51.0 57.9 70.6 0.72 
Cognitive Auditory 
>336.5 P300 86.8 70.0 73.3 84.9 0.80 
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3.5.2 Sensitivity and Specificity – Frequency domain 
 
Table 3.14: Frequency and power thresholds of evoked potentials distinguishing 
healthy controls and unimpaired patients from minimal and overt HE patients. 
 
 
Evoked Potential / 
threshold 
Sensitivity 
(%) 
Specificity 
(%) 
Positive 
predictive 
value (%) 
Negative 
predictive 
value (%) 
Area 
under 
curve 
VEP 
FFT-1(Hz) <1.0 80.56 33.33 46.0 70.8 0.58 
FFT-2(Hz) <1.4 81.8 58.6 58.2 82.0 0.71 
Pmax(dB/Hz) <-4.09 61.11 44.68 43.8 62.0 0.52 
Pmean(dB/Hz) <-56.16 77.78 34.78 45.7 68.9 0.51 
FPmax(Hz) <11.03 75.0 54.35 53.7 75.5 0.66 
SSEP 
FFT-1(Hz) <8.05 50.0 41.3 37.5 53.9 0.52 
FFT-2(Hz) <28.74 67.65 44.44 46.2 66.1 0.58 
Pmax(dB/Hz) >-18.62 82.35 43.48 50.7 77.7 0.66 
Pmean(dB/Hz) >-56.89 73.53 45.65 48.8 71.0 0.56 
 FPmax(Hz) <33.78 85.29 58.7 59.3 85.0 0.70 
BAEP 
FFT-1(Hz) <30.06 77.1 52.1 53.2 76.4 0.66 
FFT-2(Hz) <78.15 43.75 43.75 45.2 64.4 0.63 
Pmax(dB/Hz) <-37.15 65.71 41.7 44.3 63.3 0.60 
Pmean(dB/Hz) <-75.99 52.9 52.1 43.58 61.1 0.52 
FPmax(Hz) <98.74 85.7 56.25 58.0 84.8 0.72 
Cognitive Auditory P300 
FFT-1(Hz) <0.24 65.7 29.79 39.8 55.2 0.55 
FFT-2(Hz) >1.61 66.7 41.67 44.6 63.69 0.51 
Pmax(dB/Hz) >-2.92 63.89 47.92 46.4 65.3 0.55 
Pmean(dB/Hz) <-42.03 63.89 62.5 54.6 71.0 0.60 
FPmax(Hz) <5.73 80.56 56.25 56.5 80.4 0.75 
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3.5.3 Test combinations 
 
Tables 3.15-17 
EP components with the best sensitivity and specificity were combined in 
pairs to evaluate the diagnosis of any degree of encephalopathy (highlighted: 
tables 3.13 & 3.14)  Pairs of markers were analysed by binary logic regression 
using the thresholds derived from ROC analysis. EP component pairs were 
combined in the time-domain, frequency-domain and time-frequency domains.  
The optimal EP markers for distinguishing any degree of encephalopathy 
in the time-domain are the P300 and ‘wave V’ of the BAEP.  In the frequency 
domain the optimal pair of markers is the second FT peak of the VEP (FFT-2) 
and the frequency at maximum power of the cortical (N20) somatosensory 
potential. When the time and frequency domains are combined for logic 
regression analysis, the optimal pair of markers is both somatosensory – the N20 
latency and frequency at peak power. 
3.15  
Significance comparisons of different test combinations – time domain 
 
Test combination Evoked potential latency 
marker 
P value 
Combination 1 vN75 0.02 
sN20 0.001 
Combination 2 vN75 0.001 
b(wave V) 0.001 
Combination 3 vN75 0.02 
P300 0.001 
Combination 4 sN20 0.001 
b(wave V) 0.002 
Combination 5 sN20 0.003 
P300 0.001 
Combination 6  b(wave V) 0.002 
P300 0.001 
v – visual; s – somatosensory;  b – brainstem; P300 – auditory cognitive 
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3.16 
Significance comparisons of different test combinations – frequency 
domain 
 
Test combination Evoked potential spectral 
marker 
P value 
Combination 1 vFFT-2 0.04 
sF(Pmax) 0.002 
Combination 2 vFFT-2 0.05 
bF(Pmax) 0.003 
Combination 3 vFFT-2 0.04 
P300F(Pmax) 0.01 
Combination 4 sF(Pmax) 0.01 
bF(Pmax) 0.01 
Combination 5 sF(Pmax) 0.004 
P300F(Pmax) 0.02 
Combination 6  bF(Pmax) 0.01 
P300F(Pmax)  0.07 
v – visual; s – somatosensory;  b – brainstem; P300 – auditory cognitive 
FFT-2 – secondary Fourier peak; F(Pmax) – frequency at maximum power 
 
3.17  
Significance comparisons of different test combinations –  
frequency and time domains 
 
Test combination Evoked potential marker P value 
Combination 1 P300 0.001 
sF(Pmax) 0.02 
Combination 2 P300 0.001 
bF(Pmax) 0.02 
Combination 3 b(wave V) 0.001 
sF(Pmax) 0.003 
Combination 4 b(wave V) 0.001 
bF(Pmax) 0.006 
Combination 5 sN20 0.001 
sF(Pmax) 0.002 
Combination 6  sN20 0.001 
bF(Pmax) 0.003 
s – somatosensory;  b – brainstem; P300 – auditory cognitive 
F(Pmax) – frequency at maximum power 
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The identified optimal marker combinations were assessed for their 
sensitivity and specificity in each domain (Table 3.18). Latency measurements in 
the time domain have sensitivity and specificity of 66% and 85% respectively; the 
frequency domain demonstrates a modest improvement in sensitivity (70%) with 
a small comparative loss of specificity (83%). The combination of time and 
frequency domains demonstrates an improved sensitivity (68%) over latency 
markers alone with a minor loss of specificity (83%). 
 
 
Table 3.18 
Sensitivity and specificity of paired variables in distinguishing any degree of 
encephalopathy.  
 
3.18 
Comparison of sensitivity and specificity of EP markers tested in pairs. 
Test combination Evoked potential markers Sensitivity (%) Specificity (%) 
Time domain  b(wave V) + P300 66 85 
Frequency domain  vFFT-2 + sF(Pmax) 70 83 
Time-frequency domains sN20 + sF(Pmax) 68 83 
s – somatosensory;  b – brainstem; P300 – auditory cognitive 
F(Pmax) – frequency at maximum power 
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Summary 
Multimodal EPs were obtained from healthy controls and patients pre-
diagnosed with cirrhosis, who presented as either unimpaired, or with minimal or 
overt encephalopathy. In all sensory modalities (VEP, SSEP and BAEP) patients 
demonstrated statistically significant prolonged latency differences compared to 
the controls, in at least one of the waveform markers. This was also observed in 
the cognitive (P300) potential. The P300 also demonstrated significant 
differences between the three patient groups; differences between patient groups 
are less marked in VEPs and BAEPs. 
FT analysis of sensory EPs demonstrated a trend of frequency reduction in 
the main or secondary component as neuropsychiatric impairment increases. 
Between patient group differences were clearly highlighted in all sensory 
modalities, but less so for differences between patients and controls. Similar 
differences occur between groups for the cognitive FTs but these are less 
marked. The PSD analysis highlighted significant differences between controls 
and patients for frequency at peak power (all modalities) and peak power 
(SSEP). Between patient group differences are also well illustrated across all EP 
modalities. 
Multivariate analysis demonstrates that paired waveform markers from either 
the frequency domain or combined time-frequency domain have a comparable 
sensitivity and specificity to the time-domain only waveform markers.   
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The utility of latency and spectral analysis methods in evoked 
potential recordings from patients with hepatic encephalopathy. 
 
Chapter 4: Discussion 
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Control Latency Data 
The latency data recorded for the sensory evoked potentials of healthy 
controls was in keeping with previous normative studies with large test groups. 
For visual measurements the mean latency for the control groups P100 
component was either the same or within 1ms of past research (Chiappa et al 
1985; Hughes et al 1987); in addition, the spread of the data was narrower in this 
study giving smaller SDs than in the previous literature. Both the mean and SD’s 
of the main somatosensory components, N9, N13 and N20 are near identical with 
previously published normal studies while the auditory EP components - waves I, 
II and III – are within 0.2ms of the previous literature and all have similar SD’s. 
The control data obtained were also in keeping with the normal values for the 
Neurophysiology Department’s normal data set for the EP recording device used 
for this research. The cognitive auditory P300 latency is not currently utilised as a 
diagnostic tool in clinical neurophysiology, hence normative data is limited. There 
are conflicting findings due to a wide range of normal values. However, the mean 
latency and spread of the data for this group fell within the ranges of larger 
previous studies (Polich et al 1985). 
Age and Gender. 
Gender percentage was balanced within the control group but this could 
not be achieved for the patient group, although there was no significant gender 
bias within the HE sub-populations. Similarly, the control and patient group could 
not be age matched; the age difference between the patient groups was again 
not significant. 
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Differences in the visual P100 latency between genders do not become 
significant until later in life, at approximately >65yrs (Allison et al 1984). Other 
latency differences between genders have been reported, but occur for stimulus 
parameters (check-size) which were not used in this study. Gender therefore, is 
not a confounding factor when considering the latency of the control group. Since 
the mean age of the study group is below 65yrs this, and only 15% of the patients 
are over 65yrs, the age and gender bias will not be a confounding factor in 
comparative analyses. Controllable factors such as the stimulus parameters are 
more likely to have a measurable effect on the latencies. No significant 
differences between age and gender are reported for the other sensory 
modalities. The cognitive auditory P300 latency is subject to attention, vigilance 
and stimulus parameter factors but no significant variability between genders has 
been reported. It is unclear whether age affects latency in the normal population, 
with earlier studies finding both for and against a trend of increasing latency with 
age. Again, the findings are hampered by data sets, for age, having very wide 
distributions. The entire age range of the control group had a P300 latency of 
within 1SD of a reported regression line between age and latency (Polich et al 
1985). Only 10% of the patients exceeded the control group’s upper age range 
and these also fell within 1SD of the variability of age with latency. 
 Handedness and Hemispheres. 
The issue of handedness is of interest in evoked potential studies as 
sensory EP recordings are made for each hemisphere; cognitive measurements 
are not an issue as they are derived from mid-line electrodes. The previous 
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studies utilising evoked potentials in patients with hepatic encephalopathy stated 
patient and control numbers but it was unclear whether either or both 
hemispheres were used for recording. Therefore a study of …“N = 20”…may 
have had 40 recordings in total with left and right hemispheres averaged for each 
patient before being added to the overall mean ± SD analysis. Alternately, one 
side may have remained unreported, using an unstated criteria and the analysis 
undertaken such that the number of samples is equal to the number of patients. 
The third option would be that the left and right hemisphere data were added into 
an average of the population, the sample number being double the patient 
number. In this study, measurements for each hemisphere were recorded and 
the average for each individual used throughout the analysis. This has the 
advantage of guaranteeing statistical sample independence between patients 
and so maintains a level of robustness for the statistical tests. These latency 
data, if added hemispherically would effectively double the sample size for all 
patients and controls. A calculation exercise made with this sample arrangement 
increases levels of significance typically from p = <0.005 or <0.001 to p = 
<0.0001, (appendix VII). More importantly further significant differences are 
uncovered between HE populations, particularly between both unimpaired and 
minimal HE compared to overt HE for somatosensory and auditory EPs, and 
minimal HE compared to unimpaired for visual EPs. These samples are not 
independent as an underlying pathophysiological process that may be affecting 
one individual would influence two sets of recorded data. This is also true of the 
current method, taking an average for an individual. However, the data strongly 
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suggests that clinical recordings of larger populations would enhance significant 
differences between population groups and uncover further distinctions between 
HE sub-groups. 
Data reduction during EP acquisition. 
In order to perform frequency analysis on the evoked potentials the 
voltage values were exported and converted into the appropriate formats. Fourier 
transforms of this data type are normally dependant on the sample frequency and 
the epoch duration. Initially, upon observing a poor frequency resolution it was 
discovered that a significant amount of data reduction is built into the EP 
recording software, presumably to reduce the file size. Given the sample rate and 
sweep duration it appears that only one in five data points are saved. 
Subsequently, the FTs were obtained by using a ‘sampling interval’ calculated 
from the actual number of data points for the sweep, adjusting for each EP 
modality. It is unclear if any previous research encountered this problem. 
Although the FT analysis eventually used a Matlab™ code to compensate for the 
data loss and produce appropriate spectra there is still an issue with frequency 
resolution. Since power spectral density estimates (PSD) are also based on the 
FFT, these also are affected. Cursor movement for frequency measurement 
appears to follow discrete steps with a modest resolution. It follows therefore, that 
if additional data points are available for the time-frequency domain conversion 
the frequency resolution would increase so reducing the minimum step between 
cursor points. This may change the frequency measurements, particularly for the 
PSD data, and so alter the final statistical findings. 
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Alternative signal processing techniques. 
The ongoing EEG activity can be considered background noise from which 
the EP waveforms were extracted by signal averaging. It is assumed when 
obtaining measurements of the final waveform, that the signal had a constant 
time correlation with the stimulus onset and that the morphology of the EP was 
consistent throughout. Should this not be the case, the EP signal becomes 
incorporated into the noise and the amplitude becomes reduced. Similarly, the 
noise content of the sweep must have zero correlation with the stimulus and the 
amplitudes of the noise should be constant across all frequencies. The EEG as a 
signal does not comply with these noise prerequisites, particularly where 
pathological conditions may generate a rhythmic background; further, the EP 
may not comply with signal requirements particularly where there is a global 
metabolic process affecting the whole of the CNS, such as hepatic 
encephalopathy. The morphology of the final EP waveform is the average of all 
the morphologies generated by each stimulus, therefore the cursor placement 
measures the average latency for a given component.  
These uncertainties could be overcome by presenting waveform data such 
that each point had an overall average with its ± standard deviation. The device 
used in this study and for most routine clinical applications discards an earlier 
epoch once the next one has been added to the recalculated average. A large 
amount of data is lost which could be useful in highlighting the small variations in 
response that occur for individual stimuli. This also precludes other signal 
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analysis methods that would require the waveforms for every stimulus-response 
epochs in an EP investigation, such as auto-regression analysis. 
The FT and PSD frequency domain representations used in the study both 
require the sampled epoch to be a stationary signal, that is, the interval must start 
and stop at zero amplitude. A window is imposed on the sampled epoch in order 
to force the start and end of the signal to zero and achieve stationarity. The 
default window in Matlab™ is ‘rectangular’, the simplest (Appendix VI) which 
effectively attenuates only the epoch end points. This appears to be 
advantageous as the signal content is mostly preserved. However, the 
consequence of a sudden onset and offset is to cause a rippling artefact – 
spectral leakage; this is clearly demonstrated in the EP waveforms, particularly 
the VEP and P300 investigations (figs 3.9 & 3.12). This cyclic fall to zero 
amplitude potentially removes data that will cause erroneous cursor placement. 
The alternate windows in common use, for example Hamming, Kaiser and 
Blackman-Harris, solve the problem of spectral leakage; however, all have steep 
roll-offs in the lower frequency part of the bandwidth where there is the most 
physiological activity, and so are also unsuitable (Appendix VI).  
While spectral leakage repeats at integer values of the sample rate, this is 
always some distance away from the area of interest in the spectra since the 
epoch has been band-limited during the EP recording process; the lowpass filter 
being no higher than the Nyquist frequency for each recording modality.  No 
cursor measurements were made for frequencies above the low-pass settings for 
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any of the EP modalities and under these two circumstances the rectangular 
windowing was employed throughout the study. 
Neurophysiological processes. 
Evoked potential components can be characterised by latency, amplitude 
and topographical features as well as external attributes that elicit the response, 
such as the stimulus variables and the recording montage. The concept of an EP 
generator is somewhat unclear as it can indicate an anatomical structure that is 
the origin of the signal, or a theoretical model of a voltage source. It is assumed 
that the EP signal arises from a synchronous activity of a neuronal population; 
this is not easily modelled as each neuron possesses multiple excitatory and 
inhibitory inputs and exists in a complex neural network which has a given 
orientation to the convoluted cortex of the brain and thence surface recording 
electrodes. A single EP component therefore, may arise from a combination of 
responses from separate cell populations which may have been activated by 
simultaneous parallel pathways, and may not have been in response to the 
originating axonal volley. 
The PSD analysis of the VEP investigations in this study reveals a peak 
power at frequencies (~15Hz) that correspond to durations of ~65ms; (in the 
control group and increasing with encephalopathic severity). This duration 
corresponds to the main wave centred on the P100 component; however, simply 
looking at the width of the wave may not reveal all of the underlying activity. The 
FT’s indicate that there are two main harmonics contributing to the waveform at ~ 
1Hz and 2Hz. The main wave is composed of these two harmonics; however, if 
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they originate from different neural networks or processes, they may be 
differentially affected by the underlying pathophysiology. This is suggested in this 
study as the two harmonics reveal different behaviours across the patient groups, 
with the second harmonic absent from patients with overt encephalopathy. Both 
FFT and PSD spectral methods therefore, can make useful contributions to 
monitoring or visualising the on-going physiological processes. 
The somatosensory and brainstem auditory EPs, by contrast, have PSD 
frequencies at peak power which do not appear to be in keeping with the FFT 
components or the duration of the main waveforms.  For example, in the SEPs 
the PSD peak is lower at ~70Hz and in the BAEPs it is higher at ~ 175Hz; (in 
both modalities the frequencies decrease with increasing severity). 
Electrocorticographic (invasive EEG) recordings made in patients in preparation 
for brain surgery have revealed well replicated gamma (>30-90Hz) and high-
gamma (≥200Hz) frequencies; these bandwidths have demonstrated, in other 
research areas,  power fluctuations which are linked to information processing 
(Crone et al 2006). It has been assumed that gamma band activity does not 
transition through the skull with sufficient power to be detected by surface 
electrodes. However, auditory and somatosensory stimuli have been combined in 
cognitive studies using surface electrode recordings (Onton & Makeig 2009); 
high-density EEG data contains gamma-band activity that overlaps spatially with 
lower frequency bands. The SEP and BAEP investigations in this study have 
bandwidths that allow recording of gamma activity; further, the signal averaging 
process overcomes the attenuation from the skull and scalp transition. It follows 
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that in the frequency domain activities, such as the gamma-band, can be 
identified and monitored that would not be apparent in latency-only 
measurements. As gamma activity in combined EPs can be modulated by stress 
level, mood changes and attention (Kisley & Cornwell 2006), PSD findings in 
BAEP and SEP investigations may be particularly sensitive to physiological 
changes that occur in encephalopathy.  
The FFT components of the auditory cognitive P300 EP shared a similar 
feature to the VEP finding in that the Fourier harmonic of 2.6 Hz (duration 
~380ms) corresponds to the duration of the main positive wave. However, the 
PSD peak frequency of 8Hz (decreasing with increasing encephalopathic state) 
corresponds to a wave of duration of 130ms. This corresponds to the P3a 
component of the P300 which is normally 75-100ms earlier than the main peak, 
with a latency of 250-280ms. The main peak is termed the P3b when the earlier 
component is elicited. The dissociation of P3a from P3b normally occurs when 
the rare tone includes a ‘non-target’ or ‘deviant’ tone; however it can be elicited 
from the simpler P300 ‘odd-ball’ paradigm if the subject is told not to listen or if 
there is difficulty in discriminating the rare tone (Comerchero & Polich 1999). The 
cognitive potential, and more importantly this 8Hz component of the P300 
waveform, was the only EP to demonstrate significant differences between 
healthy controls and all patient groups and significant differences between all 
patient groups. It follows therefore that neuronal networks that are associated 
with cognition and attention combined are particularly affected by the 
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pathophysiological changes of encephalopathy; these networks can be clearly 
identified by the PSD application. 
 Anomaly of patients with minimal encephalopathy. 
 Both sensory and cognitive EPs demonstrate a trend of increasing latency 
compared to controls, the extent of delay increasing with worsening 
neuropsychiatric state. One patient group, the minimal HE, was either 
consistently anomalous in regard to latency, or had a comparatively wider 
variance, where there was significant overlap with unimpaired and overt patient 
values; (it remained significantly altered compared to the control groups). A 
possible explanation for this is a reflection of the way HE status is classified for 
this group. One patient was not encephalopathic on clinical examination but had 
both abnormal PHES and EEG findings. Of the remaining (12) patients half   
presented with abnormal PHES scores but normal EEG, while the other half 
presented with normal PHES scores but abnormal EEG. The minimal HE group 
may possibly contain a physiologically heterogeneous population; such a group 
could produce a relatively broader variance, with patient data overlapping 
significantly with control values, and also the anomalies observed in the between-
patient group mean latencies. This feature in the neuropsychiatric classification is 
a result of the absence of a gold standard test for HE, and so the diagnosis of the 
patients remains potentially sub-optimal. 
The observed trend of a reduction in peak frequency with increase in 
encephalopathic state is consistent across all EP modalities. This is highlighted in 
either the main FT component or in the frequency at peak power, and appears to 
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be resistant to the anomaly in minimal HE classification. This is particularly 
marked in the FTs for the sensory EPs and the PSDs in the cognitive potentials. 
The main advantage of frequency domain analysis over latency measurement is 
seen where alterations in waveform morphology may not be reported as 
abnormal if the peak measurements still occur within normal limits. Altered 
morphology in this study was particularly marked in the cortical SSEP and BAEP 
(figs 3.6 and 3.7 respectively). Given that varying clinical presentations, for 
example, within the minimal HE group may occur because of varying 
pathophysiological aspects, the waveform morphology may also be altered 
variably, producing the wide latency variance.  However, the EP generators may 
not be affected by this aspect of the underlying physiology so that the frequency 
components are altered to a lesser extent within the group but change 
significantly between groups. This could be tested by sub-dividing the minimal 
HE group into, for example, ‘minimal: a’ – PHES abnormal and ‘minimal: b’ – 
EEG abnormal.  
ROC Thresholds. 
The choice of threshold latencies following ROC analysis was made to 
provide a balance between sensitivity and specificity. Where there were multiple 
parameters for each test, i.e. the individual latency peaks, the chosen marker 
possessed the greatest AUC (area under curve). It could be argued that the 
thresholds may not be appropriate clinical neurophysiology application given that 
‘abnormal’ latencies are usually pre-defined as control mean + 2SD. Using the 
latency values obtained in this study such a definition would significantly drive 
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down the sensitivity. For example, the SSEP (N20) and BAEP (wave V) 
potentials decrease in sensitivity from 79.5% and 76% respectively to 46%. The 
P300 is less affected decreasing 86% to 79%. On this basis the logical 
regression analysis may appear not to be fully robust when utilising the higher, 
balanced sensitivity and specificity thresholds, although this does not change the 
AUC for each parameter.  Patients presenting for neurophysiological testing will 
have been previously screened for cirrhosis, the results being used as part of a 
battery of tests to assist in the assessment of neuropsychiatric status; therefore, 
the strict use of mean+2SD is not necessarily indicated for this patient group. It 
may be possible therefore to establish a set of thresholds that are unique to 
cirrhotic patients with encephalopathy.  
Frequency domain studies also produce multiple markers for each EP 
modality and so a range of sensitivity and specificity values can be considered for 
further analysis. Each EP has at least one marker with an appropriate ROC-AUC 
which immediately indicates that the frequency domain compares favourably in 
the ability to discriminate neuropsychiatric status. The issue of choice with 
frequency and power thresholds is not so apparent here as there is little data 
available which can be used to base a pre-determined normal–abnormal 
definition. 
Current utility of EPs in patients with hepatic encephalopathy. 
The initial research into the role of EPs in patients with hepatic 
encephalopathy occurred from 1983-2001 for sensory modalities and 1990-2007 
for cognitive investigations, (Appendix II). Inconsistent findings have led the 
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ISHEN working party to the general consensus that EPs are a useful adjunct to 
the neurological examination but are often preserved in the presence of an 
altered EEG (Guerit et al 2009); cognitive potentials may be more sensitive to 
overt HE but it too may not be as reliable as the EEG. Their conclusion, using the 
graded recommendation scheme, (EASL (European Association for the Study of 
the Liver) 2009), suggests that further research is required as the current 
evidence is of moderate quality and the variability invokes a weak 
recommendation only. 
 Work has continued using EPs in this area although not with the intensity 
of the original investigations. The P300 has been further evaluated as a detection 
method for minimal HE with some success (Teodoro et al 2008) . As a result the 
P300 has been incorporated into the diagnostic criteria to categorise minimal HE 
for investigations in related areas. Minimal HE has been defined as patients with 
an abnormal P300 latency and one or more psychometric tests in  studies of  the 
role of arterial ammonia (Bragagnolo et al 2009), venous ammonia (Sharma & 
Sharma 2010b) and evaluation of the response to lactulose treatment (Sharma et 
al 2009). Categorising patients with the psychometry and the P300 EP has also 
been adopted for studies evaluating recent developments, such as the utility of 
critical flicker frequency in assessing patients recovering from minimal HE 
(Sharma et al 2010a). Cognitive function has been further investigated in the 
minimal HE group, but again related to time-domain; it has been reported that the 
shorter latency mismatch negativity (MMN) has a reduced area in cirrhotic 
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patients with minimal HE than cirrhotic patients without minimal HE (Felipo et al 
2012). MMN area also increases with increasing PHES score. 
Latency studies with sensory EPs therefore, appear to have currently lost 
some favour in clinical application. Motor EPs however, have been utilised in 
animal models, where investigation of the underling mechanism of 
encephalopathy continues. Alterations in MEP amplitude and latency occur with 
induced liver failure (Oria et al 2010); further, experimental drug treatment of HE 
can be assessed for by monitoring the preservation of MEPs (Oria et al 2012).  
Both the original and more recent EP investigations for this patient group 
were confined to latency measurements. Few studies have explored beyond the 
time-domain, and where this has occurred the EP latency data has not been 
used for comparison. For example, source localisation has been obtained from 
sensory EP recordings in patients with HE through brain activity reconstruction 
(Blauenfeldt et al 2010). VEPs were not sensitive to neuropsychiatric state, but 
the SSEP source demonstrated an increasing degree of lateralisation with 
increased level of HE. Frequency domain analysis has been applied to EMG with 
MEG signals in coherence studies of the motor system (Timmermann et al 2008), 
which demonstrated a significant lowering of frequency with increased grade of 
HE. 
EP utility in this study. 
 Few researchers have utilised multimodal EP studies, while most highlighted 
inappropriate EP methodology or patient neuropsychiatric classification. In this 
study of multiple sensory and cognitive EPs the data allowed for regression 
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analysis with a bank of tests in time, frequency and time-frequency domains. 
Multivariate binary logic regression from the time-domain has indicated a 
combination of selected modalities and markers successfully discriminates 
normal from encephalopathic status; markers tested in pairs also have an 
improved specificity than a lone EP mode. A similar approach with frequency 
analysis demonstrates that a comparable discrimination of neuropsychiatric state 
can also be made. A combination of the time and frequency parameters 
produces a discrimination that is a modest improvement over time-domain 
analysis alone.  
 One of the contentions of this study was that frequency content is not 
addressed by latency measurements, yet these markers continue to be 
exclusively used in clinical waveform reporting. The findings from this small study 
group has provided evidence  that when time and frequency are used together 
patients with altered waveforms, but with normal or near-normal peak 
measurements will have a higher chance of being screened positively where they  
are neuropsychiatrically impaired.  
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Conclusions. 
The scope of this investigation was twofold: to determine the suitability of 
evoked potential recording in patients with hepatic encephalopathy, and 
secondly, to determine if frequency domain signal processing could be 
additionally applied as an adjunct to investigating neuropsychiatric status.  
This study has clearly demonstrated that the EP latencies of cirrhotic 
patients are prolonged in comparison to healthy controls. Delayed latency in one 
EP modality may not be reflected as abnormalities in the other sensory systems; 
this study has  confirmed that all modalities should be investigated. The patient 
cohort studied here demonstrated that the combinations of brainstem auditory 
and cognitive modalities are most suitable for distinguishing encephalopathy. 
The alteration of frequency with worsening neuropsychiatric state has 
been observed consistently across all EP modalities; in addition, contrast is 
better differentiated between the patient subgroups in the frequency domain. In 
this patient group, frequency-domain processing was found to distinguish 
neuropsychiatric status with a sensitivity and specificity similar to that of time-
domain processing. In this form of processing however, it is the visual and 
somatosensory modalities that are the most useful in distinguishing 
neuropsychiatric state. 
When frequency and time domains are combined to detect 
encephalopathy it is the somatosensory EP that is most useful. In this cohort the 
SSEP latency and frequency variables provide a sensitivity that is a modest 
improvement over latency measurement alone. This study therefore, suggests 
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that a combination of frequency and time domain processing will achieve the 
optimal sensitivity for investigating neuropsychiatric status.  
The findings of this study indicate that a bank of EPs, combined with 
spectral analysis, could provide a sensitive and specific method for the 
monitoring the neuropsychiatric status of patients with hepatic encephalopathy.  
 
 
*
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Summary 
 
This study has two purposes; i) to determine the utility of evoked potentials 
in the diagnosis of encephalopathy, using the standard latency measurements; ii) 
to investigate the role of signal processing in EPs by determining if frequency 
analysis can add to the diagnostic potential of EPs. 
 
 sensory and cognitive modalities demonstrate delayed 
latencies in these patients: figs 3.1-3.4 
 combinations of EP latency markers are sensitive to 
encephalopathic state: table 3.15 
 the frequency domain demonstrates clear alterations in 
patients; differences between neuropsychiatric states are more 
apparent than latency: figs 3.5-3.12 
 combinations of frequency parameters are sensitive to 
encephalopathic state: table 3.16  
 in the detection of encephalopathy frequency domain 
measurements have comparable sensitivity and specificity to 
latency measurements: table 3.18 
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Further work. 
Before this study can be repeated instrumentation issues should first be 
addressed. Waveform acquisition must be made so that there is no data 
reduction prior to signal averaging or recording. In addition, it is advantageous if 
every recorded epoch is saved. This would allow further work to benefit from 
higher resolution for measurements; the preservation of raw data would also 
allow additional signal analysis calculations, such as autoregression, component 
analysis and changes in phase relationships. The role of windowing on 
physiological waveforms can be investigated by both revisiting the data from this 
study and for a future repeat study. As many of the proprietary windows were 
unsuitable for the bandwidths typical of EP recordings alternatives could be 
investigated that are custom designed.  
The numbers of patients and controls investigated, with their respective 
age and gender ratios, was determined by the time limits of this investigation. A 
larger prolonged repeat of this study would immediately serve to validate the 
results observed. It would also allow further investigations of sensitivity and 
specificity thresholds and hence suggest appropriate latency and frequency 
values specifically for the use of EPs in screening for neuropsychiatric 
impairment. If a repeat EP study were to have a multi-centre approach, additional 
demographic factors affecting test sensitivity may be uncovered, for example 
cultural and educational differences. The control subjects could also be 
psychometrically tested to reduce the possibility of including individuals with sub-
clinical features, due to undisclosed alcohol use. In addition, a larger subject 
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cohort would enable the aetiologies to be further restricted to include, for 
example, alcohol-related patients only. 
There are additional EP modalities that can be investigated. Motor evoked 
potentials were not addressed in this study; the bereitshaftspotential (BP) is a 
non-invasive and painless stimulation that is appropriate for this patient group. 
The BP is a pre-motor cortical component and therefore may be subject to 
alterations in waveform morphology or latency where neuropsychiatric state is 
compromised. The auditory cognitive P300 potential can be further examined for 
its component waveforms the P3a and P3b. This would require a more complex 
stimulus paradigm than was available for this study, but recent changes in EP 
recording devices could allow for the additional programming. An analogous 
paradigm may also be developed for a visual cognitive potential. 
In this study six patients presented for repeat recordings, although only 
one session from each individual was included in the analysis in order to maintain 
independence of samples. Three of these patients presented with different levels 
of neuropsychiatric impairment at each session; all three patients demonstrated 
an improvement in at least two EP modalities with improvement in HE state. This 
suggests that a prolonged repeat study could incorporate longitudinal 
investigations of recurring patients. Variations in latency and frequency 
components with altered state may therefore be further clarified by serial 
recordings. 
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Appendix I 
 
Fig 7.1 (above): The 10-20 electrode placement system 
Fig 7.2 (below): An EP recording device; the amplifier headbox is indicated. 
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Appendix  II 
Table 7.1: Summary table of previous VEP studies in patients with hepatic encephalopathy. 
 
Publication 
period 
 
 
1983 - 2001 
 
Number of 
studies 
 
 
21  
20 adult  
Number of 
patients 
 
584, of which 569 
adult 
Age: 45.210.6* yrs (range 13 – 78) 
 Paediatric study 8.62.5* yrs (range 5-15) 
 
* 
meanSD 
Diagnoses of 
liver pathology 
Serum biochemistry* and 
biopsy 10 
Biopsy 8 exclusive method 
Others not stated 
common serum parameters: albumin 
                                              prothrombin time 
                                              ammonia levels 
 
Aetiologies 
 
Cirrhotic only: 8 
Cirrhosis with other 
aetiologies*: 9  
Non-cirrhotic liver disease: 5 
* 
Alcoholic cirrhosis 
Hepatitis (viral and autoimmune) 
Primary Billiary Cirrhosis 
Non-cirrhotic firbrosis 
Extra-hepatic billiary atresia 
Paracetamol overdose 
Malnutrition 
ALD 
Cryptogenic 
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Patient 
selection 
criterion 
 
 
Inclusion: 
No clinical signs of hepatic encephalopathy 
(HE0) 
No history of alcoholism (Mehndiratta et al 
1990) 
No medication within previous 24hrs that has a 
known neurological effect 
Normal visual acuity 
Normal ERG 
Exclusion: 
Abnormal visual acuity 
Neurological disorders 
Sedation within 24hrs  
Psychotropic medication 
Metabolic disorders including diabetes and 
uraemia 
Overt HE (Demirturk 2001) 
History of alcoholism (Nora 2000) 
Malnutrition 
Treatment with Lactulose & Neomycin 
(Zenerolli 1984) 
GI bleeding 
 
Assessment of 
encephalopathy 
 
Parsons-Smith (1957)  9 
 Child-Pugh 2 
Adams & Foley (1953) 1 
Zenerolli (1984) 1 
Zeive (1987) 1 
Conn / Child-Pugh 1 
MMSE & Reitan 1 
Not stated 3 
EP 
Investigation 
Flash 7:  5/7 one channel recording; bilateral studies not 10- 
20 system 
 
Pattern 14: 3 bilateral recordings only. 20 reported 10-20 
electrode system 
Post processing not stated in 15 studies 
Results Flash: 6/7 studies demonstrate at least one VEP component significantly different vs control group 
 
Pattern: 2 studies clear significant differences  
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Table 7.2: Summary table of previous BAEP studies in patients with hepatic encephalopathy. 
Publication 
period 
 
 
1985 - 1995 
Number of 
studies 
 
12  (adult data) 
Number of 
patients 
 
400  Age 41.9±6.8* (range 27 – 71yrs) 
 
*Mean ± 1SD 
Diagnoses of 
liver pathology 
 
Cirrhosis  
Fibrosis (1) 
Hepatocellular carcinoma (1) 
Serum biochemistry (exclusive: 1) 
Histopathology 
Ultrasonography 
Not stated (3) 
Aetiologies 
 
Unspecified cirrhosis (exclusive:2) 
Chronic active hepatitis 
Cryptogenic 
Idiopathic 
Alcoholic cirrhosis 
Coma following hepatic insufficiency 
Patient 
selection 
criterion 
 
Inclusion: 
Normal tonal audiometry 
No clinical signs of hepatic encephalopathy 
(HE0) 
> 6 weeks post variceal bleed 
 
Exclusion: 
previous h/o alcoholism 
previous h/o hepatitis 
psychiatric illness 
neurological trauma 
current medication affecting CNS 
infection 
diabeties, renal failure, uremia 
sedation within previous 24hrs 
malnutrition 
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Assessment of 
encephalopathy  
 
Parsons-Smith (1957) 5 
Conn (1977) 3 
MMSE & Reitan (A & B) 1 
Zieve (1987) 
N/A (Coma study using GCS) 1 
EP 
Investigation 
 
Stimulation: monoaural with white noise: (4) - remainder not 
stated 
Threshold + SPL: 4 
SPL only: 4 
10 – 20 recording system 9; not stated in other studies 
 
Three dedicated studies; remainder 
mixed EP’s 
 
Post processing not fully stated in 6 
studies 
Results 
 
Changes v controls 
 
Latencies waves I – V: 2 
IPL’s:1 
Both waves I – V and IPL’s: 5 
No significant electrophysiological changes:3 
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Table 7.3: Summary table of previous SSEP studies in patients with hepatic encephalopathy. 
 
 
Publication 
period 
 
 
1983 – 1998 
 
Number of 
studies 
 
 
13 (adult data) 
11 Experimental studies 
1 review paper 
1 Case study 
Number of 
patients 
 
552  Age 42.4±12* 
(Range 17 – 74) 
 
* 
meanSD 
Diagnoses  Cirrhosis only studies (2) 
WD (1)  
‘LD’ (4) 
Mixed patient group: 
Active hepatitis 
ALD 
Cryptogenic 
Serum biochemistry* and biopsy  
Biopsy (3) exclusive method  
Biochemistry (2) exclusive  
Ultrasonography 
not stated (4) 
 
*common serum 
parameters:  
albumin   
prothrombin time   
ammonia levels 
 
Aetiologies 
 
Hepatitis B 
Hepatitis C 
Hepatitis B & C 
Alcoholic cirrhosis 
Cholestatic LD 
Hepatocellular disease 
Hepatocellular Carcinoma 
Not stated (2) 
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Patient 
selection 
criterion 
 
Patient 
selection 
criterion (cont.) 
Inclusion: 
No clinical signs of hepatic encephalopathy 
(HE0) 
No history of alcoholism (Mehndiratta et al 
1990) 
No medication within previous 24hrs that has a 
known neurological effect 
 
 
 
 
 
Not stated (4) 
Exclusion: 
Neurological disorders (including psychiatric) 
Sedation within 24hrs  
Psychotropic medication 
Metabolic disorders including diabetes and 
uraemia 
Overt HE  
History of alcoholism  
Malnutrition 
GI bleeding 
Renal failure 
Infection 
 
Assessment of 
encephalopathy 
 
Parsons-Smith (1957)  5 
Conn 4 
MMSE & Reitan 1 
Not stated 1 
N/a 1 (liver transplant case study) 
EP 
Investigation 
Median nerve (12) 
Median & Peroneal nerves (1) 
Cortical recording only 3 
Cortical & Central 3 
Cortical, Central & Peripheral 5  
 
Post processing*: incomplete data (9) 
 
* Reproducibility, no. trials per 
average, Summing R & L limb 
data 
 
Results  Only 2 reports suggest that SEP adds no further information, while a single paper suggests this 
modality is only sensitive to moderate-severe hepatic injury. 
One paper – unspecified SEP abnormalities.  
Peroneal SEP reported as abnormal. 
Remaining papers find changes in cortical potentials; only 2 of the studies containing central & 
peripheral potentials reported significant differences. 
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Table 7.4: Summary table of previous cognitive (P300) studies in patients with hepatic encephalopathy. 
 
 
Publication 
period 
 
1976 - 2007 
Number of 
studies 
 
12 (all adult ) 
Number of 
patients 
 
631 Age: 45.9±12.5* yrs (range 19 – 75)# 
Age not stated in 5 studies (n = 275) 
* meanSD 
# from 3 studies; 
remainder not 
stated 
Diagnoses of 
liver pathology 
Unspecified clinical 
observations: 1 
Not stated: 2 
Cirrhotic: 6 
Chronic liver disease: 2 
Transplant patients: 1 
Histology  
Imaging 
Biochemical liver function  
Aetiologies 
 
Alcoholic cirrhosis 
1º billiary cirrhosis 
idiopathic cirrhosis  
Chronic hepatitis 
non-A, non-B hepatitis 
drug abuse 
cancer  
Gauchers disease 
Not stated : 3 studies 
Patient 
selection 
criterion 
 
 
Inclusion: 
Not stated: 1 
Language native to country of research centre 
No alcohol within 2 weeks / 6 months / 2 years 
Normal sensory function 
Exclusion: 
Not stated: 1 
Alcoholic toxicity 
Sedatives or centrally acting medication 
Neurological conditions 
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Other major diseases 
Overt HE (SHE / minimal HE studies) 
Assessment of 
encephalopathy 
 
Parsons-Smith (1957)  2 
Conn  4 
Not stated 3 + (unspecified clinical features 2) 
Holm (1980) 1 
EP 
Investigation 
Variable ‘rare’ stimulus incidence 12%, 15%, 20%; not stated 
in 1 study 
Visual P300:  large & small visual angle for rare. Variable: 
12.5′, 15′, 64′, 200′ 
Auditory P300: low & high tones used as ‘rare’, (0.5, 1 & 
2kHz). Stimulus intensity variable, stated in 4 studies; no 
thresholds. 
Recording (visual & auditory) positions stated / complete in 6 
studies only 
One study – CNV 
Post processing not stated in one 
study, incomplete in 5 studies. 
Results P300: sensitive, similar to NCT-B & superior to EEG / improved evaluation – 8 studies (2 visual) 
P300 no discrimination / unspecific findings – 4 studies (1 CNV, 1 visual) 
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Appendix III 
Table 7.5: Summary table of signal analysis applications in neurophysiology 
NOTES: 
1
Local Field Potentials 
2
Steady State 
3
Hyperbaric Oxygen 
4
Transient Frequency Response Characteristic 
5 
Electrocorticography 
6
Maximun Entropy 
7
Fractal Dimension analysis
 
8
Slow Wave Index 
9
Dorsal Root Entry Zone 
10
 Non-Linear Prediction Model (Mathworks™) 
 
 Investigation type Signal 
Analysis 
EP EEG / 
LFP1 
Outcome Study Group 
Animal 
Studies 
 
 
 
 
Normal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dog 
 
 
Lizard 
 
 
 
Rat 
 
 
 
Macaque 
 
 
 
Duck 
 
 
Instrumentation: digital 
filter effect 
 
Effect of body temp / 
sleep on power  
 
 
Invasive cortical 
surface recording 
 
 
Relationships between 
sensory & higher 
cortical areas 
 
Stimulus assessment 
 
 
Power 
spectra 
 
 
“ 
 
 
“ 
 
 
 
spectral 
power; 
coherence 
 
FFT 
 
 
BAEP 
 
 
 
fVEP 
 
 
 
AEP 
& 
(SS)2 
 
 
vLFP 
 
 
 
SEP 
 
 
0 
 
 
 
√ 
 
 
 
0 
 
 
 
 
√ 
 
 
 
0 
 
 
FFT of EP demonstrates 4 main 
power bands 
 
Peak power increases with 
temperature; VEP morphology only 
studied. 
 
Spatiotemporal investigation of 
middle latency AEP components (not 
related to gamma oscillations)  
 
Power and coherence analysis 
suggest synchronised anticipation 
pathways 
 
Spectral analysis suggests 
appropriate stimulation 
characteristics 
(Kawasaki Y1993) 
 
 
 
(De Vera L 1994) 
 
 
 
(Franowicz MN1995) 
 
 
 
(Liang2002) 
 
 
 
(Beyssen2004) 
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Rat 
 
 
 
Rat 
 
 
 
 
Macaque 
 
 
 
Dolphin 
 
Gamma activity with 
anaesthetic dose 
 
 
Corrections for spectral 
leakage 
 
 
 
Instrumentation: single 
unit & LFP comparison 
 
 
Instrumentation: 
Stimulus amplitude & 
carrier frequency 
investigated 
 
PSD 
 
 
 
FFT 
 
 
 
 
Power 
spectra 
 
 
FFT 
 
 
ERG, 
VEP 
 
 
 
AEP 
(SS) 
 
 
 
vLPF 
 
 
 
AEP 
(SS) 
 
 
 
0 
 
 
 
 
0 
 
 
 
 
0 
 
 
 
ECoG5 
 
 
Gamma band power is observed 
before and after halothane 
administration  
 
Time-interpolation / coherence 
coefficient calculations 
 
 
 
Spectral analysis separated frequency 
bands from spike / noise 
contamination 
 
Power content in ECoG; SEP 
morphology only 
 
(Guarino2004; Imas 
OA2004) 
 
 
(Felix L.B.2009; 
Felix LB2005) 
 
 
 
 
(Asher I2007) 
 
 
 
(Finneran JJ2007) 
 
Patho-
physiological 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cat 
 
 
Dog 
 
 
 
Pig 
 
 
 
 
Cat 
 
 
 
Rabbit 
 
 
Drug effects: phenytoin 
& Phenobarbital 
 
Bremazocine sedation 
 
 
 
Induced hepatic 
encephalopathy 
 
 
 
Naloxone precipitated 
epileptic seizures 
 
 
Acute & Chronic spinal 
chord injury 
 
FFT 
 
 
PSD 
 
 
 
PSD 
 
 
 
 
PSD 
 
 
 
Power 
spectra 
 
SEP 
 
 
 
SEP 
 
 
 
VEP, 
BAEP 
 
 
 
 
VEP 
 
 
 
 
MEP 
 
√ 
 
 
 
√ 
 
 
 
√ 
 
 
 
 
 
√ 
 
 
 
 
0 
 
EEG spectral changes; EP – 
amplitudes 
 
Dose related θ and δ power changes; 
EP – amplitude & latency (late 
component) changes 
 
EEG δ- power increases with HE0 -3; 
EP latency and morphology only 
studied 
 
 
VEP & LFP spectral dose related 
changes 
 
 
MEP spectral power alters with 
degree of injury & indicates level of 
residual function 
(Kaplan BJ1977) 
 
 
 
(Freye E1983) 
 
 
 
(De Groot GH1985) 
 
 
 
 
(Fernandez-
Guardiola A1988) 
 
 
 
(Simpson RK 
Jr1993a; Simpson 
RK Jr1993b) 
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Rat 
 
 
 
Rat 
 
 
 
Cat 
 
 
 
Rat 
 
 
 
Mouse 
 
 
 
 
Rat 
 
 
 
 
 
Colchicine &  
kainic acid injection to 
hippocampus 
 
Midazolam drug 
therapy for 
experimental HBO
3 
 
Surgical monitoring (in 
hypoxic injury) 
 
 
Cadmium treatment in 
experimental diabetes 
 
 
Cholinesterase 
inhibitors & EEG 
activity 
 
 
Effects of organic 
toxins (solvents / 
organophosphates) 
 
 
Spectral 
analysis 
 
 
FFT/ CSA 
PSD 
 
 
Time-
Frequency 
 
 
Amplitude 
spectral 
analysis 
(TFRC)
4
 
Spectral 
EEG 
(FFT) 
 
 
FFT 
 
 
 
 
 
Olfac-
tion 
 
 
 
SEP 
 
 
 
SEP 
 
 
 
 
fVEP 
 
 
fVEP 
 
 
 
 
 
VEP 
 
 
 
 
0 
 
 
 
 
√ 
 
 
 
0 
 
 
 
0 
 
 
√ 
 
 
 
 
 
0 
 
 
Odour stimulation produces peak at 
15-20Hz; abolished by granule cell 
elimination 
 
Power band alterations in EEG; SEP 
used for latency measurements 
 
 
Peak energy / frequency and peak 
frequency change during hypoxia – 
earlier that time-domain recording. 
 
Amplitude decrement observed on 
lower frequency band. 
 
 
EEG changes in θ-band; latency / 
amplitude studies for EP 
 
 
 
Main harmonics (peaks) are 
identified; dose-related frequency 
domain changes demonstrated for 
solvents. 
 
 
(Heale VR1995) 
 
 
 
 
(Russell GB1995) 
 
 
 
 
(Brauna JC1996) 
 
 
 
(Yargicoglu P1998) 
 
 
 
(Tebano MT 1999) 
 
 
 
 
(Boyes W.K. 2009; 
Boyes WK 2005; 
Boyes WK 1999) 
Human 
Studies 
 
 
 
 
 
 
 
 
Normal 
 
 
 
 
 
 
 
 
 
Effects of stimulus intensity, rate and 
barbiturates on slow oscillations 
 
 
 
 
Effects of plasma levels of 
chlorpromazide 
 
 
FFT 
 
 
 
 
 
FFT 
 
 
 
SEP 
 
 
 
 
 
 
pVEP, 
fVEP, 
AEP 
 
0 
 
 
 
 
 
 
√ 
 
 
 
Specific harmonics can be enhanced 
by stimulus rate. Barbiturates 
demonstrate a redistribution of 
energy – away from lower frequency 
components. 
 
Decrease in θ & α EEG band power; 
plasma level dependant changes in 
EP amplitude & latency 
measurements. 
(Rush JL1976) 
 
 
 
 
 
 
(Laurian S Le 
PK1981) 
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Instrumentation: spectral & phase 
shift comparisons with filter 
applications 
 
Instrumentation: improving signal to 
noise ratio for threshold detection 
 
 
Instrumentation: optimum passband 
& filtering methods investigated. 
 
 
Instrumentation: contrast sensitivities 
investigated.  
 
 
 
 
Responses isolated for stimulus 
intensity and monochromatic 
sensitivity. 
 
 
Instrumentation: effects of coil size 
& intensity, state of alertness and 
muscle contraction 
 
Brainstem, middle latency & slow 
vertex: frequency analysis 
 
 
 
Quantitative evaluation of brain 
maturation  
 
 
 
PSD 
 
 
 
PSD 
 
 
 
Power 
spectral 
analysis 
 
(ME)
6
 
spectral 
analysis 
 
 
 
FFT 
 
 
 
 
FFT 
 
 
 
PSD 
(Time-
frequency) 
 
 
PSD  
 
 
 
 
 
ABR 
 
 
 
AEP 
 
 
 
VEP 
 
 
 
 
VEP 
(SS) 
 
 
 
 
 
VEP 
 
 
 
 
 
MEP 
 
 
 
BAEP 
 
 
 
 
fVEP 
 
 
 
 
 
0 
 
 
 
0 
 
 
 
0 
 
 
 
 
0 
 
 
 
 
 
 
0 
 
 
 
 
 
0 
 
 
 
0 
 
 
 
 
√ 
 
 
 
 
Trials of zero-shift filters reduce 
power alterations of power main 
bands. 
 
Coherence analysis improves 
sensitivity at lower stimulus 
intensity. 
 
PSD used to compare analogue and 
digital effects on energy within 
varying bandwidths 
 
Frequency spectrum demonstrated 
energy changes at different spatial 
frequencies for dominant bands. 
Different energy for mono- & 
binocular stimulation. 
 
Dominant harmonic identified and 
demonstrated as a function of 
irradiance and stimulus wavelength. 
 
 
No consistent dominant frequency 
identified;  
 
 
Time-frequency analysis 
demonstrates frequency content at 
specific latencies, e.g. at waves I – V. 
 
 
Median & maximum power charted; 
discrimination improves with VEP 
data – latencies only. 
 
 
(Kavanagh KT1988) 
 
 
 
 
(Dobie RA1989) 
 
 
 
 
(Skuse NF1990) 
 
 
 
(Spileers W.1992) 
 
 
 
 
 
 
(Frederiksen 
J.L.1993) 
 
 
 
 
(Kiers L1993) 
 
 
 
(Ehara Y. 1994) 
 
 
 
 
(Manas S1997) 
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Relationship of EEG & ERP activity; 
also S:N investigation. (Acoustic 
reaction time task) 
 
 
 
 
Instrumentation: study of multiple 
pass-band filtering. 
 
 
 
 
Effect of Olanzapine on cerebral 
activity 
 
 
 
Role of cholinergic circuits in 
generation of high frequency 
oscillations 
 
Effects of antivertiginous 
medications on vigilance 
 
 
Effect of stimulus frequency on 
power and spatial distribution. 
 
 
To determine the contribution of β 
and γ oscillations to SEP 
components. 
 
Cross-modal (cortical) association: 
pairing a visual with tactile stimulus 
– topographic investigation. 
Spectral & 
coherence 
analysis 
 
 
 
 
FFT, PSD 
 
 
 
 
 
qEEG 
 
 
 
 
FFT 
 
 
 
FFT 
 (α-band) 
 
 
Laplacian,  
Spectral 
 
 
PSD, 
intertrial 
coherence 
 
ICA,  
coherence 
analysis 
 
aERP 
 
 
 
 
 
 
 
fVEP 
 
 
 
 
 
P300 
 
 
 
 
 
SEP 
 
 
 
AEP 
P300 
 
 
 
VEP 
(SS) 
 
 
SEP 
 
 
 
 
SEP / 
vERP 
 
√ 
 
 
 
 
 
 
 
0 
 
 
 
 
 
√ 
 
 
 
 
 
0 
 
 
 
√ 
 
 
 
 
0 
 
 
 
0 
 
 
 
 
0 
 
δ-power correlates with reaction 
time; faster reaction  times correlate 
with higher S:N power and amplitude 
of ERP in time-domain    
 
 
 
Power in bands >20Hz unaffected 
with the exception of γ-band (intra-
individual variation) 
 
 
 
Nine spectral [EEG] bands analysed 
– dose dependant α-and β-power 
decrease, θ-power increase. P300 
time-domain changes studied only. 
 
Narrow band (HF) changes observed; 
not reflected in N20 latencies 
 
 
Spectral changes on EEG reported; 
only latency & amplitude 
measurements studied for EPs 
 
Peaks in power (α, δ) are stimulus 
frequency dependant; band maxima 
also have spatial distributions. 
 
Power analysis determined extent of 
phase-locking over several bands; 
coincides with latency of N30 
 
Independent [SEP] components are 
enhanced by expectation (cingulated 
cortex). 
 
(Winterer G1999) 
 
 
 
 
 
 
 
(Shimoyama I.2000) 
 
 
 
 
 
 
(Hubl D2001) 
 
 
 
 
 
(Restuccia2003) 
 
 
 
(Schneider2003) 
 
 
 
 
(Srinivasan R2006) 
 
 
 
(Cheron2007) 
 
 
 
 
(Ku Y. 2007) 
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Comparison of Fractal & Fourier 
Transforms of EEG data during 
odorous stimulation 
 
Co-variation of cortical and 
cutaneous responses: emotional 
stimulation  
 
Development of auditory sensory 
system 
 
FFT /  
FD
7
 
 
 
FFT 
 
 
 
FFT 
 
 
Olfact 
 
 
 
VEP 
(SS) 
 
 
 
AEP 
 
 
√ 
 
 
 
0 
 
 
 
0 
(hi-
density 
record) 
 
FFT does not highlight elicited 
potentials but FD does for a range of 
concentrates. 
 
Main spectral power band related to 
amplitude of skin conductance. 
 
 
Spectral bands identified – evolve to 
adult profile with maturation; α-
power peaks migrate to β and γ bands 
 
 
 
(Murali S.2007) 
 
 
 
 
(Keil A.2008) 
 
 
 
(Lippe S.2009) 
Patho-
physiological 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment of prolonged dialysis & 
post transplant improvements. 
 
 
 
Unilateral cerebral (post CVA) 
lesions – deep & superficial; 
comparison of brain activity. 
 
 
Slow oscillations in cerebral lesions; 
effect of stimulus frequency. 
 
 
Hemispheric asymmetries in pre-
term neonates. 
 
 
 
 
Investigation of  electrophysiology in 
the aged. Effects of neurotropics 
 
 
 
PSD 
 
 
 
 
PSD/ 
SWI
8
 
 
 
 
PSD 
 
 
 
Auto- 
regression   
(AR 
spectral 
analysis) 
 
 
PSD 
 
 
 
VEP 
SEP 
 
 
 
 
SEP 
 
 
 
 
SEP 
 
 
 
 
fVEP 
AEP 
 
 
 
 
 
VEP 
P300 
 
 
√ 
 
 
 
 
 
√ 
 
 
 
 
0 
 
 
 
 
0 
 
 
 
 
 
 
√ 
 
 
 
Power levels of main EEG frequency 
components reduced cf normals; EP 
latencies [only] prolonged. Findings 
normalise post-transplant. 
 
Alterations in SWI power specific for 
location of lesion; latency changes 
only for SEP (similar pattern of 
alteration). 
 
Spectral distributions different from 
normals; stimulus frequency drives 
specific bands in normals only. 
 
Main AEP power band increases L > 
R, wks 40-42. Main VEP power band 
increases R > L, wks 34-36. 
 
 
 
Spectral analysis of EEG; EPs 
studied for amplitude. 
 
 
(Lewis EG1978) 
 
 
 
 
 
(Iwayama K.1979) 
 
 
 
 
(Kusske JA1980) 
 
 
 
 
(Ogawa T. 1980) 
 
 
 
 
 
(Zimmermann 
P.1982); 
(Gallois2002) 
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MS and glaucoma investigated. 
 
 
 
Assessment of cerebral function in 
schizophrenia. 
 
 
Assessment of MS: frequency & 
latency comparison. 
 
 
 
Electrophysiological study of 
hypoglycaemia on visual function. 
 
 
 
Assessment of analgesia by study of 
cortical responses to pain stimuli 
 
 
 
Spectral alterations in MS and Head 
Injury. 
 
 
 
 
Spectral content of EPs in epilepsy; 
focal abnormalities, seizure onset and 
post-operative recovery. 
 
 
 
 
 
FFT 
 
 
 
PSD 
 
 
 
PSD 
 
 
 
 
PSD 
 
 
 
 
Spectral 
analysis 
(ME) 
 
 
PSD/ME 
 
 
 
 
 
PSD 
Coherence 
 
 
 
 
 
 
ERG /  
VEP 
 
 
 
VEP 
 
 
 
VEP 
 
 
 
 
 
VEP 
 
 
 
 
SEP 
(single 
trial) 
 
 
 
BAEP 
 
 
 
 
 
 
P300 
limbic 
 
 
 
 
 
 
 
√ 
 
 
 
 
0 
 
 
 
0 
 
 
 
 
 
√ 
 
 
 
 
√ 
 
 
 
 
√ 
 
 
 
 
 
 
√  
(partial 
seizures) 
 
 
 
 
 
 
Second main frequency component 
absent in glaucoma; diagnostic yield 
for MS higher with latency studies 
 
Reduced power in α-band; 
asymmetric power in β-band 
(temporal lobe). 
 
Loss of power in high frequency 
components; does not correlate with 
latency due to deformed 
morphologies. 
 
QEEG demonstrates main power 
shift from α to θ to δ; correlates to 
amplitude and latency changes [only] 
 
 
Frequency transformed post-stimulus 
activity shows a band (2 – 4Hz) with 
consistent variability 
 
 
Three consistent frequency peaks 
identified in all subjects (170Hz, 
520Hz & 950Hz); ME-power in 
these peaks is reduced. 
 
 
Spectral power reduced in foci / 
hemisphere; normalised post-surgery. 
Limbic PSDs (high and low bands) 
altered in abnormal hemisphere. PSD 
alterations lateralised to abnormal 
side in TLE. 
 
 
(Bobak P1983) 
 
 
 
 
(Jutai JW1984) 
 
 
 
(Trick GL1984) 
 
 
 
 
 
(Harrad RA1985) 
 
 
 
 
(Bromm1987) 
 
 
 
 
(Kamath MV1987) 
 
 
 
 
 
 
(Meador KJ1988a; 
Meador KJ1988b; 
Nuwer MR1988) 
 
 
 
 
 
 
 Marc Rayan Page 219 of 227 09/07/2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detection of subclinical 
encephalopathy in cirrhotics. 
 
 
 
Spectral analysis of VEPs in 
Alzheimer’s; technical approaches 
 
 
 
Neurophysiology in children with 
autism  
 
 
Neurophysiology in children with 
reading and writing difficulties. 
 
 
Evaluation of neuromonitoring in 
diagnosis of brain death. 
 
 
Neurophysiology of delirium in 
chronic liver disease. 
 
 
Serial neurophysiological studies in 
children with ALL. 
 
 
Evaluation and prediction of coma 
outcome. 
 
 
 
 
 
n/a 
 
 
 
 
FFT 
 
 
 
 
Spectral 
EEG (AR) 
 
 
Power 
spectra 
 
 
PSD 
CSA 
 
 
Spectral-
EEG 
 
 
PSD 
 
 
 
Spectral 
EEG 
CSA 
 
 
 
 
EEG*  
 
 
 
 
 
VEP 
 
 
 
 
 
BAEP 
 
 
 
AEP 
 
 
 
SEP 
BAEP 
 
 
 
SEP 
BAEP 
 
 
VEP 
BAEP 
 
 
 
BAEP 
SSEP 
 
 
 
 
 
√ 
 
 
 
 
 
0 
 
 
 
 
 
√ 
 
 
 
√ 
 
 
 
√ 
 
 
 
 
√ 
 
 
 
√ 
 
 
 
 
√ 
 
 
 
 
 
 
Baseline reactivity from *EEG 
feedback arousal are inversely 
correlated to trail-making 
performance. 
 
Comparisons of windowing effects; 
lo-sinh & Gaussian recommended -  
cosine & rectangular may cause 
misclassifications. 
 
Alterations in brainstem functions. 
AEP – latency measurements. 
 
 
All EEG spectral bands - power 
increase; AEPs - amplitude changes 
in late components. 
 
CSA (EEG) aids diagnosis; EP 
latency changes studied. 
 
 
Mean power in α and θ range 
reduced; EP – latency studies only 
 
 
Main spectral EEG peak reduces in 
frequency; EP - latency only (VEP 
not significant). 
 
Frequency analysis can classify 
groups which match underlying 
pathology and prognosis; EP latency 
studies only (alterations concur with 
EEG findings) 
 
 
(McLaughlin TJ 
1989) 
 
 
 
 
(Moody EB Jr1989) 
 
 
 
 
 
(Ogawa1989) 
 
 
 
(Pinkerton F1989) 
 
 
 
(Shiogai T1989; 
Shiogai T1993) 
 
 
 
(Trzepacz PT1989b) 
 
 
 
(Korinthenberg R 
1990) 
 
 
 
(Liesiene R2006; 
Tsubokawa T1990) 
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Physiological changes in 
Alzheimer’s and non-specific 
cognitive decline. 
 
 
Study of main frequency components 
in patients with optic neuritis 
 
 
Objective evaluation of pain-relief 
surgery (DREZ)
9
 
 
 
Treatment and monitoring of mild 
hepatic encephalopathy in cirrhotics. 
 
 
Effect on brain function of tyrosine 
treatment in adults with 
phenylketonuria. 
 
Physiological effects of substance 
abuse in psychiatric patients. 
 
 
Electrophysiological diagnosis of 
hepatic and portosystemic 
encephalopathy. 
 
Depth of anaesthesia monitoring. 
 
 
Induction of anaethesia and  
moderation of inadequate 
anaesthesia. 
 
 
Spectral 
EEG 
 
 
 
FFT 
 
 
 
PSD 
Coherence 
 
 
EEG 
power 
spectrum 
 
Spectral 
analysis 
 
 
QEEG 
 
 
 
Spectral 
EEG 
 
 
FFT 
ARX
10
 
 
FFT 
PSD 
 
 
 
CNV 
P300 
 
 
 
 
VEP 
 
 
 
VEP 
SEP 
 
 
 
P300 
 
 
 
VEP 
 
 
 
AEP 
VEP 
P300 
 
 
pVEP 
mVEP 
 
 
 
AEP 
 
 
AEP 
 
 
 
 
√ 
 
 
 
 
 
0 
 
 
 
√ 
 
 
 
 
√ 
 
 
 
√ 
 
 
 
√ 
 
 
 
 
√ 
 
 
 
 
√ 
 
 
√ 
 
 
 
 
EP latency studies only; CNV 
demonstrate with treatment / clinical 
improvement. 
 
 
Pathological changes can be  
observed in different frequency 
harmonics - reversal rate dependant 
 
spectral EEG changes (<θ),  EP 
latency & morphology normalisation 
coincide with clinical improvement. 
 
EEG changes with treatment α-power 
increases, δ-power decreases; P300 
latency only [improvement]. 
 
EP latencies studied only, EEG β-
power reduced in patients cf controls; 
(treatment ineffective). 
 
Significant power changes in EEG; 
latency changes only for EPs 
 
 
EEG spectrum shifts towards lower 
frequencies; mVEP more sensitive 
than pVEP (latency measurements) 
 
Both EEG & EP spectra alter during 
transitions through conciousness. 
 
AEP amplitude changes studied only;  
Ketamine reduces α-power [EEG] 
amplitude of AEP,  remifentanil 
exerts no effects. 
 
(Zappoli R1991; 
Zappoli R.1991) 
 
 
 
 
(Hasegawa S 1992) 
 
 
 
(Arkhipova NA 
1993) 
 
 
 
(Higuchi K1994) 
 
 
 
(Pietz J1995) 
 
 
 
(Braverman ER1996) 
 
 
 
(Kuba M1996) 
 
 
 
(Capitanio L1997) 
 
 
 
(Bischoff P1998; 
Plourde G1997) 
 
 
 
(de Tommaso 
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Investigation of migraine attacks. 
 
 
Repeated periods of conscious – 
unconsciousness mediated by 
Propofol infusion. 
 
Spectral study of fusiform gyrus 
(pharmaco-resistant epileptics). 
 
 
Neurophysiological investigation of 
lead absorbtion. 
 
 
A preliminary demonstration of a 
continuous wavelet transforms 
(CWT). 
 
 
A study of chronic fatigue syndrome 
in workers from the Chernobyl 
incident. 
 
 
 
Spectral power estimates in patients 
with vertigo or deafness. 
 
 
 
Spectral comparisons in juvenile 
patients with headache (migraine and 
tension-type) 
 
 
 
FFT 
 
 
PSD 
FFT 
 
 
PSD 
 
 
 
FFT 
PSD 
 
 
 
Wavelet 
 
 
 
 
QEEG 
 
 
 
 
FFT 
 
 
 
 
FFT 
 
 
 
 
 
VEP 
 
 
 
AEP 
 
 
 
ERP 
Word 
/ face 
 
VEP 
SEP 
BAEP 
P300 
 
 
VEP 
 
 
 
 
SSEP 
 
 
 
 
 
BAEP 
 
 
 
 
 
VEP 
 
 
 
 
 
√ 
 
 
 
√ 
 
 
 
 
√ 
 
 
√ 
(auto-
nomic) 
 
 
 
0 
 
 
 
 
√ 
 
 
 
 
 
√ 
 
 
 
 
0 
 
 
 
 
 
 
Main frequency component reduced 
during attack phase 
 
AEP frequency index varies 
significantly during transitions. 
 
 
Spectral changes are anatomically 
distinct and vary with stimulus type. 
 
 
(Review article); spectral 
postulography, EPs studied for 
latency. 
 
 
First order wavelet distinguishes 
norms from patients with fewer trials. 
The spectral analysis has improved 
S:N ratio cf signal averaged EPs. 
 
Lateralised decrease in α-power, 
lateralised increase in θ-power EEG; 
SEP alterations in amplitude & 
latency. 
 
Frequency components are identified 
in controls that are absent in patient 
group.  
 
 
P100 latencies not [stat.] altered  but 
main frequency components show 
differences. 
 
 
 
M1998) 
 
 
(Gajraj RJ 1998) 
 
 
 
(Klopp J 1999) 
 
 
 
(Araki S2000) 
 
 
 
 
 
(Drissi H. 2000) 
 
 
 
 
(Loganovsky 
K.N.2000) 
 
 
 
 
(Nagaraj HC 2000) 
 
 
 
 
 
(Marrelli2001) 
 
 
 
 
 
(Canafoglia L. 2003) 
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Myoclonus in HIV-encephalopathy 
 
 
 
Diagnosis of minimal hepatic 
encephalopathy. 
 
 
Effects [acute] of solvents on the 
nervous system (toluene  & actone) 
 
Contralateral cortical reorganisation 
following capsular stroke. 
 
 
 
Neurophysiological monitoring 
during carotid endarterectomy.  
 
 
Deficits in gamma band in patients 
with schizophrenia 
Spectral  
(AR) 
 
 
Spectral 
analysis 
 
 
QEEG 
 
 
EEG 
spectral 
coherence 
 
 
Spectral 
analysis 
 
 
Time-
frequency 
analysis 
PSD 
SEP 
 
 
 
 
P300 
 
 
 
VEP 
 
 
MEP 
 
 
 
 
 
SEP 
 
 
 
AEP 
(SS) 
√ 
 
 
 
 
√ 
 
 
 
√ 
 
 
 
 
√ 
 
 
 
√ 
 
 
 
0 
SEP latency only; EEG / EMG 
coherence similar to cortical 
myoclonus. 
 
Dominant frequencies established for 
EEG; P300 latency only. 
 
 
Insignificant spectral EEG changes; 
P100 latencies unchanged. 
 
No EP analysis – TMS fails to elicit 
response. Coherence analysis 
suggests a an activity shift to 
contralateral hemisphere 
 
SEP changes before EEG in reduced 
(TCD) blood flow; spectral analysis 
of EEG only, SEP – N20 amplitude 
 
Schizophrenic patients demonstrate 
reduced power and phase-locking in 
γ-band 
 
 
 
 
(Amodio2005) 
 
 
 
(Muttray 2005) 
 
 
(Gerloff2006) 
 
 
 
 
 
(Stejskal L 2007) 
 
 
 
(Krishnan G.P.2009) 
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Appendix IV 
 
Fig: 7.3 (and overleaf): Confirmation of ethics approval. 
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Appendix V 
 
 
 
 
Fig 7.5 (above): a rectangular window function (left) and its effect on a sinusoid 
waveform (right). 
Fig 7.6 (below): a comparison of window functions in the frequency domain.  
Data is generated by Matlab™ code (Oppenhiem & Schafer 1989) 
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Appendix VI  
 
 
(Table 7.5): EP latency measurements for combined hemispheres, by 
neuropsychiatric status. 
 
Evoked 
Potential 
 
Controls 
(n = 96) 
Unimpaired 
(n=53) 
Minimal  
(n= 25) 
Overt 
(n=59) 
VEP (ms) 
N75 73.1±5.2 79.4±8.4**** 78.7±8.7****
+
 81.0±6.9***** 
P100 101.7±4.8 105.7±5.4*****º 109.3±6.9**** 107.5±7.5***** 
N145 137.2±11.2 137.0±10.2
+
ºº 144.112.4* 141.8±10.7 
SEP (ms) 
N9 9.5±0.7 10.8±1.1***** 10.5±1.4***
+
 11.2±0.8***** 
N13 13.2±0.8 14.6±1.4***** 14.5±1.7
+++
 15.0±1.0***** 
N20 19.1±1.0 20.9±1.5***** 20.3±2.0* 21.1±1.3***** 
BAEP (ms) 
Wave I 1.5±0.2 1.6±0.2 1.6±0.1* 1.6±0.1 
Wave III 3.7±0.2 3.8±0.2*** 3.8±0.2** 3.8±0.2**** 
Wave V 5.6±0.2 5.7±0.2*
+++
 5.8±0.3*** 5.9±0.3***** 
Auditory Cognitive (ms) 
P300 306.5±19.4 354.3±55.4**
+
 351.8±44.9**
+++
 401.5±42.4*****  
 
Data are expressed as (mean ± SD) for the combined right and left hemispheres. 
 Significance of the difference from controls: *p < 0.05, **p <0.01, *** p <0.005, ****p 
<0.001, *****p <0.0001. 
Significance of the differences from patients with overt HE: +p < 0.05, ++p <0.01, +++p 
<0.005. 
Significance of the differences from patients with minimal HE: °p < 0.05, °°p <0.01. 
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